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ABSTRACT

Cimen Bozkus Cansu. Ph.D., Purdue University, December 2015. Impact of L-Arginine
Transportation on Myeliod-derived Suppressor Cell Function. Major Professor: Timothy
L. Ratliff.

Inflammatory chronic prostatitis/chronic pelvic pain syndrome has been linked to
autoimmune inflammation. Likewise, prostatitis has been linked to prostate cancer
development and progression. A better understanding of the mechanisms by which
inflammation is regulated may provide the foundation for novel approaches to controlling
inflammation. Myeloid-derived suppressor cells (MDSC) are a heterogeneous population
of immature cells that expand during benign and cancer-associated inflammation. MDSC
are characterized by their ability to potently inhibit T cell responses. Therefore, by
dampening inflammation, MDSC benefit autoimmune diseases. Instead, they aggravate
cancer by blocking antitumor immune responses. Identification of mechanisms
underlying MDSC activities can enable the development of strategies to modify MDSC
function in disease. Thus, in this study we investigated the mechanisms that regulate
MDSC functions. Using murine models of prostatitis and cancer, we identified two novel
pathways, p38 and p53 signaling, that are involved in MDSC functional activity and
differentiation capacity, respectively. We showed that p38-MAPK pathway is involved in
the regulation of MDSC-mediated immunoregulatory processes such that inhibition of
p38 diminished MDSC expansion at the inflamed prostate, leading to greater numbers of
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T cells. Furthermore, inhibition of p38 reduced Nos2 expression and abolished MDSC
suppressor activity. Our studies also demonstrated that the in vitro differentiation
capacity of MDSC is restricted to cells at the peripheral sites. Tumor site monocyticMDSC lacked the ability to differentiate into other cells types such as osteoclasts and
granulocytic-MDSC, whereas the bone marrow and spleen counterparts could form both
cell types. Notably, we identified p53 as a critical regulator of MDSC differentiation.
Induction of p53 signaling elevated the differentiation of the bone marrow MDSC into
granulocytic cell types. A well-established mechanism for MDSC suppressive activity is
the metabolism of L-Arginine (L-Arg) by Arginase 1 (ARG1) and nitric oxide synthase 2
(NOS2). Therefore, we hypothesized that restricting MDSC uptake of L-Arg is a critical
control point to modulate their suppressor activity. To this end, we have identified the
mechanisms by which extracellular L-Arg is transported into MDSC. We have shown
that cationic amino acid transporter 2 (Cat2) expression is induced in MDSC at the
inflammatory sites in parallel to Arg1 and Nos2 expression. CAT2 acts as an important
regulator of MDSC suppressive function. MDSC that lack CAT2 have reduced capacity
to suppress T cell responses both ex vivo and in vivo, as evidenced by increased T cell
expansion in prostatitis and decreased tumor growth in cancer models. The abrogation of
suppressive function is due to low intracellular L-Arginine levels, which leads to the
impaired ability of NOS2 to catalyze L-Arginine metabolic processes. In summary, here
we identify 3 components that regulate MDSC: L-Arg transportation through CAT2, p38MAPK signaling and p53 signaling. CAT2 and p38 are critical regulators of MDSC
suppressive function and p53 acts as an inducer of MDSC differentiation. Targeting of
these molecules can be utilized as a strategy to modulate MDSC function in disease.
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CHAPTER 1. INTRODUCTION

Prostate Biology and Diseases
The prostate is an exocrine gland and is a part of male reproductive system. It is
located in the pelvic cavity: above the base of the penis, below the bladder and in front of
the rectum (1). The development of prostate is dependent on androgen. The hormone
androgen is required for prostate morphogenesis, it regulates expression of prostatespecific proteins and it is important for the maintenance of normal prostate function (2).
The prostate produces a fluid that forms semen together with sperm and seminal vesicle
fluid. In addition to its role of secreting the prostatic fluid that protects and nourishes
sperm, the prostate helps the control of urine flow. Anatomically, the prostate consists of
many prostatic ducts surrounded by fibromuscular tissue and is structured as a single
gland (2). The human prostate is not composed of external lobes, instead it contains
anatomic zones: the peripheral zone, the central zone, the transition zone and anterior
fibromuscular stroma. These zones differ from each other histologically and biologically.
Each zone displays differential susceptibility to different prostate related diseases (3, 4).
The major diseases of prostate include benign prostatic hyperplasia (BPH),
prostate cancer (PCa) and the inflammation of prostate (5). BPH is the most prevalent
urological disease among aging men (6). BPH forms in the transitional zone of the
prostate and is characterized by hyperproliferation of stromal and epithelial cells that
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results in the non-malignant enlargement of the prostate (7). BPH patients have more
severe lower urinary tract symptoms (LUTS) and increased risk of acute urinary retention
(AUR) (8). PCa is the most common noncutaneous cancer (9) and the second leading
cause of cancer related death in men (10). PCa develops in the peripheral zone of the
prostate (4). Both BPH and PCa are chronic diseases and associated with early initiation
and slow progression (11). Numerous factors contribute to development of BPH and
PCa, such as hormone changes, proliferation imbalances and genetic alterations (1, 7,
12). Prostatic inflammation is indicated to be a common causative factor for both
diseases. Inflammatory mediators in prostate can contribute to development of BPH by
releasing cytokine and growth factors that induce the epithelial and stromal cell
proliferation, leading to fibromuscular growth and eventually the enlargement of prostate
(13, 14). A role for inflammation in cancer oncogenesis is described and inflammation is
defined as an enabling characteristic of cancer (15, 16). Reactive oxygen species
produced by immune cells can cause DNA instability by damaging DNA. In addition,
mediators secreted by immune cells can inhibit DNA repair mechanisms, thereby
promoting cancer (17). Indeed a history of prostatitis correlates with higher risk for
developing prostate cancer in patients. A study investigating the link between prostatitis
and PCa reported that 20% of the patients with chronic inflammation developed PCa after
5 years, whereas this ratio was only 6% for patients that did not have chronic
inflammation in the initial screening (18). In addition to its role in the onset of BPH and
PCa, epidemiological studies point to a strong positive correlation between the incidence
of prostate inflammation and progression of both diseases. Approximately 40% of BPH
and 80% of PCa patients present histological evidence for some level of inflammation
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(19, 20). Nickel et al.’s pioneering study, in which 8224 patients were evaluated,
provides strong evidence for a role for prostatitis in the pathogenesis of BPH. Patients
with prostatitis had significantly higher prostate volumes than those without
inflammation and the prostate inflammation grade positively correlated with international
prostate symptom score (IPSS) (20). Other studies also showed strong correlations
between prostatitis and prostate volume, IPSS, LUTS severity and AUR risk (21, 22). To
further support for the role of inflammation in the progression of BPH, anti-inflammatory
drugs are shown to ameliorate BPH associated symptoms (23, 24). Similarly, the level of
prostate inflammation has also been shown to correlate with PCa grade (25). In line with
these observations, the progression of PCa has been demonstrated to slow down upon
dietary and medicinal intake of anti-inflammatory molecules (26-29).
Prostatitis, the inflammation of prostate, is a highly common disease. 16% of the
men in the US are reported to have experienced prostatitis (30). Despite its prevalence,
there is limited knowledge about the etiology and pathophysiology of prostatitis. Prostate
inflammation is a heterogeneous disease. Multiple factors are described to cause
prostatitis including dietary factors, infectious agents, urine reflux, hormonal imbalance
and autoimmune reaction to self-antigens (31). The clinical diagnosis of prostatitis
includes evaluation of urogenital pain, voiding or storage problems and sexual
dysfunction (32). However, the wide range of clinical manifestations presented by
prostatitis necessitate the improvement of its diagnosis and treatment. To this end, the
National Institutes of Health (NIH) classified prostatitis syndromes into 4 categories: 1)
acute bacterial prostatitis; 2) chronic bacterial prostatitis; 3) chronic prostatitis/chronic
pelvic pain syndrome: inflammatory and noninflammatory (CP/CPPS); 4) asymptomatic
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inflammatory prostatitis (33). Among these different categories, CP/CPPS is the most
common form and comprises 90% of all prostatitis cases (33). CP/CPPS manifests the
processes of chronic inflammation, which is the type of prostate inflammation that is
most commonly associated with BPH and PCa. The limited knowledge about the origin
and regulation of prostate inflammation necessitates further studies to identify the
underlying mechanisms of this disease, especially given the prevalence and its strong
associations to BPH and PCa.

Animal Models of Prostate Inflammation
Several rodent models of prostate inflammation have been utilized to better
characterize prostatitis. Although some of these models reflect human prostatic diseases
well and have provided a lot of valuable information about the etiology and regulation of
prostate inflammation, data obtained from rodent models should be interpreted cautiously
since there are also major anatomical and pathological differences between the human
and rodent prostate. Human prostate is a single gland that is surrounded by stroma and is
devoid of adipose tissue (34). In contrast to the human, rodent prostate consists of
anatomically distinct lobes (35, 36). Mouse prostate can be separated into anterior
prostate or coagulating gland, ventral prostate, dorsal prostate and lateral prostate. Each
of these lobes are separated from each other by fibrous and adipose connective tissue and
the mouse prostate lacks the interconnecting stroma of the human prostate (34, 36). In
addition, mice do not spontaneously develop PCa and the incidence of non-neoplastic
hyperplasia is very rare (34). Despite all these differences, mouse models still are
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extremely valuable tools to study prostatic diseases. There are considerable similarities
between the human and mouse prostate. Prostate in both species has common
developmental origins, is androgen-sensitive and functions similarly (34). Therefore,
under the guidance of published classification of prostate pathology, mouse models
provide significant advantages to elucidate the mechanisms of regulation of the prostate
inflammation.
Spontaneous development of nonacute prostatitis has been reported in Wistar,
Copenhagen and Lewis rats (37, 38). In these rat models, the development of prostatitis is
age-dependent since the incidence rates increase as animals age (39). In all three strains,
the inflammation is restricted to the lateral lobe of the prostate. However, the severity of
inflammation is not consistent between animals. In addition, the susceptibility to
prostatitis is drastically different among different rat strains. In one study the rate of
spontaneous inflammation was reported to be 72% in Lewis rats, 27% in Wistar rats and
no incidence occurred in Sprague-Dawley rats (39).
The evidence provided by rat models for the association of prostatitis incidence
and advancing age suggests a role for hormones in the regulation of prostate
inflammation. The hormonal balance in prostate changes with the advancing age as
testosterone levels decrease and estrogen levels increase (40). Indeed several rodent
models have provided a role for hormones in the regulation of prostatitis. Both castration
and administration of 17β-estradiol have been shown to increase the incidence rate and
severity of prostatitis in Wistar rats (39). Another study demonstrated that 17β-estradiol
administration induces an autoimmune response against prostate-specific antigens in rats,
indicating a role for autoimmunity as a cause of prostatitis (41).
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Several other mouse models also have demonstrated a role for autoimmunity in
the initiation of prostatitis, stressing the importance of self-tolerance mechanisms in the
maintenance of the healthy prostate. Thymus plays a vital role in the selection of
functional self-tolerant T cells (42). The removal of thymus 3 days after birth results in
development of prostatitis in mice without any additional treatment (43). However, the
susceptibility to induction of prostatitis due to thymectomy varies greatly among different
strains of mice. The frequency of prostatitis incidence in thymectomized C57BL/6 mice
is low, ranging between 20-30%. Notably, prostatitis is not the only autoimmune disease
that is induced in thymectomized mice. Several autoimmune diseases such as gastritis
and thyroiditis are also manifested in mice post-thymectomy (43).
Several experimentally-induced autoimmune prostatitis (EAP) models have been
developed to further demonstrate the importance of autoimmunity in the induction of
prostatitis. Immunization of Wistar rats with male accessory gland (MAG) extract in
complete Freund’s adjuvant (CFA) results in prostatitis (44). To further show that the
induction of prostatitis is due to an autoimmune response, same group isolated prostatein,
a prostate-specific target antigen, and immunized rats with this antigen in CFA. Direct
immunization with prostate-specific antigen also induced prostatitis in Lewis rats (45).
Similar to rats, immunization with MAG also induces prostatitis in mice (46). The
frequency of prostatitis induction in these EAP models is low and can be elevated by
using Non-obese diabetic (NOD) mice as the background (46). Administration of MAG
into NOD mice results in a more severe form of prostatitis and affects 100% of the
animals unlike the control mice. Although using NOD mice increases the efficiency of
this EAP model, it still presents problems in that the inflammation is restricted to lateral
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and dorsal lobes (46). In addition, NOD mice are genetically predisposed to autoimmune
diseases and manifest other autoimmune diseases as well, such as thyroiditis (47).
Although the aforementioned rodent models have provided valuable insight about
the initiation, progress and regulation of prostatitis, there are problems associated with
them. The susceptibility to prostatitis varies a lot between different strains, the
inflammation is commonly contained in certain lobes of the prostate and in some models,
such as thymectomy and NOD mice, autoimmune inflammation is not limited to prostate,
convoluting the understanding prostatitis-specific processes. Therefore, the development
of animal models that mimic the human disease better are needed. To this end, the Ratliff
group has generated the Prostate Ovalbumin Expressing Transgenic 3 (POET-3) mouse
model. POET-3 mice express membrane bound ovalbumin (mOVA) protein under the
control of prostate-specific, androgen-regulated probasin promoter. Therefore, mOVA is
specifically expressed in the prostate, but not in other tissues. Inflammation can be
induced by the adoptive transfer of mOVA-specific CD8+ T (OTI) cells (48). In POET-3
model, inflammation is restricted to the prostate and kinetics of prostatitis development
and severity of inflammation are comparable in all of the anatomical lobes of the prostate
(49). OTI transfer initially induces acute inflammation at POET-3 prostates that peaks
within one week of transfer. Acute inflammation is followed by the development of
chronic inflammation in POET-3, as indicated by analyses performed at later time points.
Hence, POET-3 mimics the human disease and is an excellent model in which antigen
specific, autoimmunity-mediated acute and chronic inflammation can be studied to
understand the underlying mechanisms of the initiation, progression and regulation of
prostatitis.
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Immunobiology of Prostate Inflammation
Prostate is an immunocompetent organ. Low numbers of endogenous
inflammatory cells are found inside the normal prostate. The immune cells of the normal
prostate, comprised of T and B cell lymphocytes and macrophages, are important for
keeping the reproductive tract free of pathogens (50). Prostate inflammation is identified
by the increase in the density and the type of prostate infiltrating immune cells (51). Data
obtained from clinical assessments of patients and rodent models of prostatitis have
provided valuable information regarding the characterization of inflammatory cells and
molecules in the diseased prostate. Comparison between inflamed and normal prostate
has revealed that total number of immune cells are markedly increased in inflamed
prostates. These CD45+ cells are predominantly CD3+ T cells (70-80%) containing both
CD4+ and CD8+ subpopulations (51). While CD8+ T cells in the normal prostate provide
defense against pathogens and contribute to the maintenance peripheral tolerance (52), in
BPH patients they can cause destruction of prostate gland (50). CD8+ T cells are also
detected in cancer-associated prostate inflammation, where they involve in antitumor
activities (53). Interestingly, the ratio between CD4 and CD8 T cells is drastically
different in normal and inflamed prostates. Unlike the preponderance of CD8+ cytotoxic
T cells in the normal prostate, CD4+ cells constitute the majority of T cell populations in
the inflamed prostates (54). Another striking difference between the T cells of normal and
inflamed prostate is the activation state. T cells residing in the inflamed prostates carry
markers such as HLA-DR and IL-2R that indicate that they have experienced antigen and
are in an activated state (55). In fact, several studies have demonstrated that the T cells
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from CP/CPPS patients can react against prostate antigens. Alexander et al. isolated T
cells from the peripheral blood of CP/CPPS patients and healthy individuals and
stimulated them in vitro with seminal plasma that contains prostate antigens. Only T cells
from the patients proliferated in response to prostate antigens (56). Another study also
showed that in chronic prostatitis patients, T cells were able to respond to prostatespecific antigen (PSA) and prostatic acid phosphatase (PAP) (57). Together, these
findings emphasize the presence of autoimmune-mediated inflammatory responses in
prostatitis.
In response to prostate-specific antigens T cells from prostatitis patients secrete
high levels of inflammatory cytokines IFN-γ, IL-1 and TNF-α (57). This cytokine profile
suggests an imbalance towards Th1 immunity in the inflamed prostate. In fact, Th1dominant responses are also observed in prostates of BPH patients (54). In BPH, together
with the Th17 cells (58), Th1 responses stimulate epithelial and stromal cells to
proliferate and secrete cytokines (59). The extensive characterization of T cell responses
by Steiner et al. demonstrated that Th1 responses can be attributed mostly to CD4+ Thelper cells. Despite the pronounced Th1 skewing, Th0 and Th2 responses are also
present in T cells (54). As seen in the progression of various inflammatory diseases (60),
Steiner et al. also reported that Th1 predominance is associated with acute inflammation,
whereas chronic inflammation was mostly skewed towards Th2 responses (54). This shift
from Th1 to Th2 immunity reflects anti-inflammatory mechanisms in chronic stages of
prostatitis (61). One population of cells with counter-regulatory roles against
inflammation is CD4+CD25+ T regulatory (Tregs) (62). Tregs in the prostates of PCa
patients play inhibitory roles against antitumor responses (63).
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In addition to T cells, B lymphocytes also infiltrate the inflamed prostate (55).
Although not studied in depth, presence of prostate-specific humoral responses is
documented (64). Another important inflammatory population found in the inflamed
prostate is the myeloid cells of innate immune system. Immunocytochemical analysis of
leukocyte subpopulations in prostatic secretions of men suffering from bacterial or
chronic prostatitis indicated presence of granulocytes and macrophages together with the
T and B lymphocytes (65). Although all of these leukocyte populations were significantly
elevated, the prostatic inflammation was predominantly granulocytic (65). Notably, other
studies reported a lack of granulocytes in prostatic inflammation (50), highlighting the
heterogeneity of prostatitis. Macrophages are typically classified as M1 and M2
macrophages with pro- and anti-inflammatory properties, respectively (66). M1
macrophages exert their cytotoxic roles mainly through the activities of nitric oxide
synthase 2 (NOS2). The findings of Baltaci et al. documenting the expression of NOS2 in
inflamed prostate suggest the contribution of M1 macrophages in prostatitis (67). In
tumor-associated inflammation, however, M2 macrophages are more prominent than M1
subsets, consistent with the immunosuppressive nature of tumor microenvironment (53).
Another factor that is proposed to be regulating macrophage function in prostate
inflammation is the macrophage inhibitory cytokine 1 (MIC-1). MIC-1 levels are shown
to be downregulated in BPH (68), but up-regulated in PCa (69), leading to the hypothesis
that MIC-1 is a link connecting prostate inflammation and cancer. Myeliod-derived
suppressor cells are another population with immunosuppressive properties that is
recruited to inflammatory tissues (70). Haverkamp et al. demonstrated that MDSC are
present both in acute and chronic prostate inflammation (71, 72). The presence and
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distinct roles of multiple populations in the inflammatory prostate emphasize the
complexity of prostatic immune regulation. Therefore, it is important to understand the
mechanisms regulating the interplay between the components of prostate inflammation.

Impact of p38 MAPK Pathway in Inflammation
The complex interactions between the inflammatory molecules involved in
prostate inflammation can be regulated by means of signal transduction pathways. As a
matter of fact, nuclear factor-κB (NF- κB) is considered to be the master transcription
factor in inflammatory responses and NF- κB signaling is defined as a crucial mediator of
prostate inflammation (73). Another signal transduction pathway that is known to have
key roles in the regulation of inflammatory processes is p38 mitogen-activated protein
kinase (MAPK) pathway (74).
MAPKs are signaling molecules with key roles in numerous biological processes
such as cell growth, differentiation, stress responses and inflammation (75). MAPK
pathways are organized as 3-tiered functioning units consisting of 3 kinases: a MAPK, a
MAPK activator (MAPKK) and a MAPKK activator (MAPKKK) (76). There are 4
distinct classes of MAPKs: the extracellular-signal regulated kinases (ERK1-2), Big
MAP kinase (ERK5), c-jun N-terminal kinase (JNK1-3) and the p38 MAPK (77). Among
these subclasses of MAPK pathway, p38 MAPK signaling is particularly known for its
regulatory roles in inflammation (77). p38 was first discovered in a pharmacological
screening when the anti-inflammatory compound SB 203580 inhibited the expression of
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IL-1 and TNF-α (78). Subsequent mechanistic analysis revealed that SB 203580 inhibits
IL-1 and TNF-α expression by interfering with p38 activity (78, 79).
Since the discovery of its involvement in the regulation of IL-1 and TNF-α
expression, p38 has been shown to control the expression of numerous other
inflammatory molecules in a wide variety of cell types. For example, multiple important
inflammatory enzymes, such as cyclooxygenase-2 (COX-2) and NOS2 are subject to
regulation by p38 signaling in macrophages (80, 81). In addition, p38 signaling is
required for IFN-γ and IL-17 formation in Th1 and Th17 cells, respectively (82, 83). In
lipopolysaccharide (LPS)-induced macrophages and dendritic cells (DC), inhibition of
p38 is reported to enhance IL-12 production by increasing IL-12 mRNA stability (84).
On the contrary, another study showed that CD40-ligand induced expression of IL-12 in
DC is blocked in the absence of p38 signaling (85). The same study also showed that the
inhibition of p38 had no effect on CD40-induced expression of IL-10 and IL-1β in DC,
while in B cells both cytokine expression were downregulated under the same conditions
(85). These studies highlight the involvement of p38 signaling in the regulation of
immunity and the discrepancies suggest that p38 signaling exerts its immune regulatory
effects in a cell type and context dependent manner.
The multiplicity of immune responses regulated by p38 signaling has motivated
researchers to investigate the role of p38 signaling in the pathogenesis of inflammatory
diseases. Recent studies have described a role for p38 in the pathogenesis of experimental
autoimmune encephalomyelitis (EAE). Blockade of p38 signaling ameliorate the
progression of the EAE by decreasing IL-17 production (86). In support of these
observations, another group reported that p38 signaling contributes to EAE by promoting
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DC to drive Th17 cell differentiation (87). Interestingly EAE-promoting effects of p38
pathway is restricted to DC. While DC-specific deletion of p38 suppresses EAE, deletion
of p38 in macrophages or T cells does not impact the disease progression. Similarly, p38
is activated in arthritis and deletion of p38 reduce the severity of inflammation (88).
However, myeloid cell-specific deletion of p38 exacerbates arthritis (89). These
seemingly contrasting results both in EAE and arthritis models underline that p38mediated regulation of immune responses is cell type specific. There are four different
isoforms of p38: α, β, γ and δ (77). The expression of these isoforms are cell type
specific. For example, in macrophages the expression of p38α and p38δ are highly
abundant, whereas p38β is not expressed (90). Moreover, the isoforms can be activated
by different upstream kinases (90). The differential regulation of distinct isoforms may at
least partially account for the cell type and context dependent activities of p38 signaling
in inflammatory diseases.
Existing data regarding the regulatory role of p38 in multiple inflammatory
diseases propose the involvement of p38 MAPK signaling in prostatic inflammation as
well. The cytokine balance in prostate inflammation is predominantly skewed towards
Th1 type (57). The Th1-associated cytokines, IL-1 and TNF-α, are powerful activators of
p38 pathway (91). Moreover, their expression is directly regulated by p38 activity (78).
Hence, a regulatory role for p38 in prostate inflammatory diseases is a priori.
Unfortunately, the function of p38-MAPK signaling in the prostatic inflammation is far
from being characterized. The limited number of studies investigated the p38 pathway in
diseased prostate reported that p38 is over-expressed in the prostates of BPH and PCa
patients (92). In these studies, the contribution of p38 signaling to BPH and PCa is
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mostly argued in the context of cellular proliferation and apoptosis (92). Therefore,
further investigations are needed to elucidate the regulatory roles of p38 pathway in the
cells of innate and adaptive immune system that are involved in prostate inflammation.

Myeliod-Derived Suppressor Cells in Benign Inflammatory Diseases
Myeliod-derived suppressor cells (MDSC) are a group of immature myeloid cells
that expand both in humans and mice during pathological conditions including benign
inflammatory diseases (93). MDSC regulate both innate and adaptive immune responses.
Most notably, they are recognized by their ability to inhibit T cell responses (93). Due to
their ability to control T cell-mediated inflammation, MDSC have the potential to play
regulatory roles in inflammatory diseases.
Infection with pathogenic agents induces MDSC expansion and activity (93). A
recent study demonstrated that infection with Staphylococcus aureus (S. aureus), a type
of pathogen known for its ability to survive under high immune pressure, leads to a
marked increase in MDSC numbers in mice (94). Moreover, adoptive transfer of MDSC
into S. aureus-infected mice further aggravated the infection (94). This study indicates
that pathogens can induce MDSC as a strategy to evade immune responses and describes
a role for MDSC in pathogenic infections.
MDSC are also important in autoimmune diseases in that by suppressing T cellmediated responses they can help ameliorate the disease. Indeed, a beneficial role for
MDSC in autoimmune diseases is demonstrated in several studies. MDSC are shown to
increase in numbers in the spleen and the diseased tissue of animals with autoimmune
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diseases including collagen-induced arthritis (95), experimental autoimmune
encephalomyelitis (96, 97), colitis (98) and prostatitis (72). Moreover, ex vivo
evaluations of these MDSC indicate that they possess the ability to inhibit T cell
proliferation. Importantly, several adoptive transfer studies described the in vivo
participation of MDSC in the regulation of autoimmune disease pathology. Adoptive
transfer of MDSC is shown to reduce the severity of the disease in several autoimmunity
models including arthritis (95), myasthenia gravis (99) and inflammatory bowel disease
(100). In addition, a study using type 1 diabetes murine models suggested that MDSC can
prevent the onset and significantly reduce the incidence of diabetes (101). Altogether
these studies indicate a direct role for MDSC as a critical component of the regulatory
mechanisms involved in the pathogenesis of autoimmune diseases.

Myeliod-Derived Suppressor Cells in Cancer
The tumor microenvironment is composed of a variety of different cell types,
including malignant cells, fibroblasts, endothelial cells and infiltrating immune cells
(102). The immune cells in the tumor microenvironment can exert both pro- and antitumorigenic effects (102). Although the composition of immune cells is very
heterogeneous, tumor microenvironments are commonly considered to be
immunosuppressive. Through several mechanisms tumors favor an immune-tolerant
microenvironment, in which anti-tumorigenic immune responses are suppressed (103).
One of these mechanisms is the induction of MDSC (93).
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Most of the current knowledge about MDSC has come from animal models of
cancer and cancer patients. MDSC practically accumulate in all types of cancer and have
detrimental effects in cancer patients (104). MDSC are associated with worse prognosis,
increased metastasis rates and decreased survival (105-107). MDSC potently inhibit
antitumor immune responses and protect tumors from T cell-mediated killing (93).
Therefore, MDSC are a major obstacle to both pre-existing immune responses and cancer
immunotherapy. Additionally, MDSC can support tumor progression and metastasis
through several other mechanisms that are independent of their immunosuppressive
activities. MDSC produce the pro-angiogenic factor vascular endothelial growth factor
(VEGF), therefore facilitate tumor growth (108). MDSC also produce matrix
metallopeptidase 9 (MMP9), a pro-angiogenic protease that is critical for tumor cell
dissemination and invasion of other tissues (108). MDSC-secreted MMP9 is crucial for
tumor metastasis. In a lung metastasis tumor model, MDSC mediate metastasis into lungs
by producing high levels of MMP9 and deletion of MMP9 abrogate metastasis (109). In
addition, recent studies implied a role for MDSC in inducing tumor plasticity and
supporting epithelial-mesenchymal transition (EMT) (110, 111). Although more studies
are needed, induction of EMT can be another MDSC-mediated mechanism for tumor
metastasis. These multiple pro-tumorigenic and immunosuppressive properties of MDSC
clearly indicate their harmful effects and emphasize the necessity of their elimination in
cancer.
Multiple strategies have been adopted to control MDSC in cancer. These
strategies can be broadly categorized into four groups: 1) blockade of MDSC formation;
2) induction of MDSC differentiation into mature cells; 3) depletion of MDSC and 4)
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inhibition of immunosuppressive properties (112). Various agents that target MDSC
through one of the aforementioned mechanisms are currently being tested in animal
models and in clinic. For example, zoledronic acid can potentially prevent MDSC
generation (113). Administration of zoledronic acid in a pancreatic cancer model results
in reduced MDSC accumulation and slower tumor growth (114). Another agent that can
modify myelopoiesis is all-trans-retinoic-acid (ATRA). ATRA has been shown to induce
MDSC differentiation into mature immunostimulatory cell types (115). ATRA treatment
lowers MDSC numbers and improves T cell responses in metastatic renal cell carcinoma
patients (116). Several chemotherapy drugs can eliminate MDSC in cancer patients.
When used at low doses, gemcitabine (117), cisplatin (118) and 5-fluorouracil (119)
preferentially deplete MDSC and associate with improved antitumor immunity.
Administration of agents that modulate MDSC suppressive functions such as tadalafil
(120) and nitroaspirin (121) also enhance antitumor T cell responses.
Their critical roles in immune regulation and deleterious effects in cancer have
rendered MDSC population an attractive target for cancer therapy. Studies showing the
positive correlation between MDSC inhibition and improvement of antitumor responses
greatly encourage the use of MDSC inhibitors in clinic. Unfortunately, so far none of the
current strategies have found clinical translation. A better understanding of molecular
mechanisms underlying MDSC functions is necessary for improving the efficacy of
current therapies and developing more specific methods for targeting MDSC.
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The Biology of Myeliod-Derived Suppressor Cells
MDSC are a highly heterogeneous population and contain immature mononuclear
and polymorphonuclear myeloid cells at different stages of differentiation (93). In mice,
MDSC are identified by the co-expression of CD11b and Gr-1 cell surface molecules.
The expression of Gr-1 on MDSC usually presents a spectrum of intensity. This
heterogeneity has prompted the need for better characterization of MDSC
subpopulations. Anti-Gr-1 monoclonal antibody recognizes two distinct molecules: Ly6C
and Ly6G (122). Ly6C is expressed on the surface of monocytes and Ly6G is expressed
on granulocytes. Therefore, utilization of these two markers phenotypically distinguishes
the two main MDSC subsets: CD11b+Ly6ChighLy6G- monocytic (M-MDSC) and
CD11b+Ly6ClowLy6G+ granulocytic (G-MDSC) (122). The characterization of MDSC
in humans is more complicated. The human homologue of Gr-1 is unknown. Therefore, a
different combination of cell surface molecules is used to define MDSC subpopulations.
Most commonly, M-MDSC and G-MDSC subsets are identified as CD14+HLA-DR-/lo
and CD14-CD11b+CD33+ CD15+/CD66b+, respectively (122).
Cells bearing the same phenotypic markers as MDSC are constantly generated in
the bone marrow. In healthy individuals these immature myeloid cells (IMCs)
differentiate into mature cell types. However, in cancer the normal process of
myelopoiesis is altered. Tumors stimulate myelopoiesis and inhibit differentiation of
myeloid cells, thereby resulting in an expansion of the CD11b+Gr-1+ immature myeloid
population (123). The expansion of CD11b+Gr-1+ cells are mostly mediated by tumorinduced granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF and M-
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CSF (124, 125). The key transcription factors that regulate MDSC expansion are the
signal transducer and activator of transcription 3 (STAT3), the CCAAT/enhancer binding
protein-β (C/EBPβ) and interferon regulatory 8 (IRF-8) (126). These transcription factors
promote MDSC expansion by upregulating the expression of survival related factors,
such as B-cell lymphoma XL, MYC, cyclin D1 and survivin (126). Furthermore, STAT3
induces the expression of calcium-binding protein S100A9 in myeloid precursors.
S100A9 expression in myeloid precursors inhibits their differentiation and promotes the
expansion of immature CD11b+Gr-1+ cells (127). In addition to their role in MDSC
expansion, S100A8/A9 proteins regulate MDSC recruitment to tumor sites (128). The
chemokine receptor CXCR2 has also been indicated to control MDSC infiltration to the
tumor in a colitis-associated tumorigenesis model (129).
Although the aforementioned factors are sufficient to expand the immature
myeloid cell population, another set of factors are required for CD11b+Gr-1+ cells to
gain immunoregulatory function (72). Since the suppressive function is the defining
characteristic of MDSC, these activating factors are essential for the formation of the
bona fide MDSC. Various inflammatory cytokines secreted by the cells of tumor
microenvironment induce immunoregulatory functions in MDSC. These cytokines
include, IFN-γ, TNF-α, IL-1β, IL-4 and IL-13 (93). Therefore, CD11b+Gr-1+ cells
residing at the tumor site represent the bona fide MDSC population. In fact, a growing
body of evidence indicates that the anatomical location of CD11b+Gr-1+ cells dictates
their suppressor activity. Only the cells at the pathological site, but not at the periphery,
possess immediate suppressor activity and hence are the bona fide MDSC (72, 130). The
action of activating cytokines on MDSC are shown to converge on a common pathway.
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The cytokine-induced MDSC activity is completely dependent on the transcription factor
C/EBPβ. Therefore, C/EBPβ is considered as the master regulator of MDSC suppressive
function (131). STAT1 is another key transcription factor for the regulation of MDSC
functions (132). Additionally, signaling through IL-4Rα and STAT6 also involve in
MDSC activation (133). Endoplasmic reticulum (ER) stress is recently proposed as
another factor inducing MDSC activity. Tumor infiltrating MDSC have increased levels
of C/EBP-homologue protein (Chop), a downstream effector of ER stress related
pathways and deletion of Chop reduces suppressive activity of MDSC (134).
MDSC help the generation of an immunosuppressed tumor microenvironment by
modulating both innate and adoptive immune responses. For example, MDSC suppress
antitumor immunity by altering the phenotype of macrophage populations at the tumor
site. The communication between MDSC and macrophages shifts the immune response
towards an anti-inflammatory Th2 type. Macrophages induce IL-10 production by
MDSC, and in return MDSC-secreted IL-10 polarizes macrophages to an M2 phenotype
by reducing their IL-12 production (135). Since IL-12 is an inducer of natural killer (NK)
cell differentiation, the cross-talk between macrophages and MDSC can be argued to
diminish NK cells (136). NK cells are an important arm of immune response against
tumors (137). Therefore, reducing NK numbers in the tumor microenvironment might be
another mechanism through which MDSC induce immunosuppression. A recent study
has provided further support for the modulation of antitumor NK responses by MDSC.
MDSC express immunosuppressive adenosine A2A receptors (A2AR) and myeloid cellspecific deletion of A2AR increases NK cell number and inhibits tumor growth (138).
MDSC have also been shown to modulate IL-17-producing CD4+ T cells (Th17). In a
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skin cancer model, Gr-1+ myeloid cells induced the recruitment of Th17 cells into tumor
microenvironment, where Th17 cells contributed to tumor development (139). Notably,
IL-17 is also been demonstrated to play a role in the recruitment of MDSC to tumor sites
(140). Hence, a feedback loop between MDSC and Th17 cells might exist. Another
mechanism through which MDSC further augment the immune-tolerance of tumors is the
induction of Treg cell expansion (141) and recruitment to tumor sites (142). Like MDSC,
Treg are immunosuppressive cells and their activities favor tumor growth (143). As can
be appreciated, MDSC-mediated immune-tolerance mechanisms are quite complex and
involve multiple players. However, the most important immunosuppressive mechanism
that MDSC utilize is the inhibition of CD4+ and CD8+ effector T cells (93).
MDSC inhibit effector T cell responses through a multitude of mechanisms. One
of these mechanisms is the impairment of T cell trafficking. Following the activation at
lymph nodes, tumor-specific T cells migrate to the tumor site, where they exert their
antitumor activities. This process is regulated by L-selectin, a molecule that controls T
cell migration and extravasation (144). MDSC express ADAM17, an enzyme that cleaves
extracellular portion of L-selectin on T cells. Thus, by interfering with T cell trafficking,
MDSC-mediated L-selectin down-regulation causes T cell dysfunction (145). MDSC can
also block antitumor T cell activity by stimulating the immune checkpoint receptor PD-1
on T cells. A recent study demonstrated that hypoxia preferentially induces PD-L1, a PD1 ligand, expression in tumor site MDSC. Moreover, PD-L1 blockade abrogated the T
cell inhibitory effects of MDSC, thereby defining PD-L1 expression as an MDSC
suppressive mechanism (146). Metabolism of several amino acids by MDSC is also a
critical mechanism through which MDSC regulates T cell responses. For example, tumor
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site MDSC express high levels of indoleamine 2,3-dioxygenase (IDO), an inducible
enzyme that catabolizes tryptophan (147, 148). Tryptophan metabolism by IDO produces
several catabolites that are toxic to T cells. Moreover, tryptophan is a necessary amino
acid for T cell proliferation. Depletion of tryptophan due to increased IDO activity also
suppresses T cell responses (149). Another essential amino acid required for T cell
activity is cysteine. Cells produce cysteine either by converting methionine or by
reducing imported cystine into cysteine (150). T cells lack the cellular machinery to
produce cysteine from methionine and they do not express the transporter that imports
cystine. Instead they directly import cysteine in the local microenvironment that is
exported by antigen-presenting cells (APC) (150). MDSC consume cystine and produce
cysteine. However, unlike other APC, they do not export cysteine, thereby depleting
cysteine levels in the local microenvironment. This MDSC-mediated cysteine depletion
results in T cell dysfunction (150). Arginine metabolism by MDSC is also critical for the
regulation of T cell responses. In fact, the products of arginine metabolism can inhibit T
cells in many ways that arginine metabolism is considered to be the most important
mechanism for MDSC suppressive function (151).
The elevated expression and activities of arginase 1 (ARG1) and nitric oxide
synthase 2 (NOS2) are the hallmarks of MDSC suppressor function. Both of these
enzymes use L-Arginine (L-Arg) as their unique substrate (151). ARG1 converts L-Arg
into L-Ornithine and urea. NOS2 uses L-Arg and produces nitric oxide (NO) (151). The
greatly elevated activities of ARG1 and NOS2 deplete L-Arg in the local
microenvironment. L-Arg is essential for T cell proliferation. L-Arg starvation in T cells
induces T cell anergy via the inhibition of T cell receptor (TCR) CD3ζ chain (152). In
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addition, an absence of L-Arg leads to cell cycle arrest at G0-G1 phase in T cells (153).
The products of L-Arg metabolism are also potent inhibitors of T cell responses. The cell
penetrating product of NOS2 activity, NO, mediates T cell dysfunction through multiple
mechanisms. For instance, NO-mediated protein nitrosylation can alter protein function
and inhibit key pathways involved in T cell activity, such as IL-2 signaling (151). In
addition, by reacting with other molecules such as O2-, NO contributes to formation of
reactive oxygen and nitrogen species (ROS/RNS) and induces T cell death (151).
The heterogeneity of CD11b+Gr-1+ cells raises the question whether the
observed suppressor activities of MDSC are restricted only to a subpopulation. In fact the
characterization of M-MDSC and G-MDSC supports the idea that distinct MDSC subsets
vary in their suppressive activities. M-MDSC primarily utilize NOS2-associated
mechanisms to exert their suppressive effects, whereas G-MDSC utilize ROS (93).
Moreover, a convincing number of studies indicate that M-MDSC is the dominant
suppressor subset. On a per cell basis, they are much more suppressive than G-MDSC
(154). However, depending on the tumor model, G-MDSC may mediate significant
suppression as well (155). Due to these variations between the subsets, researchers are
highly encouraged to conduct MDSC-related characterizations in individual subsets.
Since the primary suppressor mechanisms of both subsets rely on L-Arg metabolism,
further elucidation of L-Arg-mediated MDSC activity can provide more specific targeting
of the suppressive subset.
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Transportation and Metabolism of L-Arginine in Myeloid Cells
Arginine transportation in mammalian cells is carried out by the activities of
distinct transport systems: y+, y+L and b0,+, B0,+ (156). y+ system comprises four
single protein transporters that act as uniporters: cationic amino acid transporter (CAT) 14, alternatively known as solute carrier (SLC) 7A 1-4 (156). As evident from their name,
CATs preferentially transport cationic amino acids including L-Arginine, L-Lysine and
L-Histidine in a Na+ independent manner (156). y+ members are widely expressed and
they are commonly considered as the major route of entry for L-Arg in cells (157). CAT3
and CAT4 are expressed in a limited number of tissues and their specific roles are not
well characterized (158). CAT1 is ubiquitously expressed with the exception of liver and
is essential for cell viability (158). CAT2 expression is inducible and is associated with
providing rapid L-Arg uptake in cells with high L-Arg demand. There are two different
splice variants of CAT2: CAT2A and CAT2B. Among these CAT2B is the high affinity
transporter and accounts for the high L-Arg transport through CAT2 (158). y+L system
members are glycoprotein-associated amino acid transporters (gpaAT). These
heterodimeric amino acid transporters (HAT) of y+L system are composed of the
glycoprotein 4F2 heavy chain (4F2hc/SLC3A2) and a carrier protein y+LAT1 (SLC7A7)
and y+LAT2 (SLC7A6) (158). The glycoprotein is not involved in the actual
transportation process. Its role is to traffic the carrier protein to the plasma membrane of
cells (159). HATs are obligatory antiporters. They transport cationic amino acids Na+
independently and neutral amino acids, such as L-Leucine, Na+ dependently (158).
Similar to y+L, b0,+ system also consists of a heterodimeric transporter: the glycoprotein
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rBAT (SLC3A1) and the carrier protein b0,+AT (SLC7A9). b0,+ system differs from
y+L in that it can transport neutral amino acids independent of Na+ (158). ATB0,+
(SLC614) mediates B0,+ system activity. ATB0,+ also transports both cationic and
neutral amino acids. Unlike other systems, L-Arg transportation through ATB0,+ is Na+
and Cl- dependent (156). All these L-Arg carriers are distinct in their L-Arg
transportation properties. Depending on the cell type and status, a unique combination of
these transporters carry L-Arg into cells. The activities of these transporters regulate the
availability of L-Arg within the cells. As a result, L-Arg transporters may impact the
functional outcome of L-Arg-dependent cellular processes.
The importance of L-Arg metabolism in myeloid cells prompted the researchers
to elucidate the relevant transportation mechanisms in these cells. The initial observation
that the expression of CAT2 increases in parallel to NOS2 expression in activated
macrophages suggested a role for y+ system in the L-Arg transportation of macrophages.
Indeed, the increase in CAT2 expression correlates with enhanced L-Arg uptake in
activated macrophages (160). Furthermore, the activity of NOS2 enzyme, as measured by
nitrite formation, depend on L-Arg availability. Nitrite production increases dosedependently with supplied L-Arg (160). Later studies more directly evaluated the role
CAT2 in activated peritoneal macrophages using Cat2-/- cells. In the absence of CAT2 LArg uptake and NO production are reduced by 95% and 92%, respectively (161).
Although CAT1 is expressed in macrophages, its activity is not involved in providing LArg as a response to the induced requirement in activated macrophages (161). These
studies indicate that the inducible CAT2 is the main transporter that provides L-Arg and
is required for sustained NOS2 activity in activated macrophages. Notably, CAT2 is also
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shown to affect ARG1 activity in bone marrow derived macrophages (BMM).
Stimulation of BMM with Th2 cytokines such as IL-4 and IL-13 induces expression of
ARG1. In the absence of CAT2, BMM stimulated with Th2 cytokines produce increased
levels of urea, indicating a greater ARG1 activity (162). Together, these studies indicate
the opposing role of CAT2 in regulating Th1 and Th2 immunity. Despite its essential
roles in sustaining Th1 immunity, CAT2 action seems to restrict Th2 responses in
macrophages. Although y+ system almost single handedly mediates L-Arg uptake in
activated macrophages, y+L system is indicated to be predominantly responsible for LArg transport in resting macrophages (163). Notably, b0,+ and B0,+ systems do not
contribute to L-Arg uptake in BMM (163).
The L-Arg transport studies conducted in macrophages form the basis of our
understanding of myeloid cell L-Arg uptake. Unfortunately, the role of L-Arg
transporters are not well investigated in other myeloid cell types. Different cell types
utilize distinct L-Arg transport mechanisms, as can be exemplified by CAT2-dependent
and independent NO production in macrophages and fibroblasts, respectively (164).
Given the cell type dependent regulation of L-Arg transport and the importance of L-Arg
metabolism in myeloid cells, it is imperative to study L-Arg uptake in each myeloid
population.

Myeliod-Derived Suppressor Cell Differentiation
MDSC biology is mostly characterized in the context of their suppressive
function. Very little is known about their origin and fate. Tumor induced factors inhibit
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the normal differentiation of myeloid cells and give rise to the expansion of immature
CD11b+Gr-1+ cells (93). These immature cells have recently been demonstrated to be
capable of differentiating into different cell types, thereby highlighting their plastic
nature. The heterogeneity and the plasticity of CD11b+Gr-1+ population complicate the
placement of MDSC in the myeloid cell hierarchy and necessitate the detailed
characterization of factors driving MDSC differentiation.
The capacity of MDSC to differentiate into other cell types is demonstrated by the
adoptive transfer experiments performed by Gabrilovich’s group. Corzo et al. adoptively
transferred CD11b+Gr-1+ cells into tumor bearing mice and showed that CD11b+Gr-1+
cells can differentiate into macrophages and dendritic cells (DC). They further observed
that the transferred CD11b+Gr-1+ cells evenly differentiated into macrophages and DC
in the spleen. The differentiation rate of MDSC was faster at the tumor and CD11b+Gr1+ cells mostly differentiated into tumor associated macrophages (TAM). Moreover, the
differentiation of MDSC at the tumor site was regulated by hypoxia-inducible factor
(HIF) 1α (130). Consistent with these findings, TAM are reported to derive from
Ly6Chigh tumor infiltrating monocytes and the molecular profile of TAM differs
between normoxic and hypoxic tumor areas (165), indicating that it is the M-MDSC
subset that converts to TAM and M-MDSC to TAM conversion is differentially regulated
between distinct anatomical sites.
Other studies have provided further evidence indicating the plasticity of MDSC
population. Youn et al. showed that M-MDSC can differentiate into G-MDSC and this
process is regulated at an epigenetic level (166). MDSC are also shown to form
functional osteoclasts, bone resorbing cells. MDSC-originated osteoclasts contribute to
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osteolysis and facilitate metastasis (167). Furthermore, MDSC can differentiate into
fibrocytes, precursor of myofibroblasts. This differentiation is mediated by the Kruppellike factor 4 (KLF4), a transcription factor important for monocyte differentiation.
MDSC to fibrocyte differentiation is also indicated in facilitating tumor metastasis (168).
The ample evidences towards the plastic nature of MDSC add yet another layer to
the complexity of MDSC-mediated processes. More studies are needed to establish the
mechanisms that drive MDSC down to distinct differentiation pathways. The
identification of factors responsible from inducing MDSC differentiation can prove
valuable in the clinic in two ways. Firstly, M-MDSC differentiation into
immunostimulatory or less suppressive phenotypes, such as DC and G-MDSC,
respectively, can be induced, thereby eliminating the potent suppressor cells in cancer.
Secondly, MDSC differentiation into metastases-promoting phenotypes such as
osteoclasts and fibrocytes can be inhibited.

p53 Pathway and its Relation to Myeloid Cell Differentiation
The molecular pathways underlying MDSC differentiation are far from being
fully characterized. Based on its role in MDSC expansion, STAT3 can be predicted to
involve in inhibition of myeloid cell differentiation. Recently, it is shown that enhanced
activation of STAT3 in MDSC maintains the undifferentiated phenotype by blocking
signaling through protein kinase C βII (PKCβII), a signaling pathway that drives DC
differentiation in precursor cells (169). Another pathway that is involved in inhibition of
myeloid cell differentiation is WNT. The canonical WNT pathway blocks precursor cell
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differentiation into DC and contributes to MDSC expansion by maintaining myeloid cells
in an immature state (170).
In an attempt to delineate the molecular pathways that regulate MDSC related
processes, a recent study analyzed the interactome networks of signaling pathways in
MDSC. The comparative analysis of MDSC in the spleen and at the tumor site versus
their normal counterparts revealed numerous signaling molecules that are enriched in
MDSC. One of these pathways is the p53 pathway. Interactome analyses show that the
components of p53 pathway are enriched both in splenic and tumor site MDSC. Although
the functional contribution of p53 is greater in MDSC at the tumor site than in the spleen
(171).
p53 is most commonly known for its role in the regulation of proliferation,
senescence and apoptosis. However, its roles extend beyond the control of genome
stability. p53 is central to numerous cellular processes including stemness and
differentiation (172). Activation of p53 causes lengthened cell cycles, thereby allowing
the cells to go through differentiation. Thus, long cell cycles are a typical feature of
differentiated cells (172). p53 is activated in response to cellular stress. ROS, RNS and
NO productions are enhanced in tumor-induced chronic inflammatory environments.
These reactive molecules induce p53 activation by either mimicking hypoxic response or
by inducing DNA damage (173). Therefore, it can be argued that in accordance with the
interactome analyses, NO and reactive intermediates at the tumor microenvironment
induce p53 activation. Activated p53 pathway in tumor MDSC may regulate their
differentiation. It is possible that the increased differentiation capacity of MDSC at the

30
tumor site (130) may at least partially be due to the enhanced p53 activity. Further studies
are required to determine the role of p53 in the regulation of MDSC differentiation.

Conclusions and Hypotheses
Prostate inflammation is a common disease and it is associated with the
promotion and progression of prostate cancer. Unfortunately, there is limited knowledge
about the immune regulatory processes involved in prostate inflammation (18). Myeliodderived suppressor cells (MDSC) are among the predominant immune populations that
infiltrate prostate during inflammation (72). MDSC regulate both innate and adaptive
immunity. The hallmark activity of MDSC is to inhibit T cell responses mainly through
the metabolism of L-Arginine (L-Arg). Therefore, MDSC are critical players in benign
inflammation, where they contribute to contraction of immune responses. MDSC also
expand in cancer and inhibit antitumor T cell immunity, thereby promoting tumor
progression (93). Thus, MDSC are a major obstacle to cancer therapy and effective
strategies are needed to eliminate MDSC in cancer.
The central goal of this dissertation is to identify strategies to control MDSC
activity in disease. One strategy to abrogate MDSC activity in cancer is to induce their
differentiation into other cell types. To this end, we propose that identification of the
cellular mechanisms underlying MDSC differentiation will provide tools to control
MDSC phenotype in disease. Another strategy to control MDSC activity is to inhibit their
suppressive function. To this end, we hypothesize that restricting L-Arginine uptake of
MDSC is a critical control point for modulating their immunosuppressive functions. To
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test this hypothesis, we sought to identify the transporters that actively mediate L-Arg
entry into MDSC. We hypothesize that blockade of L-Arg through these transporters will
abrogate MDSC suppressive function, thereby restoring T cell responses in both benign
and tumor-induced inflammation.
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Figure 1.1. Arginine metabolism by MDSC is critical for the regulation of T cells.
The elevated expression and activities of ARG1 and NOS2 are hallmarks of MDSC
suppressor function. Both enzymes use L-Arg as their unique substrate, leading to the
depletion of L-Arginine in the microenvironment. Depletion of L-Arginine, a critical
amino acid for T cell proliferation, causes inhibition of T cell responses. Moreover, the
products of L-Arginine metabolism by NOS2 contributes MDSC-mediated T cell
dysfunction.
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CHAPTER 2. REGULATION OF IMMUNE RESPONSES DURING ACUTE
PROSTATE INFLAMMATION BY P38 MAPK PATHWAY

Abstract
Prostate inflammation, prostatitis, is a prevalent disease. 8-9% of the male
population suffer from prostatitis. Accumulating epidemiological data suggest a
relationship between prostate inflammation and prostate cancer. Therefore, it is important
to identify the underlying mechanisms that regulate inflammation to discover novel
avenues to control the inflammation-related prostate diseases. p38-mitogen activated
protein kinase (MAPK) signaling is known to regulate inflammation by modulating
inflammatory cytokine expression. However, the role of p38-MAPK signaling in
prostatitis is unknown. Using a prostate-specific mouse model (POET-3), we investigated
p38-MAPK pathway-mediated regulation of prostatitis. Treatment of POET-3 mice with
specific inhibitors of p38 and MAPK-activated protein kinase 2 (MK2), a downstream
molecule of p38, revealed that p38-MAPK signaling is a regulator of acute prostate
inflammation. Expression of inflammation related molecules, such as TNF-α, IL-1β,
c/EBPβ, arginase 1 (ARG1) and nitric oxide synthase 2 (NOS2) in the inflamed prostate
tissue was downregulated in the presence of p38 and MK2 inhibitors. Moreover,
inhibition of p38-MAPK pathway led to a decrease in numbers of total infiltrating cells
and myeliod-derived suppressor cells (MDSC) in inflamed prostate, whereas T cell
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numbers were increased. Since MDSC suppress T cell immunity, we hypothesized that
p38-MAPK signaling regulated prostatic inflammation by directly modifying MDSC
function. Data showed that p38-MAPK pathway activity was required for proper MDSC
function. MDSC that were activated in the presence of p38 inhibitor displayed greatly
lower suppressive activity than control MDSC. Overall, our results indicate that p38MAPK pathway is an important regulator of prostate inflammation and p38-MAPK is a
novel signaling pathway that can modulate MDSC suppressive function.

Introduction
Inflammation of the prostate, known as prostatitis, is a common disease. 8.2% of
men are estimated to suffer from prostatitis in their life time (1). This rate goes up to 25%
in case of the elderly population (2). Inflammation is indicated to be an enabling
characteristic of cancer (3). In fact, compelling evidence shows that prostate
inflammation is involved in the initiation and progression of prostate cancer (4-6). The
high prevalence of prostatitis and its strong association to prostate cancer necessitate
development of effective treatment strategies. Identification of underlying cellular
mechanisms that regulate prostatic inflammation is crucial to develop more effective
treatment strategies for prostatitis.
Prostatic inflammation involves numerous inflammatory molecules, such as
cytokines and chemokines, and a variety of immune cells (7). The complex interactions
that exist between these immune components are regulated by either direct cell contact or
by means of signal transducing pathways (8). One of the signaling pathways with
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profound roles in coordinating immune processes is p38-mitogen activated protein kinase
(MAPK) pathway (9). p38-MAPK has been shown to be critical in the production of
numerous inflammatory mediators including pro-inflammatory cytokines tumor necrosis
factor α (TNF-α), interleukin 1 (IL-1) and IL-6 as well as inflammatory enzyme nitric
oxide synthase 2 (NOS2) (10). MAPK-activated protein kinase 2 (MK2) is a downstream
molecule of p38 and its regulation is exclusively mediated by p38 (11). Just like p38,
MK2 is also an important regulator of inflammation (12). The regulation of immunity by
p38-MAPK pathway is considered predominantly pro-inflammatory (13). However,
several studies have indicated that p38 signaling can exert anti-inflammatory functions as
well (14, 15). Due to this dual function of p38, it is necessary to characterize the p38mediated immune regulation in specific diseases. Despite the well-established relevance
of p38 signaling to inflammatory processes, the specific contribution of this pathway to
prostatitis is unknown.
In this study, we investigated the role of p38-MAPK in prostatitis. To this end, we
utilized a murine model of prostate-specific inflammation, the Prostate Ovalbumin
Expressing Transgenic 3 (POET-3). POET-3 mice express membrane bound chicken egg
protein ovalbumin under the control of prostate-specific promoter probasin (16).
Therefore, adoptive transfer of ovalbumin-specific CD8+ T cells (OTI) results in the
induction of prostate-specific inflammation in POET-3 mice (17). In order to study p38mediated regulation of prostate inflammation, we treated inflamed POET-3 mice with
specific inhibitors of p38 and MK2, thereby impairing the p38-MAPK signaling. We
found that inhibition of p38-MAPK pathway dampened the prostatic inflammation in
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POET-3, as evidenced by the decreased numbers of prostate infiltrating immune cells and
downregulated expression of inflammatory molecules in the prostate tissue.
Myeliod-derived suppressor cells (MDSC) are a mixed population of immature
cells that accumulate in inflammatory tissues (18). MDSC are recognized by their
immunosuppressive functions, most notably by the inhibition of T cell responses (19). In
mice, they are identified by the co-expression of cell surface molecules, Gr-1 and CD11b
(19). We identified that MDSC was the predominant immune population that infiltrated
the POET-3 inflamed prostate. Our results also showed that inhibition of p38-MAPK
pathway reduced the MDSC numbers and the expression of NOS2 in the inflamed
prostate. Since MDSC suppressive activity is mainly mediated through the activities of
NOS2 (20), we directly assessed the role of p38 signaling in regulating MDSC
suppressive function. We found that p38-MAPK signaling was required for proper
MDSC suppressive activity. Together, our findings elucidate the mechanisms of p38mediated regulation in prostatitis and identify p38-MAPK signaling as a novel pathway
that controls MDSC suppressive function.

Materials and Methods
Mice
Prostate Ovalbumin Expressing Transgenic (POET-3) mice were generated as described
previously (16, 21). Thy1.1+OTI mice and Rag-/- mice were both purchased from Jackson
Laboratories. Rag-/-Thy1.1+ ovalbumin-specific T cell (OTI) mice were generated by
breeding Thy1.1+OTI mice and Rag-/- mice. Only male mice that were 7-12 weeks of age
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were used for the studies. All animal experiments were approved by the Purdue
University Animal Care and Use Committee.
Animal Models
Prostate inflammation was induced by the intravenous injection of 5x106 48-hour
activated OTI cells into POET-3 mice. Mice were sacrificed 4-5 days after the induction
of inflammation. For the in vivo inhibitor studies, POET-3 mice were injected with p38
inhibitor SB 203508 (Calbiochem), dissolved in DMSO, or MK2 inhibitor, dissolved in
PBS (22). Both inhibitors were administered at 1 mg/kg of mouse. Control mice received
the appropriate vehicle. Inhibitors or the vehicle control were injected intravenously
starting 2 days before the transfer of OTI cells, at the time of OTI transfer and 2 days
after. POET-3 that were used in inhibitor studies were all sacrificed 4 days after the
induction of inflammation.
Cell Isolation and Generation
Cells from prostate glands were obtained by harvesting and pooling anterior, ventral and
dorsolateral lobes of prostates. Prostate lobes were minced by using scissors. Minced
tissues were digested for an hour at 37°C in complete media (RPMI 1640 medium
supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 1 mM
sodium pyruvate) containing Collagenase D (2 mg/ml, Roche Life Science). Bone
marrow was collected from femurs and tibias by flushing the bones with RPMI 1640
medium. Spleens were isolated and ground using frosted slides. Red blood cells were
lysed by using ACK buffer (150 mM NH4Cl, 10 mM KHCO3, 1mM EDTA) and cells
were passed through a 70 µm filter. OTI cells were isolated from the spleens of Rag-/-OTI
mice and activated by culturing in complete RPMI 1640 media containing SIINFEKL (1
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µg/ml, Ova peptide 257-264, American peptide) and 2-ME (55 µM). Activated OTI were
purified by Fico/Lite (Atlanta Biologicals). For in vitro activation of MDSC, CD11b+Gr1+ cells were isolated from bone marrow by FACS and were cultured in complete RPMI
1640 for 3 days with GM-CSF (40 ng/ml), IFN-γ (25 ng/ml) and IL-13 (33 ng/ml,
Peprotech). For the in vitro inhibitor studies, MDSC were treated with 10 µM SB
203580 during the 3 days of activation.
Flow Cytometry
Single cell suspensions were incubated with TruStain fcX (Clone: 93) and stained with
conjugated antibodies. MDSC were labelled with anti-CD11b (Clone: M1/70) and antiGr-1 (Clone: RB6-8C5). T cells were labelled with anti-CD45 (Clone: 30-F11), antiCD8a (Clone: 53-6.7) and anti-CD90.1 (Clone: OX-7). All antibodies were purchased
from BioLegend and used at 2 µg/ml concentration. OTI proliferation was measured
using BrdU Flow Kit (BD Biosciences) according to the manufacturer’s instructions. All
analyses were performed using BD FACSCanto II and data were analyzed using FlowJo
software (Tree Star). All cell sorting was performed using a BD FACSAria III. Sort
purities were determined by flow cytometric analysis of the sorted populations and were
above 95%.
Quantitative Real Time PCR
For analysis of gene expression in the total prostate tissue, all lobes of prostate were
pooled and promptly frozen in liquid nitrogen at harvest. Frozen tissue was ground using
pestal and mortar under liquid nitrogen and was subsequently lysed in TRK lysis buffer
(Omega Bio-tek) and homogenized. For the gene expression analysis of MDSC,
harvested cells were washed and immediately lysed and homogenized. Total RNA was
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isolated using the E.Z.N.A. Total RNA Kit I (Omega Bio-tek) and cDNA synthesis was
performed using qScriptTM cDNA SuperMix (Quanta Biosciences) according to the
manufacturer’s instructions. Multiplex qRT-PCR was performed using PerfeCTa®
FastMix® II (Quanta Biosciences). All qPCR gene probes and endogenous control 18s
rRNA were purchased from Applied Biosystems. Relative mRNA expression was
calculated by the formula 2–[Ct(gene) – Ct(18s rRNA)], where Ct is the threshold cycle value.
MDSC Functional Assays
In vitro-activated MDSC were harvested by gently pipetting the cells up and down,
washed with PBS and co-cultured in 96-well U bottom plates with OTIs (105 cells/well)
preactivated for 8 hours in media containing the cognate antigen SIINFEKL. OTI
proliferation was measured by determining BrdU incorporation after 18 hours. BrdU was
added 6 hours before harvest. BrdU incorporation was measured by flow cytometry. The
percent suppression was calculated as [1-[(proliferation with MDSC)/(proliferation
without MDSC)]x100].
Statistical Analysis
Data are presented as mean ± SEM. Statistical analyses were performed using GraphPad
Prism software. p values were calculated using Student’s t test. Differences were
considered significant where p < 0.05.
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Results
2.4.1

MDSC Are Expanded in POET-3 Mice Upon Induction of Prostate-Specific
Inflammation.
In order to assess if prostate inflammation could be specifically induced in POET-

3 mice, we adoptively transferred activated OTI cells into POET-3 mice. After 5 days, we
isolated the spleens and prostates of the inflamed and control mice and investigated the
presence of CD45+ immune cells. The presence of CD45+ infiltrating immune cells in the
inflamed prostates demonstrated that prostatic inflammation was specifically induced in
POET-3 mice that received activated OTI cells, but not in control mice that were injected
with the vehicle only (Figure 2.1A). The inflamed mice did not display any healthrelated problems at the time of harvest.
We then characterized the immune cells that were infiltrating the inflamed
prostate. Since CD11b+Gr-1+ myeloid cells have been indicated to expand in
inflammatory diseases (23-25), we investigated the presence of CD11b+Gr-1+ cells in the
spleens and prostates of the control and inflamed mice. Data showed that induction of
prostatic inflammation led to a significant increase in CD11b+Gr-1+ cell population both
in the spleens and prostates of the inflamed animals (Figure 2.1B). Importantly, we
found that about 60% of all the immune cells that were recruited to the prostate upon
induction of inflammation was MDSC (Figure 2.1B). These data indicated that MDSC
constitute the main immune population that is recruited to the inflamed prostates in
POET-3 model.
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2.4.2

In Vivo Administration of p38 and MK2 Inhibitors Reduce the Expression of
Inflammatory Molecules at the Inflamed Prostate.
Next, we investigated if p38-MAPK signaling was one of the regulators of

prostatic inflammation. Since in POET-3 model MDSC are the major immune population
in inflamed prostate, we surveyed the alterations in the expression of MDSC-related
inflammatory molecules when p38-MAPK signaling was inhibited. Increased ARG1 and
NOS2 activities are the hallmark of MDSC suppressive function (20) and p38 pathway
has been implicated to modulate expression of key inflammatory enzymes such as NOS2
(26). In addition, TNF-α is one of the key molecules that are known to be regulated by
p38-MAPK signaling (13) and recent studies indicated a role for TNF-α in promoting
MDSC suppressor activities (27, 28). Another molecule that is important for MDSC
biology is IFN-γ (29). Therefore, we investigated the expression Arg1, Nos2, TNF-α and
IFN-γ. To this end, we treated inflamed POET-3 mice with a p38 inhibitor (p38i), SB
203580 (30) (Figure 2.2A). 4 days after the induction of inflammation, we harvested the
prostates and isolated mRNA from the whole prostate tissue. Comparison of gene
expression between the prostates of inflamed animals that received the p38i or the control
vehicle revealed that inhibition of p38 downregulated the expression of all of these
molecules (Figure 2.2B-E). In order to verify that the downregulation of inflammatory
molecule expression in the prostate was indeed due to the p38-MAPK signaling, we
utilized another inhibitor that targeted a p38 downstream molecule, MK2 (22). This time
we surveyed even a wider variety of inflammatory molecules in the prostates of naïve and
inflamed POET-3 that were treated or not treated with MK2i. Comparison of gene
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expression levels revealed that prostatic inflammation induced the expression of
inflammatory molecules and inhibition of p38-MAPK signaling by blocking MK2 could
downregulate the expression levels for all of the investigated molecules (Figure 2.3).
Together, the data suggest that p38-MAPK pathway plays a role in the regulation of
prostatic inflammation.

2.4.3

In Vivo Administration of MK2 Inhibitor Reduces Inflammation-Induced
Polo Like Kinase 1 (Plk1) Expression at the Prostate.
To further confirm that p38-MAPK signaling regulates inflammation during

prostatitis, we evaluated the influence of p38-MAPK signaling on the expression of pololike kinase-1 (Plk1). Plk1 is an important regulator of mitosis (31) and has been
suggested to be a key player in inflammatory processes (32). Pro-inflammatory
cytokines such as TNF-α, IL-6 and IL-1 have been indicated to induce cell proliferation
(33). Based on our results that p38-MAPK signaling regulates expression of these
cytokines, we hypothesized that prostatic inflammation induces Plk1 expression and Plk1
expression is subject to modulation by p38-MAPK signaling. To test this hypothesis, we
inflamed POET-3 animals and measured Plk1 gene expression in the normal and
inflamed prostate. Data showed that inflammation induced Plk1 expression in the prostate
(Figure 2.4). In vivo administration of MK2 inhibitor reversed the induction of Plk1 in
the inflamed prostates (Figure 2.4), further indicating the involvement of p38-MAPK
pathway in the regulation of prostatitis.
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2.4.4

Inhibition of p38 and MK2 In Vivo Modulate Infiltrating Immune
Populations at the Inflamed Prostate.

Next, we asked whether p38-MAPK-mediated changes during prostatitis modify
the composition of infiltrating immune populations at the inflamed prostate. To this end,
we induced prostatitis in POET-3. After 4 days, we analyzed the numbers of immune
cells at the prostates of mice that received either the control vehicle or the MK2 inhibitor.
Data showed that number of total infiltrating immune cells were significantly lower in
MK2i treated mice (Figure 2.5A), suggesting that inhibition of p38-MAPK pathway
reduces prostatic inflammation. Since MDSC are the predominant population during the
acute phase of prostate inflammation in POET-3 (Figure 2.1B), we investigated the
MDSC numbers in the inflamed prostates. As seen in CD45+ population, when p38MAPK pathway was inhibited, MDSC numbers at the prostate decreased (Figure 2.5B).
Since MDSC can suppress T cell proliferation (20), we wondered if the number of OTI
cells would be increased when MK2 was inhibited. Adoptively transferred OTI cells
express Thy1.1 congenic marker. Using this marker we identified OTI cell numbers at the
prostate. Inhibition of MK2 yielded a greater OTI population (Figure 2.5C). Given the
reduced MDSC numbers at the prostate upon inhibition of p38-MAPK signaling, it is
expected that the MDSC-mediated suppression of OTI cells is lessened, thereby resulting
in higher OTI numbers.
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2.4.5

Inhibition of p38 Modulates NOS2 Expression in MDSC.

Elevated OTI and reduced MDSC numbers together with the decreased
expression of Arg1 and Nos2 in the prostate upon inhibition of p38 and MK2 strongly
suggested that MDSC function might be directly regulated by p38-MAPK pathway.
Therefore, we investigated the role of p38-MAPK signaling in MDSC suppressor
function. To this end, we utilized an in vitro system in which non-suppressive
CD11b+Gr-1+ cells of the bone marrow gain suppressor activity when cultured with GMCSF, IL-13 and IFN-γ. We cultured bone marrow CD11b+Gr-1+ cells with activating
cytokines in the presence or absence of p38 inhibitor and evaluated Arg1 and Nos2
expression. As expected, cytokine cocktail induced expression of Arg1 and Nos2 in
MDSC. Inhibition of p38 resulted in significantly lower levels of Nos2 expression in
MDSC (Figure 2.6B). Although the difference was not statistically significant, Arg1 also
trended towards reduced expression when p38 was inhibited (Figure 2.6A).
Inhibition of p38 is reported to reduce L-Arginine uptake in activated
macrophages (34). Since L-Arg metabolism is crucial for MDSC suppressive function
(20), we evaluated p38-mediated regulation of L-Arg uptake in MDSC. Cationic amino
acid transporter 2 (CAT2) is the main L-Arg carrier in activated macrophages (35).
Therefore, we reasoned that CAT2 might also be important in L-Arg transportation in
MDSC. We measured Cat2 expression levels in MDSC that were in vitro activated in the
presence or absence of p38 inhibitor. Data showed that Cat2 expression was induced in
MDSC upon activation of suppressive function, suggesting that CAT2 might indeed be
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functional in MDSC (Figure 2.6C). However, induction of Cat2 expression in MDSC
was independent of p38-MAPK signaling (Figure 2.6C).

2.4.6

p38-MAPK Signaling Is Necessary for MDSC Suppressive Activity.

Since NOS2 activity is critical for MDSC suppressor function (20) and p38
signaling regulates NOS2, we evaluated the role p38-MAPK signaling in the regulation
of MDSC function. To this end, we activated bone marrow CD11b+Gr-1+ cells in vitro in
the presence or absence of p38 inhibitor and measured the suppressive activity of MDSC.
We assessed the suppressive activity by measuring the proliferation of T cells that were
cultured with MDSC. In order to avoid potential effects of p38 signaling on T cell
proliferation, we harvested and washed MDSC before using in an 18-hour suppression
assay. Since p38 inhibitor was not supplied in the suppression assay, it is possible that the
inhibitory effects of p38i treatment could be reversed by time. Therefore, we chose to
perform a short-term assay to capture p38-mediated effects on MDSC suppressive
function. Data showed that MDSC in which p38 was inhibited had greatly reduced
suppressive function (Figure 2.7), indicating that p38-MAPK signaling in MDSC is
required to maintain suppressive capacity.
Together, our results show that p38-MAPK signaling regulates prostatic
inflammation by altering the expression of inflammatory molecules and the composition
of infiltrating immune population at the prostate. Moreover, we identify p38-MAPK as a
novel pathway that controls MDSC suppressor activity.
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Discussion
p38-MAPK signal transduction pathway is one of the key modulators of
inflammatory processes (13). Due to the anti-inflammatory effects of p38 inhibitors, p38MAPK signaling is commonly recognized for its pro-inflammatory functions (10).
However, recent studies have indicated that p38-MAPK pathway is also capable of
exerting anti-inflammatory functions (14, 15, 36). Importantly, findings from these
studies demonstrated that p38-MAPK signaling mediates its effects in a cell type specific
manner, emphasizing the complexity of regulation by this pathway. In this current study,
we aimed to identify the mechanisms through which p38-MAPK signaling modulates
prostatitis.
Our results revealed that p38-MAPK signaling regulates prostate inflammation by
controlling the expression of both pro-inflammatory, such as TNF-α and IL-1β, and antiinflammatory molecules, such as IL-4 and IFN-α. In addition, the numbers of immune
cells recruited to the prostate upon induction of inflammation was also under the
influence of p38-MAPK pathway. When MK2 was inhibited, we detected a decrease in
total infiltrating immune cell numbers, suggesting that blockade of signaling through
p38-MAPK pathway can dampen prostatic inflammation. A closer examination on
immune populations revealed that when MK2 was inhibited, MDSC numbers were also
decreased as well as the expression levels of Arg1 and Nos2 in the total prostate tissue.
Haverkamp et al. reported that MDSC at the inflamed prostate could regulate T cell
functions (37). They demonstrated that when MDSC were depleted in mice with prostate
inflammation, the density of OTI population at the prostate was doubled (37).
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Accordingly, in response to the decrease in MDSC population when MK2 was inhibited,
we observed that the OTI numbers were higher. These observations suggest that blockade
of p38-MAPK pathway regulates prostate inflammation by diminishing MDSC
population, thereby impairing the MDSC-mediated OTI suppression. Interestingly, IFN-γ
gene expression levels in the prostate were also lowered upon inhibition of p38. IFN-γ
secretion by T cells is an indicator of T cell activity (38). Hence, if blockade of p38MAPK signaling reduced MDSC-mediated T cell suppression, we should have seen
increased IFN-γ expression. One explanation for this conflicting result might be that
while T cells can be recruited to the inflamed prostate and expand there in the presence of
the inhibitor, the production of IFN-γ by T cells depends on p38 kinase. Another
explanation may be that we measured IFN-γ expression in the total prostate tissue and
that IFN-γ expression is not unique to CD8+ cytotoxic T cells (39). It is possible that a
potential increase in the IFN-γ expression by OTI cells was not reflected in the total
prostate tissue if the decrease in expression in other cell types was greater than the
increase in OTI cells. As reported, effects of p38-MAPK pathway is cell type specific
(14). To address this problem additional studies will be needed to test whether IFN-γ
expression in OTI cells isolated from the inflamed prostates is impaired by the p38
inhibitor. Moreover, the activity of isolated OTI cells can also be evaluated, for instance
by measuring their cytotoxic activity in vitro. In fact, it is very important to investigate
the role of p38-MAPK pathway in each cell type individually. Our finding that Arg1 and
Nos2 expression were lowered in the prostate upon inhibition of p38 prompted us to more
directly elucidate the role of p38 signaling in MDSC suppressive function. Interestingly,
when we blocked p38 specifically in MDSC, Arg1 expression was not significantly
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affected. This observation supports the notion of cell type specific regulation of
inflammatory processes by p38-MAPK pathway.
Our results demonstrate the critical role of p38-MAPK pathway in the regulation
of MDSC suppressive function. When p38 was inactivated, MDSC were not able to
inhibit T cell proliferation. There are few studies focusing on p38 activity in MDSC.
Therefore, the role of p38-MAPK pathway in regulating MDSC biology is far from being
clearly understood. Mass spectrometry analysis in an earlier study reported that
inflammatory environments increased the expression of p38-MAPK pathway in MDSC,
where p38 pathway increased the survival of MDSC by enabling MDSC to resist Fasmediated apoptosis (40). A recent study demonstrated that transmembrane (tm)-TNF-α
increased the T cell inhibitory activity of splenic MDSC and the tm-TNF-α induced
MDSC activity could be reversed by the inhibition of p38 (27). Although this study
suggested a role for p38 to regulate MDSC function, they did not investigate the effects
of p38 blockade on MDSC that were not induced by tm-TNF-α. Our findings provide
insight regarding the molecular characterization of p38-mediated MDSC function. Since
NOS2 is a key mediator of MDSC suppressive activity (20) and Nos2 expression is
downregulated upon inhibition of p38, our data suggest that p38-MAPK pathway regulate
MDSC suppressive activity by controlling Nos2 expression. NOS2 uses L-Arginine to
mediate its immunosuppressive activities (20). L-Arginine uptake in activated
macrophages was shown to be impaired in the absence of p38 signaling (34). Therefore,
we considered that the control of L-Arginine transportation by p38-MAPK pathway
could be another mechanism through which p38 regulated MDSC suppressive function.
Transportation through the inducible transporter CAT2 alone sufficiently meets the
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elevated L-Arginine requirement in activated macrophages (35). CAT2 is indirectly
indicated to be mediating L-Arginine uptake in MDSC (41). Hence, we investigated if
induction of CAT2 expression was modulated by p38 pathway. Data showed that CAT2
expression in MDSC was independent of p38 signaling. Although this finding imply a
lack of p38-mediated L-Arginine uptake regulation in MDSC, to reach this conclusion we
need to directly measure L-Arginine uptake in MDSC in the presence and absence of p38
signaling. There are multiple transporters in cells that can import L-Arginine (42). The
mechanism of L-Arginine transport in MSDC is unknown. It is possible that transporters
other than CAT2 have active roles in L-Arginine entry into MDSC and that L-Arginine
transport through these transporters are subject to regulation by p38 pathway.
Our findings also suggest that modulation of Plk1 expression may be another
mechanism through which p38 signaling regulates prostatitis. Inflammation can induce
cell proliferation (33) and as a major regulator of mitosis, Plk1 is discussed to be a key
player in inflammatory processes (32). In support of this view, upon induction of
inflammation through Toll-like receptor activation, Plk1 has been reported to modulate
expression of several inflammatory molecules such as TNF-α, a molecule whose
expression is known to be regulated by p38 signaling (43). In addition, inhibition of p38MAPK signaling results in mitotic arrest (44), in fact MK2 has been shown to directly
interact with Plk1 and modulate its function (32). Based on these existing information we
hypothesized that Plk1 was a target to regulation by p38-MAPK pathway. Indeed data
showed that prostate inflammation induced Plk1 and this induction was reversed when
MK2 was inhibited.
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In summary, this study indicates a role of p38-MAPK pathway in the regulation
of inflammation during prostatitis. Additionally, we identify p38-MAPK transduction
signaling as a novel pathway that is required for MDSC suppressive activity. Therefore,
our findings suggest that regulation of MDSC function in disease is another avenue for
drugs targeting p38 signaling to be utilized.
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Figure 2.1. MDSC expand during prostatitis.
POET-3 mice were injected with 5x106 activated OTI cells to induce prostate
inflammation. 5 days later, spleens and prostates were collected from inflamed mice and
naïve control mice (n=3/group) and percentages of (A) CD45+ (under SSC/FSC gate) and
(B) CD11b+Gr-1+ (under CD45+ gate) populations were determined by flow cytometry.
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Figure 2.2. p38 inhibition in vivo reduces expression of inflammatory molecules at
the inflamed prostates.
5x106 activated OTI cells were transferred into POET-3 mice to induce prostate
inflammation. p38 inhibitor was administered every 2 days starting 2 days before the
induction of inflammation (A). 4 days later prostates were collected and mRNA was
freshly isolated from total prostate tissue. Gene expression of Arg1 (B), Nos2 (C), TNF-α
(D) and IFN-γ (E) were analyzed by qPCR. n=3 mice/group, pooled. Data are
representative of at least 3 independently repeated experiments.

74

Figure 2.3. MK2 inhibition in vivo reduces expression of inflammatory molecules at
inflamed prostates.
5x106 activated OTI cells were transferred into POET-3 mice to induce prostate
inflammation. MK2 inhibitor was administered every 2 days starting 2 days before the
induction of inflammation. 4 days later prostates were collected and mRNA was freshly
isolated from total prostate tissue. Gene expression of Arg1 (A), Nos2 (B), c/EBPβ (C),
IFN-α (D), TNF-α (E), IL-1β (F), IL-6 (G) and IL-4 (H) were analyzed by qPCR. n=3
mice/group. Data are representative of at least 3 independently repeated experiments.
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Figure 2.4. MK2 inhibition in vivo downregulates induction of Plk1expression at the
inflamed prostates.
5x106 activated OTI cells were transferred into POET-3 mice to induce prostate
inflammation. Naïve control mice were injected with vehicle only (PBS). MK2 inhibitor
was administered every 2 days starting 2 days before the induction of inflammation. 4
days later prostates were collected and mRNA was freshly isolated from total prostate
tissue. Gene expression of Plk1 was analyzed by qPCR. n=2 mice/group. Experiment was
performed once. Error bars indicate ±SEM.
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Figure 2.5. MK2 inhibition in vivo modifies the numbers of prostate infiltrating
immune cells.
5x106 activated OTI cells were transferred into POET-3 mice to induce prostate
inflammation. MK2 inhibitor was administered every 2 days starting 2 days before the
induction of inflammation (A). 4 days later spleens and prostates were collected and
CD45+ (* p= 0.0122) (A), CD45+CD11b+Gr-1+ (* p= 0.0231) (B) and
CD45+CD8+Thy1.1+ (* p= 0.1341) (C) populations were analyzed by flow cytometry.
Cell numbers for each population are indicated per 106 events. n=2-3 mice/group. Similar
results were reproduced at least in 2 independent experiments. Error bars indicate ±SEM.
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Figure 2.6. Effects of p38-MAPK signaling in MDSC gene expression.
CD11b+Gr-1+ cells were isolated from the bone marrow of naïve mice (n=3) and cultured
for 3 days with GM-CSF, IFN-γ and IL-13 in the absence or presence of p38 inhibitor SB
203580. At the end of culture, mRNA was isolated and analyzed by qPCR for Arg1 (A),
Nos2 (B) and Cat2 (C) expression. Data are representative of 3 independent experiments.
Error bars indicate ±SEM.
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Figure 2.7. p38-MAPK signaling is required for MDSC-mediated T cell suppression.
CD11b+Gr-1+ cells were isolated from the bone marrow of naïve mice (n=3) and cultured
with GM-CSF, IFN-γ and IL-13 in the absence or presence of p38 inhibitor SB 203580.
After 3 days, cells were harvested, washed and co-cultured with pre-activated OTI cells
at differing cell number ratios. OTI proliferation was measured by the detection of BrdU
incorporation. BrdU was added to culture 6 hours before harvest. Experiment is
representative of at least 2 independently repeated experiments.
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CHAPTER 3. REGULATION OF ACUTE PROSTATE INFLAMMATION BY
MYELOID-DERIVED SUPPRESSOR CELLS (MDSC) AND THE ROLE OF
CATIONIC AMINO ACID TRANSPORTER 2 IN MODULATING MDSC
FUNCTION

Abstract
Myeliod-derived suppressor cells (MDSC) are a heterogeneous population of
immature cells that expand during inflammation. MDSC negatively regulate innate and
adaptive immune responses, majorly through the metabolism of L-Arginine. Although
MDSC activity has been well characterized in cancer-induced chronic inflammation, their
role in acute inflammation and the factors regulating their activity are not clear.
Therefore, we aimed to identify the regulation MDSC function in benign inflammation.
Using a prostate-specific inflammation model, we showed that MDSC are expanded in
the spleen and prostate of inflamed animals. MDSC constitute the dominant population
that infiltrates the prostate during acute inflammation. MDSC at the prostate, but not at
the spleen, regulate immune responses by inhibiting T cell activity. Comparative analysis
between precursor MDSC at spleen and functional MDSC at the inflamed prostate
revealed that the expression of cationic amino acid transporter 2 (Cat2), an inducible
transporter of L-Arginine, is significantly induced in the prostate MDSC. Functional
analysis demonstrated that CAT2 is required for MDSC suppressive activity. The ability
of prostate MDSC to inhibit T cells ex vivo is greatly reduced in the absence of CAT2. In
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vivo, CAT2-ablated MDSC display impaired functions as evidenced by increased T cell
expansion and greater IFN-γ production by T cells. Together, our results indicate that
MDSC are an essential component in the regulation of prostate inflammation and MDSC
function can depend upon the expression of CAT2.

Introduction
Inflammation of the prostate, prostatitis, is a very common prostatic disease.
Epidemiological studies identified the overall prevalence rate of prostatitis as 8.2% (1)
and the prevalence rate was found to be as high as 25% among the elderly population (2).
Importantly, prostatitis is linked to the incidence and progression of benign prostate
hyperplasia (BPH) and prostate cancer (3, 4). The most common form of prostatitis is the
chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), comprising the 90% of
prostatitis cases (5). T cell specific autoimmune responses against prostate specific
antigens are an important component in the etiology of CP/CPPS (6). Therefore,
understanding the autoimmune-induced prostatic inflammatory processes and their
regulation are critical to identify control points to dampen inflammation.
Myeliod-derived suppressor cells (MDSC) are a population of immature myeloid
cells that expand both in humans and mice during pathological conditions such as cancer,
infection and inflammation (7). MDSC are a highly heterogeneous group of myeloid cells
including immature macrophages, dendritic cells, granulocytes and other myeloid
precursors. In mice, they are identified by the co-expression of cell surface molecules Gr1 and CD11b (8). Functionally, MDSC negatively regulate innate and adaptive immune
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responses. MDSC are characterized most notably by their ability to suppress T cell
immunity (7). The hallmark mechanism through which MDSC exert their suppressive
function is the metabolism of L-Arginine (L-Arg). In MDSC the expression and the
activities of Arginase1 (ARG1) and inducible nitric oxide synthase (NOS2) are greatly
elevated. Both of these enzymes use L-Arginine as their unique substrate and produce
metabolites that contribute to the inhibition of T cell responses (9).
MDSC-mediated T cell suppression has detrimental effects in cancer patients.
MDSC inhibit antitumor T cell immunity and are demonstrated to correlate with
increased tumor progression and metastasis accompanied by decreased patient survival
(10, 11). Despite their deleterious effects in the context of tumor, MDSC may play
beneficial roles in autoimmune diseases. It is possible that by limiting T cell-mediated
inflammation, MDSC can ameliorate autoimmune diseases. Although most of the
existing data about MDSC are obtained from animal models of cancer and cancer
patients, there is accumulating evidence highlighting the importance of MDSC in
autoimmunity. MDSC are shown to expand in the spleen and the diseased tissue of mice
with autoimmune diseases including collagen-induced arthritis (12), experimental
autoimmune encephalomyelitis (13) and colitis (14). Ex vivo evaluations of MDSC in all
these models indicate that autoimmune disease-induced MDSC possess the capacity to
inhibit T cell activity. The direct participation of MDSC in the regulation of autoimmune
disease pathology in vivo has also been described. Adoptive transfer of MDSC was
shown to ameliorate the disease in several autoimmunity models including arthritis (12),
myasthenia gravis (15) and inflammatory bowel disease (16). Together these studies
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indicate the contribution of MDSC in the pathogenesis of autoimmune diseases.
However, the role of MDSC in prostatitis remains to be elucidated.
In the present study, we investigated the role of MDSC in controlling autoimmune
originated prostatitis. We hypothesized that MDSC are recruited to prostate upon
induction of prostatic inflammation and serve as an important component to regulate
inflammatory processes by inhibiting T cell responses. To test this hypothesis, we utilized
the prostate specific inflammation mouse model, the Prostate Ovalbumin Expressing
Transgenic 3 (POET-3). POET-3 mice express ovalbumin protein in prostate cells (17)
and hence adoptive transfer of ovalbumin-specific CD8+ T cells (OTI) induce prostate
specific inflammation in POET-3 mice (18). Using POET-3 model, we demonstrated that
MDSC constitute the main population of immune cells that infiltrate prostate upon
induction of prostatitis. MDSC recruited to the inflamed prostate, but not to the other
distal sites such as spleen, possess the ability to inhibit T cell proliferation, suggesting a
role for MDSC in the regulation of T cell responses during prostatic inflammation.
To demonstrate if MDSC indeed regulate T cell immunity at prostatitis in vivo,
we sought to block the suppressive function of MDSC and evaluate the T cell response.
Elevated activities of ARG1 and NOS2 are the hallmark of MDSC suppressor function
(9). Both enzymes use L-Arginine (L-Arg) as their unique substrate (9). Hence, we
hypothesized that blocking L-Arg uptake in MDSC would reduce the suppressive
capacity since L-Arg is required for the activities of ARG1 and NOS2 (9). The
mechanism through which L-Arginine enters into MDSC and the importance of this
process for the suppressor activity are not known. Among the various transporters of LArginine in cells, cationic amino acid transporter 2 (CAT2), an inducible transporter of
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L-Arg, is known to supply sufficient amounts of L-Arg in a rapid fashion to meet
functional requirements (19). Importantly, studies showed that CAT2 is induced in
macrophages upon activation and that L-Arg transport through CAT2 is required for
NOS2 activity (20). Therefore, we investigated if the expression of Cat2 in MDSC is
upregulated upon induction of prostatitis. We observed that Cat2 expression is induced
only in MDSC at the prostate, but not at spleen. In addition, by utilizing Cat2-/- POET-3
mice we showed that CAT2 regulates MDSC suppressive activity. Cat2-/- MDSC
possessed reduced suppressive activity ex vivo and displayed diminish capacity to control
T cell responses in vivo.
Altogether, our observations identify MDSC as an endogenous regulatory
mechanism controlling the T cell responses in autoimmune originated prostate
inflammation. CAT2 plays an important role in the regulation of MDSC function and it is
required for MDSC-mediated T cell regulation in prostatitis.

Materials and Methods
Mice
Prostate Ovalbumin Expressing Transgenic (POET-3) and Cat2-/- mice were generated as
described previously (17, 20). Cat2-/-POET-3 mice were generated by breeding Cat2-/and POET-3 mice. Rag-/-Thy1.1+ ovalbumin-specific T cell (OTI) mice were generated
by breeding Thy1.1+OTI mice and Rag-/- mice, both purchased from Jackson
Laboratories. Only male mice aged 7-12 weeks were used for the studies. All animal
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experiments for this study were approved by the Purdue University Animal Care and Use
Committee.
Animal Models
Prostate inflammation was induced by the intravenous injection of 5x106 48-hour
activated OTI cells into POET-3 or Cat2-/-POET-3 mice. Mice were sacrificed 5 days
after the induction of inflammation. For the adoptive transfer studies, 2 days-inflamed
mice were injected intraperitoneally with 4x106 MDSC generated by culturing bone
marrow cells with GM-CSF (40 ng/ml) and IL-6 (40 ng/ml) (purchased from Peprotech)
for 5 days.
Cell Isolation and Generation
Spleens were harvested and ground using frosted slides. Cells from prostate glands were
obtained by harvesting and pooling anterior, ventral and dorsolateral lobes of prostates
and minced tissues were digested for an hour at 37°C in media containing Collagenase D
(2 mg/ml, Roche Life Science). Bone marrow was collected by flushing femurs and
tibias. Red blood cells were lysed by using ACK buffer (150 mM NH4Cl, 10 mM
KHCO3, 1mM EDTA) and cells were passed through a 70 µm filter. OTI cells were
isolated from the spleens of Rag-/-OTI mice and activated by culturing in RPMI 1640
media containing SIINFEKL (1 µg/ml, Ova peptide 257-264, American peptide) and 2ME (55 µM). Activated OTI were purified by Fico/Lite (Atlanta Biologicals).
Flow Cytometry
Single cell suspensions were incubated with TruStain fcX (Clone: 93) and stained with
conjugated antibodies. MDSC were labelled with anti-CD11b (Clone: M1/70) and antiGr-1 (Clone: RB6-8C5). T cells were labelled with anti-CD45 (Clone: 30-F11), anti-
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CD8a (Clone: 53-6.7) and anti-CD90.1 (Clone: OX-7). To measure IFN-γ production by
OTI, cells were cultured for 6-8 hours in the presence of SIINFEKL and Golgi Stop (BD
Biosciences). After staining for surface antigens, cells were prepared for intracellular
staining using the CytoFix/CytoPermTM kit (BD Biosciences) and stained with anti-IFNγ (Clone: XMG1.2). All antibodies were purchased from BioLegend and used at 2 µg/ml
concentration. OTI proliferation was measured using BrdU Flow Kit (BD Biosciences)
according to the manufacturer’s instructions. All analyses were performed using BD
FACSCanto II and data were analyzed using FlowJo software (Tree Star). All cell sorting
was performed using a BD FACSAria III. Sort purities were above 95%.
Quantitative Real Time PCR
Total RNA was isolated from freshly sorted cells using the E.Z.N.A. Total RNA Kit I
(Omega Bio-tek) and cDNA synthesis was performed using qScriptTM cDNA SuperMix
(Quanta Biosciences) according to the manufacturer’s instructions. Multiplex qRT-PCR
was performed using PerfeCTa® FastMix® II (Quanta Biosciences), PrimeTime® qPCR
gene probes (IDT): Arg1 (Mm.PT.58.8651372), Nos2 (Mm.PT.58.43705194), Slc7a2
(Cat2) (Mm.PT.58.28825099) and endogenous control 18s rRNA (Applied Biosystems).
Relative mRNA expression was calculated by the formula 2–[Ct(gene) – Ct(18s rRNA)], where Ct
is the threshold cycle value.
MDSC Functional Assays
Sorted MDSC were co-cultured in 96-well U bottom plates with OTIs (105 cells/well)
preactivated for 8 hours in media containing the cognate antigen SIINFEKL. OTI
proliferation was measured by determining BrdU incorporation after 48 hours. BrdU was
added 6 hours before harvest. BrdU incorporation was measured by flow cytometry. The
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percent suppression was calculated as [1-[(proliferation with MDSC)/(proliferation
without MDSC)]x100]. IFN-γ production was measured by intracellular IFN-γ staining
for flow cytometry.
Histology Analysis
Anterior, ventral, dorsal and lateral lobes of prostates were fixed in 10% neutral-buffered
formalin for 24 hours. Fixed samples were processed, embedded in paraffin and sectioned
for hematoxylin and eosin (H&E) staining by Purdue Histology & Phenotyping
Laboratory. H&E stained slides were scored for histological inflammation by a board
certified veterinary pathologist, Grant N Burcham, based on the criteria that 0 was no
inflammation, 1 was mild (10% tissue involvement), 2 was moderate (10% to 50% tissue
involvement) and 3 was marked inflammation (more than 50% tissue involvement) (21).
Statistical Analysis
Data are presented as mean ± SEM. Statistical analyses were performed using GraphPad
Prism software. p values were calculated using Student’s t test. Differences were
considered significant where p < 0.05.

Results
3.4.1

MDSC Are Expanded During Acute Prostate Inflammation.

Adoptive transfer of OTI cells into POET-3 mice specifically induce prostatic
inflammation (Figure 2.1A). Moreover, autoimmune-originated prostatic inflammation
in POET-3 mice induces the expansion of CD11b+Gr-1+ population both in the spleen
and the prostates. At 60% of the total infiltrating immune cells, MDSC constitute the
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main immune population that is recruited to the inflamed prostates during acute prostate
inflammation (Figure 2.1B).

3.4.2

The Immediate Capacity to Suppress T Cells Is Restricted to MDSC at the
Inflammatory Site.
Next, we investigated the functional status of CD11b+Gr-1+ cells that expanded in

the spleens and prostates of the diseased animals. MDSC are identified by their
suppressor function that is most commonly defined as their capacity to inhibit T cell
proliferation. Therefore, to assess the suppressor capacity of CD11b+Gr-1+ cells that are
recruited to the spleen and prostate, we utilized a suppression assay in which we isolated
CD11b+Gr-1+ cells from inflamed animals and co-cultured with OTI cells at differing
ratios. After 48 hours of culture, we determined the MDSC suppressor activity by
measuring the OTI proliferation. Results showed that MDSC at the prostate were able to
inhibit OTI proliferation (Figure 3.1A). In addition, the suppressive capacity of
CD11b+Gr-1+ cells isolated from the prostate was much greater than their spleen
counterparts. In fact, at a 0.5:1 (MDSC:OTI) ratio, we were unable to detect any
suppressor activity by CD11b+Gr-1+ cells at the spleen (Figure 3.1A). These data
underlined the importance of the relationship between the anatomical location of
CD11b+Gr-1+ cells and their suppressor function such that the ability to inhibit T cell
responses was limited to the MDSC that reside at the inflammatory site, but not at the
peripheral sites.
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To further demonstrate that the suppressive activity is limited to the MDSC at the
inflammatory site, we investigated the Arg1 and Nos2 expression in CD11b+Gr-1+ cells
isolated from the spleens and prostates of inflamed animals. Overexpression of ARG1
and NOS2 are well characterized as the hallmark of MDSC suppressor function (7).
Therefore, we reasoned that MDSC with the suppressor activity must possess greater
expression of Arg1 and Nos2. Indeed, comparative gene expression analysis of
CD11b+Gr-1+ cells that were freshly isolated from the spleens and prostates of inflamed
POET-3 revealed that Arg1 and Nos2 expression was greatly induced in MDSC at the
prostate (Figure 3.1B). Together, our results indicate that MDSC that are recruited to the
inflamed prostate have the ability to inhibit T cell responses, suggesting that MDSC
might have a role in the regulation of prostatitis.

3.4.3

CAT2 Regulates MDSC Suppressive Function.

Our data strongly suggested that MDSC are a critical component that regulates
inflammation during prostatitis by inhibiting T cells responses. Therefore, we
hypothesized that T cell responses in prostatitis can be controlled by modulating MDSC
function. To this end, we investigated the mechanisms that control MDSC suppressor
activity. We reasoned that in MDSC the excessive metabolism of L-Arg should
necessitate the increased uptake of this amino acid from the microenvironment and that
L-Arg uptake is required for MDSC to exhibit suppressor activity. To this end, we
wondered if CAT2 played a role in L-Arg transportation in MDSC. We investigated if
Cat2 expression was induced in MDSC with the suppressor function. Comparative gene
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expression analysis revealed that in POET-3 model Cat2 expression was induced in
MDSC at the inflamed prostate but not at the spleen (Figure 3.2A). Since Cat2
expression was only induced CD11b+Gr-1+ cells that possess suppressive activity, we
asked if CAT2 was related to MDSC function. To evaluate the role of CAT2 as a
modulator of MDSC suppressor capacity, we bred POET-3 mice with CAT2-/- mice.
Similar to POET-3, CD11b+Gr-1+ cells accumulated in the spleens and prostates of
CAT2-/-POET-3 mice upon the induction of prostatitis. We isolated CD11b+Gr-1+ cells
from the prostates of inflamed POET-3 and CAT2-/-POET-3 mice and compared their
suppressive capacity. Data showed that MDSC that lacked CAT2 had greatly reduced
suppressor capacity compared to intact MDSC (Figure 3.2B), indicating that CAT2
modulates MDSC suppressor activity in prostatitis.

3.4.4

POET-3 Mice Have More Severe Prostatic Inflammation in the Absence of
CAT2.
We then hypothesized that CAT2-/-POET-3 prostates should have more severe

inflammation since the regulatory control of prostatitis provided by MDSC is reduced in
the absence of CAT2. To this end, we harvested the different lobes of the prostates from
inflamed POET-3 and CAT2-/-POET-3 mice and performed histological analysis. All
lobes from the same mouse; anterior, ventral and dorso-lateral, displayed comparable
levels of inflammatory infiltrates. We evaluated the extent of histological inflammation in
POET-3 and CAT2-/-POET-3 prostates. Histological grading indicated that CAT2-/POET-3 prostates had a higher inflammation score than POET-3 prostates (Figure 3.3).
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3.4.5

In the Absence of CAT2 MDSC-Mediated Control of T Cell Immunity In
Vivo Is Impaired.
Next we investigated if CAT2-mediated MDSC function has a direct role in the

regulation of prostatic inflammation in vivo. Since MDSC that lack CAT2 have lower
capacity to inhibit T cell responses, we hypothesized that the T cell populations in the
prostates of inflamed CAT2-/-POET-3 mice are enlarged. To test this hypothesis, we
measured the OTI numbers in the spleens and prostates of inflamed POET-3 and CAT2-/POET-3. The adoptively transferred OTI cells express Thy1.1. Using this congenic
marker we monitored the OTI populations and found that CAT2-/-POET-3 prostates had
significantly higher numbers of OTI cells compared to POET-3 prostates. OTI population
in the spleens were comparable between the two colonies.
In order to ensure that the increase in OTI population in the prostates of CAT2-/(KO) POET-3 is due to the loss of MDSC regulatory functions, we adoptively transferred
wild type (WT) MDSC into KO POET-3. We hypothesized that the transfer of WT
MDSC would rescue the phenotype that we observed in the KO POET-3. It is previously
described that CD11b+Gr-1+ population can be expanded in vitro by culturing bone
marrow cells with granulocyte-macrophage colony-stimulating factor (GM-CSF) and
interleukin 6 (IL-6) (22, 23). We isolated the bone marrow cells from CAT2+/+ (WT) and
CAT2-/- (KO) mice and cultured in the presence of GM-CSF and IL-6 for 5 days. Then
we adoptively transferred these in vitro generated CD11b+Gr-1+ cells into inflamed mice.
WT POET-3 received WT cells and KO POET-3 received either KO or WT cells (Figure
3.4A). We observed that the OTI population in the CAT2-/-POET-3 prostates was
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significantly greater than in the POET-3 prostates. Importantly, this phenotype could
partially be rescued by the adoptive transfer of WT CD11b+Gr-1+ cells into CAT2-/POET-3 mice (Figure 3.4B). Only the MDSC at prostate but not at the spleen have
suppressor activity (Figure 3.1). Therefore the CD11b+Gr-1+ cells in spleen should not
regulate T cells. Accordingly, our results showed that OTI populations in the spleens of
WT and KO POET-3 were comparable (Figure 3.4C). In addition we measured the
interferon gamma (IFN-γ) secretion by T cells in WT and KO POET-3. Once activated
CD8+ T cells produce IFN-γ (24), therefore IFN-γ levels can be used as an indicator of T
cell activity. As expected, we observed that OTIs in the KO POET-3 prostate trend
towards greater IFN-γ production compared to WT POET-3 (Figure 3.4D), while OTIs
in the spleen produced similar IFN-γ levels in both WT and KO POET-3 (Figure 3.4E).
These observations altogether suggested a regulatory role to MDSC in
autoimmune originated prostatitis and identified CAT2 as an important mediator of
MDSC suppressor function.

Discussion
Myeliod-derived suppressor cell biology and their role in disease are well studied
in the context of tumor. However, their role is not fully evaluated in autoimmunity.
Although recent studies provide compelling evidence pointing the importance of MDSC
in the regulation of autoimmune diseases (12-16, 25), the role of MDSC in prostatitis
remains to be elucidated. Therefore we initiated studies to define the role of MDSC in the
regulation of prostate inflammation. To this end, we utilized a prostate specific
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inflammation model, POET-3. In POET-3, prostate inflammation is initiated when
ovalbumin (ova)-specific T cells recognize ova that is specifically expressed in the
prostate cells (17). Therefore, POET-3 mimics autoimmune originated prostatitis. 90%95% of all prostatitis cases have no detectable pathogenic cause (26) and in the
nonbacterial cases the disease origin is most commonly associated with T cell specific
autoimmune responses against prostate specific antigens (6). In addition, unlike other
murine prostatitis models (27-29), the kinetics and severity of inflammation are similar in
all lobes of POET-3 prostates (30). Hence, POET-3 is a very good model to recapitulate
the pathology of prostatitis in humans. We show that CD11b+Gr-1+ cells expand in the
spleen and the prostate of animals with prostatitis. At the initial stages of prostatitis,
MDSC is the dominant immune infiltrating population at the prostate and regulate T cell
responses by inhibiting their activity. Therefore, MDSC are likely to control the severity
of prostatitis. However, it is important to note that our data reflect the inflammatory
processes in an acute inflammation setting. Our previous studies indicate that the
prevalence of MDSC population in prostate peaks at day 5-6 of inflammation and starts
decreasing from then on (30). Further studies are needed to evaluate the role of MDSC in
chronic prostatitis.
Our findings also underline the significance of the anatomical location in which
MDSC reside in. Only MDSC at the inflammatory site possess suppressor activity. Based
on these findings, it can be articulated that CD11b+Gr-1+ cells at peripheral organs such
as spleen serve as precursor MDSC and they require stimulation by inflammatory
molecules to gain suppressor activity. In support of this hypothesis, we have shown that
splenic CD11b+Gr-1+ cells, with no immediate suppressor function, gain suppressor
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activity when cultured with cytokines such as GM-CSF, IL-13 and IFN-γ or with
activated T cells (30). Importantly, these data also reflect that the phenotypic markers of
MDSC, CD11b and Gr-1, are not reliable indicators for the functionally active MDSC.
MDSC are a highly heterogeneous population and it is likely that not all cells identified
as CD11b+Gr-1+ have the suppressor capacity. The best characterized MDSC
subpopulations are monocytic (M-MDSC) and granulocytic (G-MDSC) subsets (7).
Between these two subsets, M-MDSC are most commonly associated with greater
suppressive capacity per cell basis (23). However, G-MDSC have also been described as
a major suppressive population (31). The discrepancies in the description of suppressor
MDSC led to a quest to discover markers that specifically identify the MDSC subset that
possess suppressor function. Numerous surface markers, including CD124, CD115,
CD80 and CD49d (32-35), are proposed to be associated with functional MDSC subsets.
Although these markers are helpful for detailed classification of MDSC subsets, they
cannot distinguish subsets on the basis of suppressive activity. Here, we identify CAT2 as
an important mediator of MDSC regulatory functions. Both ex vivo and in vivo, we
demonstrate that CAT2 is induced in functionally active MDSC and is necessary for
MDSC to exert suppressor functions. Therefore, it can be proposed that CAT2 is a good
candidate to serve as a marker to define functionally active MDSC.
Our data clearly indicate the role of CAT2 in the regulation of MDSC-mediated
control of T cell immunity. In POET-3, in the absence of CAT2, adoptively transferred
OTI cells displayed enhanced expansion and higher frequency of IFN-γ producing cells
in the prostate. No differences were observed in splenic OTI cells, which is consistent
with their activation state. These results are in accordance with our previous findings that
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showed when MDSC function is blocked by anti-Gr-1 during acute prostate
inflammation, OTI proliferation and function are enhanced in the prostate, but not in the
spleen (30).
Additionally, histological analysis revealed that the inflammation is more severe
in CAT2-/-POET-3 prostates than POET-3. Although we clearly show that OTI
population is expanded in CAT2-/-POET-3 prostates, we have not investigated how the
absence of CAT2 affects other immune cell populations. Despite their most recognized
function that is inhibiting T cell responses, MDSC modulate numerous other components
of innate and adaptive immunity. For example, the cross-talk between MDSC and
macrophages have been shown to result in decreased IL-12 production by macrophages
and increased IL-10 production by MDSC, biasing the microenvironment towards a type
2 immune response (36). MDSC have also been shown to promote T regulatory cell
accumulation (33), Th17 cell differentiation (37) and inhibit natural killer cell
cytotoxicity (38). Therefore, it is possible that enhanced inflammation due to the
impairment of MDSC regulatory functions might involve immune populations other than
T cells. In fact, histological analysis suggested an increased accumulation of neutrophils
in CAT2-/-POET-3 prostates. Several studies reported that nitric oxide (NO), the main
product of L-Arg catabolism by NOS2, modulates leukocyte accumulation at the
inflammatory sites (39, 40). More specifically, NO is shown to inhibit neutrophil
migration (41, 42). Although we did not directly investigate the NO formation in prostate
MDSC, it is most likely that in the absence of CAT2, MDSC produce less NO, as seen in
macrophages (20). So, it can be argued that lower NO formation in MDSC in the absence
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of CAT2 results in greater accumulation of neutrophils in the prostate, thereby
contributing to the more severe granulocytic inflammation in CAT2-/-POET-3 prostates.
In summary, this work demonstrates the important role of MDSC in the regulation
of prostatic inflammation by displaying the effect of MDSC on T cell immunity.
Furthermore, here we identify CAT2 as a marker of functionally active MDSC
population and show the CAT2-mediated regulation of MDSC function.
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Figure 3.1. Suppressor activity is limited to MDSC at the inflammatory site.
Inflammation was induced in POET-3 mice by the transfer of 5x106 activated OTI cells.
5 days later, CD11b+Gr-1+ cells were isolated from the spleens and prostates (n=3,
pooled) and co-cultured with 105 OTI cells for 48 hours. BrdU was added 6 hours before
the end of culture and OTI proliferation was determined by measuring BrdU
incorporation in OTI cells by flow cytometry (A). mRNA was isolated from freshly
sorted CD11b+Gr-1+ cells and analyzed by qPCR for Arg1 and Nos2 expression. Data
represent the results of at least 3 independently performed experiments (B). Error bars
indicate ±SEM.
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Figure 3.2. CAT2 regulates MDSC suppressor function.
Prostatitis was induced in POET-3 and CAT2-/-POET-3 mice by the adoptive transfer of
5x106 activated OTI cells. 5 days later, CD11b+Gr-1+ cells were isolated from spleens and
prostates by FACS. mRNA was freshly isolated and analyzed for Cat2 expression (n=3
mice/group, **** p<0.0001) (A). MDSC were isolated from inflamed prostates of
Cat2+/+ and Cat2-/-POET-3 mice. (n=3/group, pooled) and co-cultured with preactivated
OTI cells for 48 hours. BrdU was added 6 hours before harvest. OTI proliferation was
evaluated by measuring BrdU incorporation (B). Error bars indicate ±SEM.
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Figure 3.3. CAT2-/-POET-3 have more severe prostatic inflammation
Prostatitis was induced in POET-3 and CAT2-/-POET-3 mice (n=2/group) by the adoptive
transfer of 5x106 activated OTI cells. 5 days later prostate lobes were harvested and
processed for Hematoxylin and Eosin (H&E) staining. Representative H&E stained
section of ventral lobes (4X maginification) (A). Inflammation score combined for
ventral, anterior and dorso-lateral lobes (B).
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Figure 3.4. CAT2 controls MDSC-mediated T cell immunity in vivo.
5x106 activated OTI cells were injected into POET-3 (WT) and CAT2-/-POET-3 (KO)
mice to induce prostatitis. 2 days after the induction of inflammation, mice were
adoptively transferred with 4x106 Cat2+/+ and Cat2-/- bone marrow cells that were
cultured 5 days with GM-CSF and IL-6 (A). Cat2+/+POET-3 (WT) received Cat2+/+
(WT) cells and Cat2-/-POET-3 (KO) received Cat2-/- (KO) or Cat2+/+ (WT) cells.
Percentage of Thy1.1+ (OTI) cells in 5-day inflamed POET-3 prostate (B) and spleen (C)
were represented under CD45+CD8+ gate. Each individual datum point represents a
single mouse (***p<0.001, *p<0.05). Prostate (D) and spleen (E) cells were cultured
with SIINFEKL and protein transport inhibitor for 8 hours and IFN-γ was detected by
intracellular staining for flow cytometry.
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CHAPTER 4. CHAPTER 4. REGULATION OF TUMOR INDUCED CHRONIC
INFLAMMATORY RESPONSES BY MYELIOD-DERIVED SUPPRESSOR
CELLS (MDSC) AND THE IMPACT OF L-ARGININE TRANSPORTATION
ON MDSC FUNCTION

Abstract
Myeliod-derived suppressor cells (MDSC) are a heterogeneous population of
immature cells that expand during cancer-associated inflammation. MDSC regulate
innate and adaptive immunity and notably, have been shown to inhibit T cell immunity.
Increased metabolism of L-Arginine, through the enzymes arginase 1 (ARG1) and nitric
oxide synthase 2 (NOS2), is well documented as a major MDSC suppressive mechanism
for controlling T cell responses. However, the mechanism by which extracellular LArginine is transported into MDSC has not been defined. Using murine models of cancer,
we have shown that MDSC recruited to tumor sites transport extracellular L-Arginine
through y+L and y+ systems, but not B0,+ or b0,+. We found that expression of a y+ system
member, cationic amino acid transporter 2 (Cat2) is induced in tumor site MDSC. Cat2
expression is not upregulated in MDSC at the spleen or bone marrow, but is coordinately
induced with Arg1 and Nos2 at inflammatory sites. CAT2 acts as an important regulator
of MDSC suppressive function. MDSC that lack CAT2 have significantly reduced
suppressive ability ex vivo and display impaired capacity for regulating T cell responses
in vivo as evidenced by decreased tumor growth in Cat2-/- mice. The abrogation of
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suppressive function is due to low intracellular L-Arginine levels, which leads to the
impaired ability of NOS2 to catalyze L-Arginine metabolic processes. Together, these
findings demonstrate that CAT2 is an important regulator of MDSC suppressive function.
In the absence of CAT2 MDSC display diminished capacity for controlling T cell
immunity in cancer models, where the loss of CAT2 results in enhanced antitumor
activity.

Introduction
The beneficial, anti-tumorigenic properties of myeloid cells are altered in cancer
(1). By blocking the differentiation of myeloid cells, tumors promote the development of
an immature myeloid cell population with immunosuppressive functions (2, 3). This
heterogeneous population of immature cells, called myeliod-derived suppressor cells, are
found in all cancers and facilitates tumor progression by blocking anti-tumor T cell
responses (4). In cancer patients, MDSC expansion correlates with worse prognosis,
increased metastasis and decreased survival (5, 6). Consequently, blocking
immunosuppressive activities of MDSC has been a critical strategy to improve cancer
therapy. Unfortunately, current strategies for controlling MDSC suppressor function have
not found clinical application.
In mice, MDSC are identified by the co-expression of cell surface molecules Gr-1
and CD11b (3). MDSC are a highly heterogeneous population comprising of myeloid
cells at various stages of differentiation. The most commonly studied MDSC
subpopulations are CD11b+Ly6ChighLy6G- monocytic (M-MDSC) and
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CD11b+Ly6ClowLy6G+ granulocytic (G-MDSC) subsets (3). Although both subsets can
exert suppressive function, M-MDSC is considered to be the major suppressive
population (7, 8). The hallmark mechanism of MDSC suppressive function is the
increased metabolism of L-Arginine (L-Arg) through arginase1 (ARG1) and inducible
nitric oxide synthase (NOS2). Both of these enzymes use L-Arginine as their unique
substrate and produce metabolites, such as reactive oxygen and nitrogen species (ROS
and RNS), that contribute to the inhibition of T cell responses (9). The elevated ARG1
and NOS2 activities in MDSC necessitate L-Arg import (10). Despite its importance as
the unique substrate for ARG1 and NOS2, the mechanism by which L-Arg is transported
into MDSC has not been defined.
There are four transporter systems for L-Arg uptake through mammalian cellular
membranes: y+, y+L, bo,+, Bo,+ (11). Different types of cells can express a distinct
combination of these transporters (12). Additionally, the activities of these transporters
are dynamically modulated by certain environmental factors such as inflammatory
cytokines (13). y+ is recognized as the major transport route for L-Arg in most cells due
to its high selectivity for cationic amino acids, such as L-Arg (14). y+ system comprises
four carrier proteins: CAT1 – CAT4. The specific functions of CAT3 and CAT4 are not
well characterized. CAT1 is ubiquitously expressed, with the exception of adult liver.
However, CAT1 transport of L-Arg is slow and therefore cells with a high demand of LArg induce CAT2 expression to provide rapid transport of L-Arg to meet functional
requirements (15). For example, macrophages upregulate CAT2 expression upon
activation and the lack of CAT2 results in a significant decrease in L-Arg transport and
NO production, indicating CAT2 is required for sustained NOS2 activity (16, 17). Mature
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tumor-associated myeloid cells, CD11b+Gr-1-, also display increased CAT2 expression
and the concomitant L-Arg uptake (18). Although CAT2 is well studied in the context of
L-Arg transport in various cell types, its importance in the transportation of L-Arg in
MDSC and its impact in the regulation of MDSC suppressive function is unknown. In
this study, using murine models of cancer we identified y+ and y+L systems as active
routes of L-Arg uptake in MDSC. Moreover, we provide evidence that Cat2 is
coordinately induced with Arg1 and Nos2 in functionally active MDSC and L-Arg uptake
through CAT2 is required for MDSC to sustain their optimal suppressive activity. CAT2
deficient-MDSC display an impaired capacity for regulating T cell responses both ex vivo
and in vivo.

Materials and Methods
Mice
C57BL/6 mice were purchased from Jackson Laboratories. Cat2-/- and POET-3 mice
were generated as described previously (16, 19). Rag-/-Thy1.1+ ovalbumin-specific T cell
(OTI) mice were generated by breeding Thy1.1+OTI mice and Rag-/- mice, both
purchased from Jackson Laboratories. Both female and male mice between 7 and 12
weeks of age were used for all tumor studies. All animal experiments for this study were
approved by the Purdue University Animal Care and Use Committee.
Animal Models
C57BL/6 and Cat2-/- mice were used for tumor studies. For prostate cancer studies, 1x106
RM1 prostate cancer cells were injected intraperitoneally. Mice were sacrificed 6-7 days
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after tumor cell inoculation. For the bladder cancer model, 5x105-106 MB49 bladder
cancer cells were injected subcutaneously in the flank area. Mice were sacrificed after 14
days when tumors reached 1.5 cm in diameter. For tumor growth experiments, mice were
injected with 3x106 Fico/Lite (Atlanta Biologicals) purified EG7 or EL4 cells
subcutaneously in the flank area or intradermally in the shoulder area. After 7 days 11.5x106 activated OTI cells were injected intravenously. For the Winn assay, 3x106 EG7
cells were injected intradermally in the shoulder area with or without 104 activated OTI
cells in the presence or absence of 104 WT or KO CD11b+Gr-1+ cells isolated from
ascites of RM1 mice. Tumor size was measured using calipers and calculated by the
formula [(small diameter)2 x (large diameter) x 0.5].
Cell Isolation and Generation
Bone marrow was collected from femurs and tibias. Spleens were harvested and ground
using frosted slides. Cells from ascitic tumors were collected by flushing the peritoneal
cavity with 10 ml PBS. Solid tumors were collected and minced by razor blades. Single
cell population was obtained by digesting the minced tissue at 37°C for 1 hour in media
containing Collagenase D (2 mg/ml, Roche Diagnostics) and DNAse I (10 µg/ml, SigmaAldrich). Red blood cells were lysed by using ACK buffer and cells were passed through
a 70 µm filter. OTI cells were isolated from the spleens of Rag-/-OTI mice and activated
by culturing in RPMI-1640 media containing SIINFEKL (1 µg/ml, Ova peptide 257-264,
American peptide) and 2-ME (55 µM). Activated OTI were purified by Fico/Lite.
Macrophages were obtained by collecting cells from mice by washing the peritoneal
cavity with 10 ml PBS 5 days after thioglycollate injection (i.p.). Cells were cultured and
unattached cells were removed after 2 hours. Macrophages were then cultured for another
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17 hours in the absence or presence of LPS (100 ng/ml, Sigma-Aldrich) and IFN-γ (25
ng/ml, Peprotech). For in vitro activation of MDSC, CD11b+Gr-1+ cells were isolated
from bone marrow by FACS and were cultured for 3 days with GM-CSF (40 ng/ml),
IFN-γ (25 ng/ml) and IL-13 (33 ng/ml, Peprotech).
Flow Cytometry
Single cell suspensions were incubated with TruStain fcX (Clone: 93) and stained with
conjugated antibodies. MDSC were labelled with anti-CD11b (Clone: M1/70), anti-Gr-1
(Clone: RB6-8C5), anti-Ly-6C (Clone: HK1.4) and anti-Ly-6G (Clone: 1A8). T cells
were labelled with anti-CD45 (Clone: 30-F11), anti-CD8a (Clone: 53-6.7) and antiCD90.1 (Clone: OX-7). To measure IFN-γ production by OTI, cells were cultured for 6-8
hours in the presence of SIINFEKL and Golgi Stop (BD Biosciences). After staining for
surface antigens, cells were prepared for intracellular staining using the
CytoFix/CytoPermTM kit (BD Biosciences) and stained with anti-IFN-γ (Clone:
XMG1.2). All antibodies were purchased from BioLegend and used at 2 µg/ml
concentration. OTI proliferation was measured using BrdU Flow Kit (BD Biosciences) or
Click-iT® EdU Flow Cytometry Assay Kit (Molecular Probes, Life Technologies)
according to the manufacturer’s instructions. For ARG1 and NOS2 protein detection,
following surface antigen staining cells were fixed and permeabilized using
CytoFix/CytoPermTM kit (BD Biosciences). Cells were then stained for ARG1 and NOS2
for 30 minutes at room temperature. ARG1 staining was performed in 20 µl of 25 µg/ml
PE-conjugated anti-ARG1 polyclonal antibody or the isotype control PE-conjugated
polyclonal sheep IgG (R&D Systems). For NOS2 detection, FITC conjugated anti-NOS2
monoclonal antibody (BD Transduction Laboratories, Clone: 6) and the FITC conjugated
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mouse-IgG2a isotype control (Clone: RMG2a-62) were used at 10 µg/ml. All analyses
were performed using BD FACSCanto II and data were analyzed using FlowJo software
(Tree Star). All cell sorting was performed using a BD FACSAria III. Sort purities were
above 95%.
Quantitative Real Time PCR
Total RNA was isolated from freshly sorted cells using the E.Z.N.A. Total RNA Kit I
(Omega Bio-tek) and cDNA synthesis was performed using qScriptTM cDNA SuperMix
(Quanta Biosciences) according to the manufacturer’s instructions. Multiplex qRT-PCR
was performed using PerfeCTa® FastMix® II (Quanta Biosciences), PrimeTime® qPCR
gene probes (IDT): Arg1 (Mm.PT.58.8651372), Nos2 (Mm.PT.58.43705194), Slc7a2
(Cat2) (Mm.PT.58.28825099), Slc3a1 (rBAT) (Mm.PT.58.7144169), Slc3a2 (4F2hc)
(Mm.PT.58.43977559), Slc6a14 (ATB0,+) (Mm.PT.58.9605477), Slc7a3 (Cat3)
(Mm.PT.58.31801594.g), Slc7a4 (Cat4) (Mm.PT.58.30742436), Slc7a6 (y+LAT2)
(Mm.PT.58.32730698), Slc7a7 (y+LAT1) (Mm.PT.58.30321024), Slc7a9 (b0,+AT)
(Mm.PT.58.32845002), Slc7a1 (Cat1) (Mm01219060_m1, Applied Biosystems) and
endogenous control 18s rRNA (Applied Biosystems). Relative mRNA expression was
calculated by the formula 2–[Ct(gene) – Ct(18s rRNA)], where Ct is the threshold cycle value.
Microarray and Statistical Analysis
MDSC subsets were sorted (using iCyte reflection cell sorter) from the spleens and
ascites of RM1 (i.p.) bearing mice after 14 days of tumor inoculation. RNA was
immediately isolated from the sorted cells. Standard Affymetrix protocols were
performed using Affymetrix Mouse Gene 1.0 ST by the Center for Medical Genomics at
Indiana University School of Medicine, Indianapolis, IN. Expression level data of
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transcripts were obtained by pre-processing of raw data via R, ROOT and
Bioconductor/xps. Annotations were obtained via Expression Console. Differentially
expressed transcripts were identified by comparing same phenotypic subsets from tumor
and spleen using unpaired T test. 100 permutations were used to identify False Detection
Rate (FDR). Significance for differential expression was determined at the 5% FDR.
Statistical analyses were performed using Significance Analysis of Microarray (SAM)
program.
L-Arginine Transport Assays
Isolated MDSC or macrophages were cultured overnight with GM-CSF (40 ng/ml), IFNγ (25 ng/ml), IL-13 (33 ng/ml) and LPS (100 ng/ml), IFN-γ (25 ng/ml), respectively.
Transport assays were carried out at 25°C in a buffer containing 118.5 mM NaCl, 5.6
mM KCl, 1.3 mM CaCl2, 0.6 mM MgCl2, 11.1 mM glucose, 0.03 mM EDTA, 0.06 mM
L-Ascorbic Acid and 20 mM HEPES. Transport through the y+ system was blocked by
pretreating cells with N-ethyl maleimide (NEM) (5 mM) (Sigma-Aldrich) at 25°C for 5
min. To block transportation through the y+L system 5 mM L-Leucine (L-Leu) was added
to the transport buffer. Cells were pulsed with L-3[H]-Arginine (6µCi/ml, PerkinElmer)
for 3 min and were washed with stop solution (transport buffer containing 10 mM
nonradioactive L-Arg). Cells were then lysed with 4% Triton X-100 and the uptake was
measured using a scintillation counter. The protein concentration of cell lysates was
measured using the Bradford assay (Sigma-Aldrich) according to the manufacturer’s
instructions. Uptake was represented as CPM/mg protein for normalization purposes.
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MDSC Functional Assays
Sorted MDSC or MDSC subsets were co-cultured in 96-well U bottom plates with OTIs
(105 cells/well) preactivated for 8 hours (or naïve, where indicated) in media containing
the cognate antigen SIINFEKL. OTI proliferation was measured by determining BrdU or
EdU incorporation after 18 hours for short-term assays and 48-72 hours for long-term
assays. BrdU and EdU were added 6 and 2 hours before harvest, respectively. BrdU and
EdU incorporation were measured by flow cytometry. Where indicated LNMMA (0.5
mM, Calbiochem), nor-NOHA (0.5 mM, Calbiochem) and NAC (1 or 10 mM, SigmaAldrich) were added to the suppression assay at the beginning of co-culture. The percent
suppression was calculated as [1-[(proliferation with MDSC)/(proliferation without
MDSC)]x100]. IFN-γ production was measured by intracellular IFN-γ staining for flow
cytometry.
Measurement of Nitrite, ROS and Urea
Sorted cells were cultured for 24 hours with or without LPS (100 ng/ml) and IFN-γ (25
ng/ml). Nitrite formation was quantified using the Standard Griess Assay (Molecular
Probes, Life Technologies) according to the manufacturer’s instructions. Reactive oxygen
species (ROS) formation was measured using DCFDA – Cellular reactive oxygen species
detection assay kit (abcam) according to the manufacturer’s instructions. In the arginase
assay, sorted cells were lysed in 0.1 % Triton X-100 containing protease inhibitors
(Roche) at 107 cells/ml and incubated at room temperature for 30 minutes. Subsequently,
equal volume of 10 mM MnCl2 and 25 mM Tris-HCl (pH 7.5) were added. Following 10
min incubation at 55 °C, equal volume of 0.5 M L-Arginine (pH 9.7) was added. Lysates
were incubated for 2 hours at 37 °C and the urea concentrations were determined using
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BioAssay Systems Quantichrome Urea Assay Kit according to the manufacturer’s
instructions.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analyses were performed using GraphPad
Prism software. p values were calculated using Student’s t test and one-way ANOVA
with Bonferroni’s post-test when two or multiple groups were compared, respectively.
Differences were considered significant where p < 0.05.

Results
4.4.1

MDSC Are Expanded in Tumor Models.

In order to investigate the expansion of MDSC in cancer, we injected MB49
bladder cancer cells subcutaneously (s.c.) into the flank of mice and after 2 weeks, when
tumors reached 1.5 cm size in diameter, we collected the spleen and tumor tissue. Using
the spleens from naïve, tumor free animals as controls we analyzed the accumulation of
CD11b+Gr-1+ population in tumor bearing animals. Data revealed that MB49 tumors
induced the expansion of CD11b+Gr-1+ cells both in the spleen and at the tumor site
(Figure 4.1A). Compared to naïve mice, spleens from tumor bearing animals had a
significantly greater population of CD11b+Gr-1+ cells. At the tumor site MDSC
constituted around 20% of all immune infiltrating cells (Figure 4.1A). We also
investigated MDSC expansion in another tumor model, where we inject RM1 prostate
cancer cells into the intraperitoneal (i.p.) cavity of mice. 6 days after RM1 inoculation,
we collected the spleens and i.p. exudate and analyzed the accumulation of CD11b+Gr-1+
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cells. Spleens from tumor mice contained significantly higher levels of CD11b+Gr-1+
cells compared to spleens from the tumor free mice. Analysis of ascetic fluid
demonstrated that MDSC were recruited to the tumor site (Figure 4.1B). Additionally we
showed that in the RM1 ascites model, the CD11b+Gr-1+ population that expanded in the
spleen and tumor site consists of both monocytic (CD11b+Ly6ChighLy6G-) and
granulocytic (CD11b+Ly6ClowLy6G+) subsets, M-MDSC and G-MDSC, respectively
(Figure 4.1C). Existing data indicate that MDSC accumulate in practically all cancers
(4). Accordingly, we demonstrated MDSC accumulation in two distinct tumor models.
RM1 ascites model provides rapid tumor growth and a high recruitment of MDSC to the
tumor site. In addition it allows us to study both monocytic and granulocytic
subpopulations of MDSC. Therefore, we utilized RM1 ascites models for further studies.

4.4.2

Suppressor Activity Is Limited to MDSC at the Tumor Site.

Next we investigated the suppressor activity of MDSC that accumulate in RM1
bearing mice. To this end, we isolated CD11b+Gr-1+ cells from the spleens and ascites of
RM1 bearing mice and the spleens of tumor free mice. Comparative gene expression
analysis revealed that Arg1 and Nos2 expression was induced in CD11b+Gr-1+ cells from
tumor bearing mice. Notably, the increase in expression was greatly higher in tumor site
MDSC than splenic counterparts (Figure 4.2A). We also investigated Arg1 and Nos2
expression in MDSC subsets. As expected, MDSC subsets at the tumor site displayed
elevated expression of both Arg1 and Nos2 (Figure 4.2B). In accordance with previous
findings (3), both M-MDSC and G-MDSC subsets expressed high levels of Arg1, the
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elevated Nos2 expression was mostly confined to the M-MDSC subset (Figure 4.2B).
Next, we directly evaluated the suppressive function of MDSC by measuring their ability
to inhibit T cell proliferation. To this end, CD11b+Gr-1+ cells isolated from the spleens
and ascites of RM1 mice were cultured together with pre-activated ovalbumin-specific
CD8+ T cells (OTI) at differing ratios. After only 18 hours, we measured the proliferation
of OTI cells. We chose to utilize this short-term suppression assay versus the traditional 3
to 5 days long suppression assays, because in this assay only the MDSC with immediate
suppressor function can inhibit T cell proliferation (20). Results demonstrated that MDSC
at the tumor site, but not at the spleen, possessed immediate suppressor activity (Figure
4.2C). Together with our earlier findings that showed in a prostatitis model the
immediate MDSC suppressor activity was restricted to MDSC at the inflammatory site
(Figure 3.1), we conclude that suppressive function is limited to MDSC that reside at the
pathological site.

4.4.3

Tumor MDSC Express y+L and y+ Systems L-Arginine Transporters.

Elevated ARG1 and NOS2 expression and activities are hallmarks of MDSC
suppression function (9). In order to inhibit T cells, both enzymes require L-Arginine (LArg) as their unique substrate (9). Therefore, we hypothesized that blocking L-Arg entry
into MDSC will repress MDSC suppressor function. To test this hypothesis, first we
sought to discover the routes through which L-Arg is imported into MDSC. To this end,
we investigated the expression of known L-Arg transporters in MDSC. Since tumor site
MDSC have elevated Arg1 and Nos2 levels, we utilized MDSC from ascites of RM1
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mice. Gene expression analyses revealed that MDSC express only the y+ and y+L systems
L-Arg transporters. We could not detect the expression of any L-Arg transporters that
belonged to b0,+ or B0,+ systems (Figure 4.3).

4.4.4

Cat2 Expression Is Coordinately Induced with Arg1 and Nos2 Expression in
Tumor MDSC.
Among the y+, y+L, bo,+, Bo,+ systems, y+ system is considered to be particularly

important for L-Arg import due to its high selectivity for cationic amino acids (14). One
of the members of y+ system, cationic amino acid transporter 2 (CAT2), is an inducible
protein and has been showed to provide rapid L-Arg uptake in cells with high demand of
L-Arg (15). In addition, CAT2 has been reported to be essential for sustained NOS2
activity in macrophages (16). Therefore, we hypothesized that CAT2 expression is
induced in MDSC that possess suppressor activity to supply L-Arg in response to the
elevated activities of ARG1 and NOS2. To assess if indeed acquisition of suppressive
function induced Cat2 expression in MDSC, we utilized an in vitro system in which we
can stimulate non-suppressive CD11b+Gr-1+ cells to gain suppressor activity. In this in
vitro system, we isolate CD11b+Gr-1+ cells from bone marrow of tumor free mice and
culture the cells with or without GM-CSF, IFN-γ and IL-13 for 3 days. At the end of 3
days CD11b+Gr-1+ cells that were cultured with the activating cytokines specifically gain
suppressive function as indicated by the induction of Arg1 and Nos2 expression (Figure
4.4A) and the ability to inhibit T cell proliferation (Figure 4.8A). Using this in vitro
system, similar to Arg1 and Nos2, we detected Cat2 expression only in cells that were
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cultured in the presence of cytokines (Figure 4.4A). In order to evaluate if induction in
Cat2 expression is coordinately regulated with Arg1 and Nos2 induction, we measured
gene expression of in vitro activated MDSC after 24, 48 and 72 hours of culture. Data
showed that Cat2 expression in MDSC is induced in parallel to Arg1 and Nos2
expression (Figure 4.4B). Next, we investigated Cat2 expression in CD11b+Gr-1+ cells
from RM1 bearing animals. Again, the elevated Cat2 expression was only detected in
MDSC with suppressor function that are the tumor MDSC (Figure 4.4C). Additionally,
we inspected Cat2 expression in M-MDSC and G-MDSC subpopulations. Cat2 was
expressed in both subsets at similar levels and the upregulated expression was confined to
MDSC residing at the tumor site (Figure 4.4D). In order to evaluate if the induction of
differential expression in tumor MDSC was unique to CAT2, we conducted microarray
analyses to compare gene expression levels in the splenic and tumor site MDSC. Since
MDSC only express y+ and y+L system transporters, we investigated the differential
expression of these transporters in tumor MDSC. As expected, microarray results
demonstrated that Cat2 expression was significantly upregulated in both M-MDSC and
G-MDSC subsets at the tumor site. With the exception of Cat1 (2-fold expression), none
of the other transporter expression was differentially regulated (Figure 4.5). Together,
data indicate that Cat2 is coordinately induced with Arg1 and Nos2 in MDSC that possess
suppressor function. Activation of suppressor function does not impact the expression of
other L-Arg carriers in MDSC, suggesting that CAT2 is the major transporters
responsible from increased L-Arg transportation of functional MDSC.
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4.4.5

CAT2 Mediates L-Arginine Uptake in Tumor MDSC.

Next, we tested if CAT2 was functionally active and that it transported L-Arg into
MDSC. In order to determine the specific role of CAT2 in MDSC, we utilized a Cat2-/mouse model (16). The accumulation of MDSC in the ascites and peripheral organs such
as spleen and bone marrow had similar kinetics between of Cat2+/+ and Cat2-/- RM1
bearing animals. Moreover, the distribution of monocytic and granulocytic MDSC
subsets were also similar. We measured the L-Arg uptake in tumor site MDSC isolated
from the ascites of Cat2+/+ (WT) and Cat2-/- (KO) RM1 bearing mice. L-Arg uptake was
significantly lower in MDSC that lacked CAT2 (Figure 4.6B), suggesting that CAT2 is a
functional L-Arg carrier in MDSC. CAT2 has been reported to be critical in L-Arg
transportation of activated thioglycollate-elicited peritoneal macrophages (16). Therefore,
we measured L-Arg transport in peritoneal Cat2+/+ and Cat2-/- macrophages as a control.
As reported, we saw that CAT2-mediated L-Arg transport was greatly enhanced in
macrophages upon activation and in the absence of CAT2, L-Arg transport was inhibited
by 90%. Moreover, when we blocked the L-Arg transport through y+ system using an
inhibitor, N-ethyl maleimide (NEM), the L-Arg uptake in intact macrophages dropped
down to the level of L-Arg uptake in the absence of CAT2 (Figure 4.6A), further
demonstrating the importance of CAT2-mediated L-Arg import in activated
macrophages. Interestingly, unlike the 90% CAT2-mediated L-Arg transport in activated
macrophages, in tumor MDSC only about 20% of total transport was mediated by CAT2.
Since MDSC expressed multiple carrier proteins that can transport L-Arg (Figure 4.3),
we investigated the possibility of any of these transporters being over-expressed in Cat2-/-
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MDSC, thereby compensating for the lack of CAT2. To this end, we compared the
expression of L-Arg transporters in Cat2+/+ and Cat2-/- tumor MDSC. In accordance with
our previous observations, both WT and KO MDSC only expressed the members of y+
and y+L systems. The expression levels for all transporters were comparable between the
WT and KO MDSC (Figure 4.7). We then evaluated the specific contributions of y+ and
y+L systems in L-Arg import into MDSC. To this end, we blocked the transportation of
L-Arg through y+ and y+L systems using NEM and L-Leucine (L-Leu), respectively. In
addition to transporting L-Arg, y+L systems transports L-Leu (21). Hence, addition of
excessive amount of L-Leu in the transportation medium competitively blocks L-Arg
uptake through y+L system. L-Leu treatment revealed that about 20% of total L-Arg
transport in MDSC was through the y+L system (Figure 4.6C). Consistent with the
similar expression levels of y+L carriers in WT and KO MDSC, L-Arg uptake through
the y+L in MDSC was comparable in the presence or absence of CAT2 (Figure 4.6C).
NEM treatment blocked around 25% of total transport in intact tumor MDSC (Figure
4.6D). Importantly, the inhibition of L-Arg transport in intact MDSC upon the blockade
of y+ system was comparable to the inhibition in Cat2-/- MDSC, suggesting that CAT2 is
the major y+ system transporter in MDSC. Indeed, the reduction in total L-Arg transport
in Cat2-/- MDSC upon NEM treatment was significantly lower than the reduction in intact
MDSC (Figure 4.6D).
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4.4.6

CAT2 Regulates MDSC Suppressive Function.

Since CAT2 is a mediator of L-Arg transport in MDSC, we hypothesized CAT2
regulates MDSC suppressor activity. To test this hypothesis we compared the suppressive
ability of in vitro activated Cat2+/+ (WT), Cat2+/- (Het) and Cat2-/- (KO) MDSC. Results
demonstrated that the suppressive ability of MDSC was greatly reduced in the absence of
CAT2 at all ratios tested. (Figure 4.8A). The suppressive activity of Cat2+/- MDSC and
intact MDSC was similar, indicating that CAT2 needs to be completely absent in order to
modulate MDSC suppressive function. Hence, the rest of the study was performed using
Cat2+/+ (WT) and Cat2-/- (KO) MDSC. To investigate if CAT2 was modulating tumorinduced MDSC suppressive activity in vivo, we isolated CD11b+Gr-1+ cells from the
spleens and ascites of RM1 bearing mice and tested the suppressive activity in a shortterm assay. In accordance with the previous findings, suppressive activity was restricted
to tumor site MDSC. Similar to in vitro activated MDSC, the ability to inhibit T cell
proliferation was significantly reduced in Cat2-/- MDSC in tumor bearing animals. In fact
Cat2-/- MDSC could exert suppressive activity only at 2:1 (MDSC:OTI) ratio (Figure
4.8B). We also evaluated CAT2-mediated MDSC suppressive activity in a more
traditional long-term suppression assay. We co-cultured tumor MDSC and OTI cells for
48 hours and measured T cell proliferation. As expected, KO MDSC had reduced
suppressive capacity (Figure 4.8C). Additionally, we determined the IFN-γ production in
T cells that were co-cultured with either intact or Cat2-/- MDSC. KO MDSC were much
less capable of inhibiting IFN-γ production in T cells than intact MDSC (Figure 4.8D),
further confirming the decreased suppressor capacity of CAT2 ablated MDSC. To verify
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that our observations were not limited to RM1 ascites tumor model, we evaluated CAT2
dependent suppressive activity of tumor-induced MDSC isolated from MB49 (s.c.) tumor
mice in a long-term assay. MDSC isolated from both tumor site and spleens of MB49
tumor bearing animals had lower suppressive activity in the absence of CAT2 (Figure
4.9), suggesting that our observations are broadly applicable. Since CAT2 is expressed in
both M-MDSC and G-MDSC subpopulations, we next investigated the role of CAT2 in
modulating the suppressive activity of each subsets. Long-term suppression assays with
CD11b+Ly6ChighLy6G- (M-MDSC) and CD11b+Ly6ClowLy6G+ (G-MDSC) cells isolated
from bone marrow, spleen and tumor site of RM1 mice indicated that CAT2 modulated
suppressive activity of both subsets (Figure 4.10). In a long-term assay, prolonged
culture time enables MDSC from peripheral sites to gain suppressive function due to
exposure to endogenous and T cell-secreted activating factors. Therefore, unlike the
results from short-term suppression assays, spleen and bone marrow MDSC are expected
to suppress T cells in a long-term assay. Together, these results indicate that CAT2 is an
important regulator of MDSC suppressive capacity. In the absence of CAT2 MDSC
display significantly reduced levels of suppressive activity.

4.4.7

CAT2 Regulates MDSC Suppressive Function through the Modulation of
NOS2 Metabolism.
Next we aimed to identify the mechanisms through which CAT2 regulates MDSC

suppressive function. NO production through NOS2 is one of the hallmark mechanisms
MDSC use to inhibit T cell responses (9). L-Arg is the only substrate that NOS2 uses to
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produce NO (9) and in the absence of CAT2 L-Arg entry into MDSC is lessened.
Therefore, we hypothesized that in Cat2-/- MDSC, NO production is decreased. To test
this hypothesis we measured production of nitrite, a stable end product of NO (22), in
intact and Cat2-/- MDSC. It is reported that in peritoneal macrophages upon activation
CAT2 was required to sustain NOS2 activity. The absence of CAT2 resulted in a 92%
reduction in NO production (16). Therefore, we used thioglycollate-elicited macrophages
as a control. As reported, activated macrophages that lacked CAT2 had significantly
lower nitrite production (Figure 4.11A). Similar to macrophages, MDSC also required
CAT2 for sustained NOS2 activity (Figure 4.11B). Additionally, we measured nitrite
formation in individual MDSC subsets and expectedly observed that in both M-MDSC
and G-MDSC subsets, absence of CAT2 resulted in lower NO formation (Figure 4.11C).
In line with the observation that Nos2 gene expression in G-MDSC subset was much
lower than M-MDSC, we detected lower nitrite formation in granulocytic subpopulation
than in monocytic (Figure 4.11C).
Another important suppressive mechanism MDSC use for inhibiting T cell
responses is the activity of ARG1 (9). Like NOS2, ARG1 also uses L-Arg as its unique
substrate (9). CAT2 has been reported to modulate ARG1 activity in macrophages (23).
Therefore, we investigated the possibility that CAT2 might be modulating ARG1 activity
as well. ARG1 catalyzes L-Arg to L-Ornithine and urea (13). Thus, we measured urea
formation in Cat2+/+ and Cat2-/- MDSC to inspect the role of CAT2 in ARG1 activity.
We isolated CD11b+Gr-1+ cells from the bone marrow and ascites of RM1 bearing mice
and evaluated the ARG1 activity in freshly isolated cells. Data demonstrated that ARG1
activity was comparable in Cat2+/+ and Cat2-/- MDSC (Figure 4.11D). It is important to

124
note that unlike in the Griess reaction, in this urea detection assay we lyse the MDSC and
supply extracellular L-Arg for ARG1 enzyme to use. Hence, this assay measured the
capacity of the enzyme to catalyze L-Arg, it does not reflect the intracellular activity of
ARG1 in intact MDSC in the absence or presence of CAT2. We anticipate that in Cat2-/MDSC, like NOS2 ARG1 activity is also reduced due to reduced L-Arg uptake. To
eliminate the possibility that CAT2 modulates ARG1 and NOS2 expression and hence
affects the total activities of these enzymes in MDSC, we inspected ARG1 and NOS2
protein levels in Cat2+/+ and Cat2-/- MDSC. Data showed that both ARG1 and NOS2
proteins were expressed in similar levels in the absence or presence of CAT2 (Figure
4.12). This observation that ARG1 and NOS2 expression are not regulated with CAT2 is
in agreement with the finding that when L-Arg is supplied ARG1 activity in MDSC is the
same in the absence or presence of CAT2. Furthermore, it strongly suggests that since the
amount of NOS2 enzyme is the same, reduced NO production in Cat2-/- MDSC is likely
to be due to decreased L-Arg availability.
Lastly, we evaluated the contribution of ARG1 and NOS2 activities to MDSC
suppressor function by blocking each pathway. To this end, we utilized a NOS inhibitors,
L-NG-monomethyl Arginine (L-NMMA), and arginase inhibitor, Nω-hydroxy-norArginine (nor-NOHA). We measured suppressive activity of MDSC in the presence or
absence of these inhibitors. Data revealed that inhibition of NOS2 alone completely
abrogated suppressive activity. On the other hand, ARG1 inhibition had no effect on the
suppressive function in either WT or KO MDSC (Figure 4.12E). Together, these data
suggest that in RM1 ascites model NOS2 metabolism is the main suppressive mechanism
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in MDSC. Reduced L-Arg uptake results in lower NO formation, hence lower
suppressive activity, in Cat2-/- MDSC.

4.4.8

Elevated Reactive Oxygen Species Production in Cat2-/- MDSC Contributes
to the Suppressor Activity.
Although at a reduced capacity, MDSC are still able to inhibit T cells in the

absence of CAT2. Therefore, we aimed to identify the MDSC suppressive mechanisms
that act independent of CAT2. Previously, NOS2 activity has been reported to be
modified by L-Arg availability in the microenvironment. When L-Arg is depleted,
instead of forming NO NOS2 mostly produces .O2- (24). Subsequent reaction of .O2- with
other molecules, such as H2O and NO, can result in the formation of reactive oxygen
species (ROS). ROS formation by MDSC is one of the mechanisms that MDSC utilize to
inhibit T cells (25). We hypothesized that the reduced L-Arg transportation in Cat2-/MDSC triggers NOS2 to produce higher levels .O2- leading to enhanced ROS production.
To evaluate if ROS formation is modified by CAT2 expression, we measured ROS levels
in Cat2+/+ and Cat2-/- MDSC isolated from the ascites of RM1 bearing mice. DCFDA
staining of MDSC revealed that ROS formation was increased in CAT2 ablated MDSC
(Figure 4.13A). When we investigated the ROS formation in MDSC subsets, we found
that the ROS formation in M-MDSC was similar in the absence or presence of CAT2.
The differential ROS formation was confined to G-MDSC (Figure 4.13B).
Next, we investigated if the enhanced ROS formation could be responsible from
the suppressive activity of Cat2-/- MDSC. To this end, we inhibited ROS by using free
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radical scavenger N-acetyl-L-cysteine (NAC) (26) and measured MDSC suppressive
function. Since Cat2-/- MDSC have low inhibitory activity, we used a high MDSC:OTI
ratio (2:1) in the suppression assay. So that we could monitor possible reductions in Cat2/-

MDSC suppressor activity due to inhibition of ROS. Results showed that NAC

treatment greatly reduced the suppressor activity of Cat2-/- MDSC. However, it did not
affect the suppressive activity of WT MDSC (Figure 4.13C). ROS is expected to play a
greater role in the suppressive activity of KO MDSC due to its enhanced levels compared
to the WT MDSC. Yet, as a known mediator of MDSC suppressive function (25), ROS
should play a part in the inhibitory activities of intact MDSC too. Hence, we reasoned
that the high MDSC:OTI ratio in the suppression assay prevented us to observe the ROSmediated suppression in WT MDSC. To address this possibility, we used differing
MDSC:OTI ratios and measured WT MDSC suppressor activity in the absence and
presence of NAC. As we expected, at low ratios the contribution of ROS to WT MDSC
suppressor activity could easily be detected (Figure 4.13D). Together, our data
demonstrate that the absence of CAT2 leads to greater ROS formation in MDSC. ROS
production mediates MDSC suppressive function in a CAT2 independent fashion and the
contribution of ROS to MDSC suppressor activity is enhanced in Cat2-/- MDSC due to
elevated levels.
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4.4.9

In the Absence of CAT2, MDSC Display Impaired Ability to Control T Cell
Immunity In Vivo, Resulting in Slower Tumor Progression.
Next, we evaluated whether CAT2 can modulate MDSC regulatory functions in

vivo. To this end, we performed a Winn assay (27). In this Winn assay, we injected tumor
cells, tumor antigen specific T cells and tumor site MDSC together into mice. In order to
avoid potential T cell inhibitory effects exerted by endogenous MDSC that were recruited
to the tumor site we injected Cat2-/- mice, where the endogenous MDSC have low
suppressive activity. More specifically, we injected mice intradermally with 3x106 EG7
lymphoma cells with or without activated OTI cells in the presence or absence of MDSC.
EG7 tumor cells express ovalbumin, the antigen that is specifically recognized by OTI,
and hence are target to killing by OTI cells. When implanted alone EG7 tumors grew
progressively. EG7 growth was inhibited by the presence of 104 activated OTI. Although
slower, addition of WT MDSC restored the progressive tumor growth even in the
presence of OTI. On the contrary, the presence KO MDSC had no effect on OTI function
(Figure 4.14). These results demonstrate that the ability to inhibit T cell activity at the
tumor microenvironment was limited to intact MDSC. Since Winn assay did not reflect
the regulatory function of endogenous tumor-induced MDSC, we further analyzed the
role of CAT2 in regulating MDSC function in vivo using another tumor model. To this
end, we adopted an EG7 immunotherapy model in which we inject EG7 lymphoma cells
into Cat2+/+ and Cat2-/- mice. After 7 days of tumor inoculation, once the tumors are
established, we adoptively transfer OTI into mice and monitor tumor growth. In this
model, adoptively transferred OTI can kill the EG7 tumor cells, thereby leading tumor
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regression. Additionally, tumors induce MDSC recruitment that can control OTI
responses. In order to monitor the differential regulatory capacity of Cat2+/+ and Cat2-/MDSC, we intended to use a minimal number of OTI cells. To determine the minimal
number of OTI cells that can induce tumor regression, we adoptively transferred differing
numbers of OTI cells into EG7 bearing mice and monitored tumor growth. Based on our
results we decided to use 1-1.5x106 OTI cells (Figure 4.15A). Next, we implanted 3x106
EG7 lymphoma cells either subcutaneously (s.c.) (Figure 4.15B) or intradermally (i.d.)
(Figure 4.15C) into WT and KO mice. We also injected EL4 cells as a control to show
EG7 killing by OTI is specific. EG7 cells are EL4 thymoma cells that are stably
transfected to express ovalbumin (28). Hence, the parent EL4 cell line is not subject to
destruction by OTI cells. 7 days after tumor inoculation, we adoptively transferred 11.5x106 activated OTI intravenously and monitored tumor growth. As expected, OTI
specifically targeted EG7 cells and led to tumor regression in both s.c. and i.d. models.
Importantly, we observed significantly slower tumor progression in KO mice compared
WT mice (Figure 4.15B-C). Together, these observations suggest that the ability of
MDSC to regulate effector T cell function in vivo is impaired in the absence of CAT2.
In summary, our results identify that y+ and y+L systems transport L-Arg into
MDSC. The y+ system member CAT2 is induced in MDSC upon acquisition of suppressive
function. As a regulator of MDSC suppressor activity CAT2 is required for MDSC to
control T cell immunity ex vivo and in vivo.
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Discussion
Tumors induce various mechanisms to escape the destruction by immune cells.
One of these mechanisms is the recruitment of myeliod-derived suppressor cells and
generating an immunosuppressive environment (1). With the ability to impair T cell
functions and promote tumor progression, MDSC are a major obstacle for the success of
cancer immunotherapy (29). As a result, blocking MDSC function has been an attractive
endeavor to complement cancer therapies. Indeed several studies demonstrated that
depletion of MDSC or inhibiting MDSC function impaired cancer progression (30, 31).
Although these studies are very promising, more specific strategies to block MDSC
suppressive function are needed.
MDSC mediate their inhibitory effects on T cells through diverse mechanisms
(32). MDSC metabolism of several amino acids impacts T cell responses (33). For
example, MDSC express enzymes that metabolize L-Arginine, L-Trytophan and cysteine,
leading to their consumption from the microenvironment. Depletion of these amino acids
results in T cell dysfunction (34-36). Additionally, MDSC can metabolize L-Arginine
and L-Phenylalanine and generate end products that block T cell activities (37, 38).
Since L-Arginine metabolism by ARG1 and NOS2 enzymes is the hallmark mechanism
for MDSC suppressive function (9), in this study we focused on the mechanism and the
functional impact of L-Arg uptake on MDSC. We postulated that we could control
MDSC activity by modulating L-Arg entry into cells. Therefore, we initiated studies to
identify the routes of L-Arg entry into MDSC.
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Gene expression analysis of L-Arg transporters revealed that only the members of
y+ and y+L systems are expressed in MDSC. L-Arg uptake experiments further verified
this observation. Blockade of L-Arg transport through b0,+ or B0,+ systems in MDSC did
not result in any alterations in total L-Arg uptake (data not shown). These results are
similar to Martin et al.’s findings that b0,+ or B0,+ systems do not contribute to L-Arg
transport in bone marrow derived macrophages (17). We also determined the
participation of y+ and y+L systems in L-Arg transport in MDSC. Results showed that y+
and y+L account for about 25% and 20% of total uptake, respectively. It is reported that
in bone marrow cells in addition to carrier-mediated transport through y+ and y+L
systems, L-Arg can be taken up into cells by basal diffusion (17, 39). Indeed, we
observed that a component of L-Arg uptake in MDSC could not be blocked by addition
of saturating levels of non-radioactive L-Arg in transportation assays (not shown).
Therefore, it is likely that in MDSC, basal diffusion or an unidentified L-Arg carrier is
responsible for the y+ and y+L independent L-Arg transport. Notably, comparison of LArg transport in intact and CAT2-deficient MDSC when y+ system was blocked revealed
that L-Arg import through y+ system is predominantly mediated through CAT2.
Interestingly, the total transport mediated by CAT2 in MDSC was ~10-fold lower than in
active macrophages. Comparative qPCR analysis revealed that macrophages had higher
Cat2 expression than MDSC (not shown). Although this observation might explain why
macrophages have higher L-Arg uptake than MDSC, it is previously reported that mRNA
levels of CATs do not necessarily reflect protein levels (14). Therefore, it is possible that
the increase in Cat2 mRNA expression in MDSC may not directly correlate with the
functional protein levels. Unfortunately, due to the lack of availability of specific
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antibodies we could not monitor CAT2 protein levels. Despite the compelling differences
in L-Arg uptake through CAT2, NO production between MDSC and macrophages was
altered in an equivalent manner in the absence of CAT2 (~70% for each cell type). One
possible explanation for these observations is that L-Arg compartmentalization might
vary between the two cell types. It is proposed that there are distinct L-Arg pools inside
the cells and the access of NOS2 to distinct pools might differ between different cell
types (14, 40).
Importantly, our data revealed that CAT2 expression in MDSC regulates
suppressive function. Characterization of CAT2-mediated MDSC suppressive
mechanisms revealed that in the RM1 ascites model MDSC activity is mainly mediated
through NOS2 metabolism. NOS inhibitor L-NMMA completely abrogated the
suppressive function in MDSC even at high MDSC:OTI ratios, whereas arginase
inhibitor, nor-NOHA had no effect. In support of these results, Raber et al. also showed
L-NMMA completely blocked MDSC suppressive effect, while nor-NOHA had no effect
(7). Although L-NMMA further inhibited the already reduced suppressive effect of Cat2/-

MDSC, we still detected residual suppressive activity, unlike Cat2+/+ MDSC. It was

reported previously that L-NMMA is transported through the y+ system and has the same
affinity for transporters as L-Arg (41). Therefore, it is likely that L-NMMA uptake in
CAT2 ablated MDSC is lower and may be insufficient to completely block suppressive
activity. Alternatively, ROS-mediated suppression, at least in part, might account for the
residual suppression in Cat2-/- MDSC since Cat2-/- MDSC depend more on ROS to
suppress T cells than Cat2+/+ MDSC. More studies are needed to investigate the other
CAT2 related suppressive mechanisms.
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We also demonstrated that CAT2 is an important mediator of MDSC regulatory
functions using in vivo models of tumor formation. In EG7 cancer immunotherapy
models, we showed that loss of CAT2-mediated MDSC suppressor activity leads to
slower tumor growth. However, it is important to mention that in the absence of OTI
transfer, EG7 growth was not significantly different between Cat2+/+ and Cat2-/- mice. In
fact, tumor growth rate was comparable also in EL4, MB49 and RM1 tumor models.
When we injected male-derived MB49 bladder cancer cells into male mice, initially
tumor formation was slower in Cat2-/- mice. However, as tumors continued to progress
they reached to similar sizes in Cat2+/+ and Cat2-/- mice (Supplementary Figure 4.1A).
CAT2 is an important regulator for other cell types as well, including macrophages and T
cells (42, 43). The reason that tumor growth in Cat2-/- mice is not slower is most likely
because of the CAT2 related deficiencies in other cell types, especially T cells. Cat2 is
expressed in activated T cells (43, 44) and L-Arg is essential for T cell functions (45, 46).
In fact, our tumor growth experiments with MB49 cells support the hypothesis that the
similar tumor growth rate in Cat2+/+ and Cat2-/- mice is due to T cell deficiencies of Cat2/-

mice. When we injected male-driven MB49 cells into male mice, initially as expected

tumor growth was slower in Cat2-/- mice (Supplementary Figure 4.1A). On the
contrary, when MB49 cells were injected into female mice, the initial growth was faster
in Cat2-/- mice (Supplementary Figure 4.1B). When male-driven MB49 cells are
injected into female mice, Y chromosome associated antigens induce a tumor-antigen
specific immune response that target tumor cells for destruction (47). Therefore, it is
likely that the underlying reason for faster tumor formation Cat2-/- mice is the CAT2ablation related T cells deficiencies. Further studies are needed to elucidate the CAT2-
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dependent regulatory functions of multiple populations present in the tumor
microenvironment.
Together, our findings describe the contribution of different L-Arg transportation
systems in MDSC and define CAT2 as a major transporter that is induced in MDSC with
immediate suppressor function. Therefore, CAT2 is a marker for functionally active
MDSC. In addition, we demonstrate that CAT2 is a novel molecule mediating MDSC
suppressive function and causing diminished antitumor immune responses. Hence, CAT2
may be utilized as a target to modulate MDSC activity in inflammatory diseases.
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Figure 4.1. MDSC expand in tumor bearing animals.
Mice were injected with 106 MB49 bladder cancer cells subcutaneously (s.c.) on the
flank. 2 weeks after tumor inoculation, spleen and tumor were harvested. Population
percentages were measured by flow cytometry. The percentage of CD11b+Gr-1+ cells
were demonstrated under CD45+ gate (n=4). Data are representative of 2 independent
experiments. (* p= 0.0211) (A). Mice were injected with 106 RM1 prostate cancer cells
intraperitoneally (i.p.). After 6 days, spleen and i.p. exudate were collected. The
percentage of CD11b+Gr-1+ cells were demonstrated under SSC/FSC gate (n=4). Data are
representative of at least 20 independent experiments. (*** p=0.0002) (B). Percentages of
CD11b+Ly6ChighLy6G- (M-MDSC) and CD11b+Ly6ClowLy6G+ (G-MDSC) were
demonstrated under CD11b+ gate. Data are pooled from 6 independent experiments (C).
Error bars indicate ±SEM.
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Figure 4.2. Suppressor activity is limited to MDSC at the tumor site.
CD11b+Gr-1+ (A) and CD11b+Ly6ChighLy6G- (M-MDSC) and CD11b+Ly6ClowLy6G+
(G-MDSC) cells (B) were isolated from the spleens and i.p. exudates of RM1 tumor
bearing mice and naïve control mice (n=3-4). mRNA was isolated from freshly sorted
cells and analyzed by qPCR for Arg1 and Nos2 expression. Data are representative of at
least 5 experiments. Sorted CD11b+Gr-1+ cells were co-cultured with OTI cells for 18
hours. BrdU was added 6 hours before the end of culture and OTI proliferation was
determined by measuring BrdU incorporation in OTI cells by flow cytometry. Data are
pooled from 3 and 6 independent experiments for spleen and tumor, respectively (C).
Error bars indicate ±SEM.
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Figure 4.3. Tumor site MDSC express y+ and y+L system L-Arginine transporters.
CD11b+Gr-1+ cells were isolated by FACS from the i.p. exudates of RM1 tumor bearing
mice (n=5). mRNA was isolated from freshly sorted cells and analyzed by qPCR for the
expression of L-Arginine transporters that are members of y+, y+L, b0,+, B0,+ systems.
Data are representative of 2 independent experiments. Error bars indicate ±SEM.
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Figure 4.4. Cat2 is induced in functionally active MDSC.
CD11b+Gr-1+ cells were isolated from the bone marrow of naïve mice (n=3) and cultured
for 3 days in the absence or presence of GM-CSF, IFN-γ and IL-13. At the end of culture,
mRNA was isolated and analyzed by qPCR for Arg1, Nos2 and Cat2 expression (A).
Arg1, Nos2 and Cat2 expression in in vitro activated MDSC were monitored after 24, 48
and 72 hours of culture (B). CD11b+Gr-1+ (C) and CD11b+Ly6ChighLy6G- (M-MDSC)
and CD11b+Ly6ClowLy6G+ (G-MDSC) (D) cells were isolated from the spleens and i.p.
exudates of RM1 tumor bearing mice and naïve control mice. mRNA was isolated from
freshly sorted cells and analyzed by qPCR for Cat2 expression. Data are representative of
at least 3 experiments. Error bars indicate ±SEM.
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Figure 4.5. CAT2 expression is differentially regulated between tumor site and
splenic MDSC.
CD11b+Ly6ChighLy6G- (M-MDSC) and CD11b+Ly6ClowLy6G+ (G-MDSC) cells were
isolated by FACS from spleens and ascites of RM1 i.p. tumor bearing mice. RNA was
freshly isolated from sorted cells and transcript profile was analyzed by using Affymetrix
Mouse Gene 1.0 ST gene arrays (n= 4/group). Fold change was calculated as the ratio
between the average gene expression in tumor site MDSC and splenic counterparts. Fold
changes smaller than 1 were adjusted by replacing fold change by the negative of its
inverse.
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Figure 4.6. CAT2 mediates L-Arginine uptake in tumor MDSC.
Thioglycollate elicited peritoneal macrophages from Cat2+/+ (WT) and Cat2-/- (KO) mice
(n=5/group) were activated with LPS and IFN-γ for 18h. L-Arginine transport was
measured by using 6µCi/ml L-3[H]-Arg in Na+ containing buffer. For N-ethyl maleimide
(NEM), cells were pretreated with 5 mM NEM for 5 min and washed with transport
buffer before measuring uptake. Data are representative of 3 independent experiments.
(**** p<0.0001) (A). CD11b+Gr-1+ cells were isolated from ascites of RM1 tumor
bearing WT and KO mice and cultured over night with GM-CSF, IL-13 and IFN- γ. Total
L-Arginine transport was measured by using 6µCi/ml L-3[H]-Arg in Na+ containing
buffer. Data are pooled from 3 independent experiments. (n=13/group, * p=0.0184) (B).
Data correspond to reduction of total L-3[H]-Arg transport when y+L system was blocked
due to the presence of 5 mM L-Leu in transport media. Data are pooled from 4
independent experiments (n=13/group) (C). Data correspond to reduction of total L-3[H]Arg transport when y+ system was blocked using 5 mM NEM in WT and KO MDSC.
Data are pooled from 3 independent experiments (n=10/group, ** p=0.0016) (D). All
error bars indicate ±SEM.
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Figure 4.7. Expression of multiple transport systems in MDSC.
CD11b+Gr-1+ cells were isolated by FACS from ascites of RM1 i.p. tumor bearing
Cat2+/+ (WT) and Cat2-/- (KO) mice and mRNA was freshly isolated and analyzed by
qPCR for expression of L-Arg carriers that are members of y+,y+L, b0,+, B0,+ systems.
Data are pooled from 2 independent experiments. Each datum point indicates the
expression level in an individual mouse.
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Figure 4.8. CAT2 modulates MDSC suppressive capacity.
CD11b+Gr-1+ cells were isolated from bone marrow of naïve Cat2+/+ (WT), Cat2+/- (Het)
and Cat2-/- (KO) mice and cultured with GM-CSF, IL-13 and IFN- γ. After 3 days naïve
OTIs were added to culture and cells were cultured for another 72 hours in the presence
of SIINFEKL at indicated ratios. Data are representative of 3 independent experiments
(n=3-4/group, ** p=0.0057, *** p=0.0001, **** p<0.0001) (A). CD11b+Gr-1+ cells were
isolated from tumor site and spleens of RM1 bearing WT and KO mice (n=3-5/group,
pooled) and co-cultured with preactivated OTIs for 18 hours. Data are pooled from 5 and
3 independent experiments for tumor and for spleen, respectively (*** p=0.0002, ****
p<0.0001) (B). CD11b+Gr-1+ cells from the ascites of WT and KO RM1 i.p. tumor mice
(n=5/group, pooled) were co-cultured with naive OTI cells with SIINFEKL for 48 hours.
Protein transport inhibitor was added 6 hours before harvest. OTI proliferation (C) and
IFN-γ levels in OT-I cells were determined by flow cytometry (D). Data are
representative of 5 independent experiments. For all experiments, BrdU was added 6
hours before harvest. OTI proliferation was evaluated by measuring BrdU incorporation.
Error bars indicate ±SEM.
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Figure 4.9. CAT2 modulates MDSC suppressive activity in MB49 model.
Cat2+/+ (WT) and Cat2-/- (KO) mice were subcutaneously injected with 5x105 MB49
bladder cancer cells (n=7 mice/group, pooled). CD11b+Gr-1+ cells were isolated by
FACS from the tumor site and spleen and co-cultured with preactivated OTI cells at 1:1
ratio for 48 hours. EdU was added 2 hours before harvest. OTI proliferation was
evaluated by measuring EdU incorporation. Data are representative of 2 independent
experiments.
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Figure 4.10. CAT2 modulates suppressive capacity of MDSC subsets.
CD11b+Ly6ChighLy6G- (M-MDSC) and CD11b+Ly6ClowLy6G+ (G-MDSC) were isolated
by FACS from the ascites (A), spleens (B) and bone marrow (C) of RM1 i.p. tumor
bearing mice (n=3-5/group, pooled) and co-cultured with naive OTI cells with SIINFEKL
for 48-72 hours. BrdU was added 6 hours before harvest. OTI proliferation was evaluated
by measuring BrdU incorporation. Data are pooled from 4-5 independent experiments (*
p=0.0312 at 0.5:1 and 0.0139 at 0.25:1). For all experiments, Error bars indicate ±SEM.
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Figure 4.11. Cat2-/- MDSC have reduced NO production.
Nitrite formation was measured in a Griess Assay in thioglycollate elicited peritoneal
macrophages from Cat2+/+ (WT) and Cat2-/- (KO) mice (n=4/group) that were activated
with LPS and IFN-γ for 18h. Data are representative of at least 2 independent
experiments (**** p<0.0001) (A) CD11b+Gr-1+ MDSC (B) and MDSC subsets (C) were
isolated from tumor site of RM1 WT and KO mice and cultured with or without LPS and
IFN-γ for 24 hours. Nitrite formation was measured in a Griess Assay. Data are pooled
from 2 independent experiments (n=5-9 mice/group for MDSC. ** p=0.0065, n=4/group,
pooled for subsets. * p=0.0426). Urea levels were measured in CD11b+Gr-1+ cells
isolated from the bone marrow and ascites of RM1 WT and KO mice (n=4/group). Data
are representative of 3 independent experiments (D). WT and KO MDSC were used in a
48-hour suppression assay with preactivated OTI at 2:1 (MDSC:OTI) ratio in the
presence or absence of NOS inhibitor, LNMMA (0.5 mM), ARG inhibitor, nor-NOHA
(0.5 mM). BrdU was added 6 hours before harvest. OTI proliferation was evaluated by
measuring BrdU incorporation. Data are pooled from 2 independent experiments (H).
Errors bars indicate ±SEM.
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Figure 4.12. Regulation of ARG1 and NOS2 expression is independent of CAT2.
Cells in the ascites of RM1 bearing Cat2+/+ (WT) and Cat2-/- (KO) mice were stained
with anti-ARG1 (A), anti-NOS2 (C) or the appropriate isotype control. Mean fluorescent
intensities (MFI) of ARG1 (B) and NOS2 (D) were reported under CD11b+Gr-1+ gate.
(n=4-5 mice/group). Data are representative of 3 independent experiments. Errors bars
indicate ±SEM.
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Figure 4.13. Cat2-/- MDSC have increased ROS production.
Cells from ascites of i.p. RM1 bearing WT and KO mice are analyzed for ROS levels.
DCFDA signal is analyzed under the gates for CD11b+Gr-1+ (n=4/group) (A) and
CD11b+LyChighLy6G- (M-MDSC) and CD11b+LyClowLy6G+ (G-MDSC) subsets
(n=8/group, data are pooled from 2 independent experiments) (B). Signal intensity is
represented as MFI. CD11b+Gr-1+ cells were isolated by FACS from the ascites of RM1
i.p. tumor bearing Cat2+/+ (WT) and Cat2-/- (KO) mice (n=5/group, pooled). 6 days after
tumor implantation and suppression assay was performed at 2:1 (MDSC:OTI) ratio for 48
hours in the presence of differing concentrations of ROS inhibitor, NAC (C). WT MDSC
were used for suppression assay at indicated MDSC:OTI ratios with or without 10 mM
NAC (D). Data are representative of at least 2 independent experiments. All suppression
assays were performed by co-culturing MDSC with preactivated OTI cells for 48 hours.
BrdU was added 6 hours before harvest. OTI proliferation was evaluated by measuring
BrdU incorporation.
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Figure 4.14. CAT2-/- MDSC display diminished capacity for controlling T-cell
immunity in vivo.
Cat2-/- mice were injected intradermally with 3x106 EG7 lymphoma cells alone, 3x106
EG7 with 104 activated OTIs, 3x106 EG7 with 104 activated OTIs and 104 Cat2+/+ or
Cat2-/- CD11b+Gr-1+ cells. Tumor growth was monitored. Tumor size was calculated as
(W2 x L) /2 [mm3]. Errors bars indicate ±SEM. Data are pooled from 2 independent
experiments (n=5-6 mice/group). p values for the comparison of WT or KO MDSC
received groups are 0.0001, 0.0003 and 0.0033 on Day 5, 8 and 11, respectively.
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Figure 4.15. CAT2-/- MDSC have reduced capacity for controlling antitumor T cell
immunity in vivo.
Cat2+/+ mice were injected subcutaneously 3x106 EG7 cells. After 7 days, mice received
differing numbers of activated OTI cells intravenously. Tumor size was measured every 3
days (A). Cat2+/+ and Cat2-/- mice were injected subcutaneously (s.c.) (B) or intradermally
(i.d.) (C) with 3x106 EG7 or EL4 lymphoma cells. 7 days after tumor inoculation, s.c. and
i.d. tumor bearing mice were intravenously injected with 1.5x106 and 106 activated OTI
cells, respectively. Tumor growth was monitored. For all experiments, tumor size was
calculated as (W2 x L) /2 [mm3]. Errors bars indicate ±SEM.
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Supplementary Figure 4.1. CAT2 regulates tumor growth at initial stages of tumor
formation.
Cat2+/+ and Cat2-/- male (n= 4-5 mice/group, * p=0.0352) (A) and female (n= 10
mice/group, * p=0.0156) (B) mice were injected subcutaneously (s.c.) with 106 and 5x105
male-driven MB49 bladder cancer cells respectively. Tumor growth was monitored. For
all experiments, tumor size was calculated as (W2 x L) /2 [mm3]. Errors bars indicate
±SEM.
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CHAPTER 5. REGULATION OF MYELOID-DERIVED SUPPRESSOR CELL
DIFFERENTIATION

Abstract
Myelopoiesis is altered in inflammation and cancer. Such pathological conditions
stimulate myelopoiesis, inhibit differentiation of immature myeloid cells and induce their
activation. These immature myeloid cells with the ability to negatively regulate innate
and adaptive immune responses are called myeliod-derived suppressor cells (MDSC).
MDSC that reside in different anatomical locations display different functional
characteristics. As immature cells, MDSC are very plastic in nature. We hypothesized
that the anatomical location where MDSC reside regulates the capacity of MDSC to
differentiate into other cell types. Using murine models of prostate cancer, we evaluated
the capacity of CD11b+Ly6C+Ly6G- monocytic MDSC (M-MDSC) to differentiate into
osteoclasts and Ly6G+ granulocytic MDSC (G-MDSC). Here we show that in vitro
differentiation of M-MDSC into osteoclast or G-MDSC is restricted to cells isolated from
peripheral organs such as the spleen and bone marrow. Tumor site M-MDSC do not form
osteoclasts or G-MDSC in vitro. Moreover, we provide evidence that osteoclast
formation by M-MDSC is regulated by cationic amino acid transporter 2 (CAT2),
suggesting a role for nitric oxide (NO) in the regulation of osteoclastogenesis. However,
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differentiation into G-MDSC is independent of NO. We also show that the tumor site
MDSC have higher p53 activity than peripheral MDSC and that induction of p53 activity
in vitro increases the differentiation capacity of the bone marrow CD11b+Ly6C+Ly6Gcells. Overall, these findings underline the impact of anatomical microenvironment in
MDSC differentiation and show that this process can be regulated by p53 activity.

Introduction
Myelopoiesis is the regulated process of myeloid cell formation. Common
myeloid progenitor cells in bone marrow give rise to immature monocytic and
granulocytic cells that develop along divergent pathways. Monocytic cells differentiate
into macrophages and dendritic cells (1) and granulocytic cells form terminal
polymorphonuclear cells (2). This process is altered in inflammation and cancer. Such
pathological conditions stimulate myelopoiesis, inhibit differentiation of immature
myeloid cells and induce their activation (3, 4). These immature myeloid cells with the
ability to negatively regulate innate and adaptive immune responses are called myeliodderived suppressor cells (MDSC) (3). MDSC are a heterogeneous population and the
cells of myeloid origin that compose MDSC display morphological, phenotypical and
functional differences (3). This heterogeneity of MDSC convolutes the understanding of
where MDSC are placed in the myeloid cell hierarchy and complicates the
comprehension of MDSC biology. Therefore, identifying subpopulations that constitute
MDSC and delineating the origin and fate of these cells has been a common goal.

158
Studies in our laboratory focus on the functional differences of MDSC that reside
in different anatomical locations. We demonstrated that in tumor bearing mice MDSC
that reside in locations other than tumors are precursors and lack suppressor activity (5).
The precursor MDSC gain suppressive function only after being exposed to inflammatory
signals present at the tumor microenvironment (5). The differential regulation of MDSC
function based on anatomical location led us to thinking that differentiation of MDSC
might also be dictated by anatomical location. It is known that factors present in the
tumor microenvironment can regulate myeloid cell differentiation/maturation (4). In fact,
early studies demonstrated that MDSC differentiation characteristics are influenced by
the presence or absence of tumor derived factors in culture media (6). In addition,
Gabrilovich et al. adoptively transferred spleen MDSC into tumor bearing animals and
observed that cells recruited to the tumor site and spleen display contrasting
differentiation patterns (7). Therefore, we hypothesized that anatomical location in
which MDSC reside regulates the differentiation of MDSC.
Increased bone destruction is a common characteristic of various cancers. Tumors
secrete or induce the production of factors that stimulate formation of osteoclasts, boneresorbing cells (8). Macrophages are the major precursors of osteoclasts. In the presence
of macrophage-colony stimulating factor (M-CSF) and receptor activator of NF-κB
ligand (RANKL), macrophages differentiate into osteoclasts (9). Recently, it is shown
that MDSC can also differentiate into osteoclasts (10, 11).
MDSC consist of two main subsets: monocytic (M-MDSC) and granulocytic (GMDSC). These subsets are phenotypically defined by the expression of cell surface
molecules CD11b+Ly6C+Ly6G- and CD11b+Ly6ClowLy6G+, respectively (3). Although
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the proportion of M-MDSC and G-MDSC populations depends on the context of tumor
microenvironment, G-MDSC is shown to be the predominant MDSC subset and is found
in higher ratios than M-MDSC in most tumor models (6). Interestingly, a recent study has
shown that M-MDSC population has much greater proliferative capacity than G-MDSC
(6). The greater expansion of G-MDSC in tumor bearing hosts instead of highly
proliferative M-MDSC was proposed to be due to the ability of M-MDSC to replenish GMDSC pool (6). It was shown that both in vitro and in vivo a proportion of M-MDSC that
are isolated from the bone marrow and spleen have the ability to differentiate into GMDSC, as identified by the acquisition of a Ly6G+ phenotype and induced reactive
oxygen species (ROS) formation that are characteristics of G-MDSC (6).
In order to test the hypothesis that anatomical location regulates MDSC
differentiation, we investigated and compared the differentiation capacity of MDSC
isolated from tumor site or peripheral sites. Comparison of MDSC subsets from tumor
site and spleen revealed that differentiation into osteoclasts was restricted to M-MDSC
subset isolated from spleen. Tumor M-MDSC were unable to differentiate into
osteoclasts. Moreover, we identified cationic amino acid transporter 2 (CAT2) as a
regulator of M-MDSC differentiation into osteoclasts, suggesting a role for NO in MMDSC osteoclastogenesis. Similarly, we determined that in vitro differentiation of MMDSC into G-MDSC was limited to M-MDSC isolated from the spleen and bone
marrow. Tumor M-MDSC did not differentiate into G-MDSC. Together, these data
suggest that the anatomical location in which MDSC reside affects differentiation of
MDSC.
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The tumor suppressor p53 is a regulator of proliferation, senescence and
apoptosis. Recent studies emphasize a relation between p53 activity and immune
responses (12). p53 is induced upon cellular stress such as DNA damage and hypoxia
(13). p53 is up-regulated at cancer-induced chronic inflammation sites due increased
formation of reactive oxygen (ROS) and nitrogen species (RNS). ROS and RNS have
been shown to induce p53 accumulation in immune cells by either mimicking a hypoxic
response or by inducing DNA damage (13, 14). In addition to its fundamental roles in
controlling genome stability, p53 is central to numerous other cellular processes
including stemness and differentiation (15). p53 is implicated to play a role in induction
of differentiation. Activation of p53 causes lengthened cell cycles. Longer cell cycles
allow the cells to go through differentiation and are a typical feature of differentiated
cells (15). One of the hallmark mechanisms of MDSC suppressive function is the activity
of nitric oxide synthase 2 (NOS2) (3). MDSC at the tumor site have elevated NOS2
activity, and hence ROS and RNS formation, compared to precursor cells at the bone
marrow and spleen (5). Therefore, we hypothesized that p53 is up-regulated in the tumor
site MDSC due to hypoxic environment and enhanced ROS/RNS production. Increased
p53 activity in the tumor site MDSC induces differentiation, thereby yielding an MDSC
population that is less plastic than precursor cells. Here we show that the tumor site MMDSC have elevated p53 activity and that induction of p53 increases the differentiation
of precursor M-MDSC in vitro.
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Materials and Methods
Mice and Animal Models
C57BL/6 mice were purchased from Jackson Laboratories. Cat2-/- mice were generated
as described previously (16). Both female and male mice between 7 and 12 weeks of age
were used for all tumor studies. All animal experiments for this study were approved by
the Purdue University Animal Care and Use Committee. For tumor studies, mice were
injected with 1x106 RM1 prostate cancer cells intraperitoneally and sacrificed 6 days
after tumor cell inoculation.
Cell Isolation and Generation
Bone marrow was collected from femurs and tibias. Spleens were harvested and ground
using frosted slides. Cells from ascitic tumors were collected by flushing the peritoneal
cavity with 10 ml PBS. Red blood cells were lysed by using ACK buffer and cells were
passed through a 70 µm filter. CD11b+Ly6ChighLy6G- and CD11b+Ly6ClowLy6G+ cells
were isolated from bone marrow, spleen and peritoneal cavity exudate by FACS. All cell
sorting was performed using a BD FACSAria III. Sort purities were above 95%.
In Vitro Osteoclast Differentiation Assay
CD11b+Ly6ChighLy6G- and CD11b+Ly6ClowLy6G+ cells were isolated from spleens and
ascites of RM1 tumor bearing mice. M-MDSC and G-MDSC were seeded at 50000 and
250000 cells/well, respectively and were cultured with M-CSF (25 ng/ml) and RANKL
(50 ng/ml) for 7 days. The presence of osteoclasts were detected by tartarate-resistant
acid phosphatase (TRAP) staining.
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In Vitro Granulocytic-MDSC Differentiation Assay
CD11b+Ly6ChighLy6G- and CD11b+Ly6ClowLy6G+ cells were isolated from spleens, bone
marrow and ascites of RM1 tumor bearing mice. MDSC subsets were then cultured with
granulocyte-macrophage colony-stimulating factor (GM-CSF) (40 ng/ml, Peprotech) for
3 or 5 days in the absence or presence of S-Nitrosoglutathione (SNOG) (25µM), NGMethyl-L-arginine acetate (L-NMMA) (0.5 µM, Cayman Chemical) or Nutlin-3 (8 µM,
Cayman Chemical) as indicated. After 3 or 5 days, cells are harvested and stained for
Ly6C and Ly6G.
Flow Cytometry
Single cell suspensions were incubated with TruStain fcX (Clone: 93) and stained with
conjugated antibodies by incubating at 4°C for 20 minutes. MDSC were labelled with
anti-CD11b (Clone: M1/70), anti-Ly-6C (Clone: HK1.4) and anti-Ly-6G (Clone: 1A8).
For p53 staining, cells were first stained for surface molecules as described and then
fixed by adding 70% cold ethanol. Ethanol was added dropwise onto cell pellet while
vortexing. After addition of ethanol, cells were incubated at -20°C for at least 2 hours.
Fixed cells were stained by incubating at room temperature for 20 minutes with undiluted
FITC Mouse Anti-p53 (BD PharmingenTM)
Quantitative Real Time PCR
Total RNA was isolated from freshly sorted cells using the E.Z.N.A. Total RNA Kit I
(Omega Bio-tek) and cDNA synthesis was performed using qScriptTM cDNA SuperMix
(Quanta Biosciences) according to the manufacturer’s instructions. Multiplex qRT-PCR
was performed using PerfeCTa® FastMix® II (Quanta Biosciences), PrimeTime® qPCR
gene probe (IDT) for p21 (Mm.PT.56a.588461) and endogenous control 18s rRNA
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(Applied Biosystems). Relative mRNA expression was calculated by the formula
2–[Ct(gene) – Ct(18s rRNA)], where Ct is the threshold cycle value.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analyses were performed using GraphPad
Prism software. p values were calculated using Student’s t test or 1-way ANOVA with
Boneferroni’s posttest as indicated. Differences were considered significant where p <
0.05.

Results
5.4.1

The Ability of M-MDSC to Differentiate into Osteoclasts In Vitro Is Limited
to Precursor Splenic Cells.
MDSC are previously reported to be able to differentiate into osteoclast (9, 10).

Therefore, in order to determine the effect of anatomical location on MDSC
differentiation, we investigated the capacity of CD11b+Ly6C+Ly6G- and
CD11b+Ly6C+Ly6G+ cells to form osteoclasts. To this end, we isolated MDSC subsets,
M-MDSC and G-MDSC, from the tumor site and spleens of RM1 tumor bearing mice
and cultured sorted cells in the presence of M-CSF and RANKL for 7 days. Then to
determine the cells that differentiated into osteoclast, we stained cells for TRAP.
Multinucleated TRAP+ cells indicated osteoclasts. In accordance with the established
knowledge that osteoclast precursors are the cells of monocyte/macrophage lineage (8),
our data showed that the capacity to differentiate into osteoclasts was confined to the
monocytic MDSC (Figure 5.1). Interestingly, only CD11b+Ly6C+Ly6G- cells isolated
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from the spleen could differentiate into osteoclasts. M-MDSC isolated from tumor site
did not form osteoclasts (Figure 5.1). These observations supported our hypothesis that
MDSC residing at different anatomical locations display different characteristics for
differentiation.

5.4.2

The Ability of M-MDSC to Differentiate into Osteoclasts Is Regulated by
CAT2.
Inducible nitric oxide synthase (NOS2) activity and the consequent nitric oxide

(NO) generation have been indicated to have inhibitory effects on RANKL-mediated
osteoclast formation (17). Therefore, we hypothesized that elevated NOS2 expression and
NO formation in tumor M-MDSC block osteoclast differentiation. Data from our
laboratory identified that in the absence of cationic amino acid transporter 2 (CAT2), NO
formation by NOS2 is impaired. CAT2-/- MDSC produce significantly lower amounts of
NO. Hence, to evaluate the contribution of NO to osteoclastogenesis of M-MDSC, we
investigated the capacity of CAT2-/- M-MDSC to form osteoclasts. Unlike intact MMDSC, CAT2-/- M-MDSC from both spleen and ascites of tumor bearing mice were able
to differentiate into osteoclasts (Figure 5.1). Together, these data highly suggest that only
precursor M-MDSC that reside at the peripheral sites can form osteoclasts. M-MDSC at
the tumor site lack the ability to differentiate into osteoclasts. The inhibition of
osteoclastogenesis of tumor site M-MDSC is likely to be due to the elevated NO
formation since CAT2-/- M-MDSC residing at the tumor site are capable of forming
osteoclasts.
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5.4.3

The Ability of M-MDSC to Differentiate into a Granulocytic Phenotype In
Vitro Is Restricted to the Bone Marrow and Spleen Precursors.
In order to investigate whether our observations were confined specifically to

osteoclastogenesis, we evaluated the ability of M-MDSC to differentiate into G-MDSC.
Based on our observation that tumor M-MDSC is incapable of differentiating into
osteoclasts unlike spleen M-MDSC, we hypothesized that the ability of M-MDSC to
replenish G-MDSC pool might be a characteristic of precursor MDSC, but not
functionally active tumor site M-MDSC. To this end, we isolated M-MDSC from the
bone marrow, spleen and tumor site of RM1 tumor bearing mice and cultured them in
vitro in the presence of GM-CSF. We observed that a proportion of bone marrow and
spleen M-MDSC converted to a granulocytic phenotype as determined by Ly6G
expression. Interestingly, M-MDSC at the tumor site were unable to induce Ly6G
expression (Figure 5.2). This finding suggests the capacity of M-MDSC to differentiate
into G-MDSC is also influenced by the anatomical location in which M-MDSC reside
and that at the tumor site M-MDSC population represents a different differentiation state
than the precursor M-MDSC populations at the bone marrow and spleen.

5.4.4

Tumor Site MDSC Have Increased p53 Activity.

Next we sought to understand the underlying mechanisms that give rise to
differential regulation of MDSC differentiation at the tumor site. p53 is induced in
inflammatory and hypoxic sites and can regulate cellular differentiation (18). In order to
test if p53 expression is induced at the tumor site in RM1 ascites model, we investigated
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p53 levels in tumor site M-MDSC and bone marrow precursor cells by flow cytometry
(Figure 5.3A) and by measuring the mRNA expression levels of p53 target gene p21
(Figure 5.3B). As expected, we detected higher p53 protein and higher p21 gene
expression in the tumor site M-MDSC in comparison to precursors.

5.4.5

Induction of p53 Activity Induces Differentiation of the Bone Marrow MMDSC into Granulocytic Phenotype.
Next, we investigated the role of p53 in inducing differentiation of M-MDSC into

G-MDSC. We isolated M-MDSC from the bone marrow and tumor site of tumor bearing
mice and cultured these cells for 3 days in the presence or absence of Nutlin-3. Nutlin-3
is a small molecule that increases p53 activity in cells by inhibiting p53 protein
degradation (19). At the end of 3 days, we monitored Ly6G expression to investigate
differentiation of M-MDSC into G-MDSC. As determined by induction of p21 gene
expression, Nutlin-3 induced p53 activity in cultured cells (Figure 5.4C). As expected a
proportion of bone marrow precursor M-MDSC, but not tumor site M-MDSC,
differentiated into G-MDSC. Nutlin-3 treatment induced differentiation of precursor cells
by about 4-fold, but it did not affect the absence of in vitro differentiation in tumor site
M-MDSC (Figure 5.4A).
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5.4.6

The Ability of M-MDSC to Differentiate into a Granulocytic Phenotype Is
Independent of CAT2 and NO.
One of the most important products of NOS2 activity is nitric oxide (NO).

Addition of NO donors or NO-secreting macrophages is shown to induce p53 activity in a
breast cancer cell line (14). Since MDSC have elevated NO levels, we suspected that NO
production in MDSC may be one of the p53 inducing factors. To test the role of NO in
the induction of p53 in tumor site M-MDSC, we utilized Cat2-/- mice. We have
previously shown that in the absence of CAT2, MDSC produce lower levels of NO.
Hence, if NO plays a role in increased p53 levels in tumor site MDSC, CAT2-/- MDSC
should have lower p53 levels. Interestingly, we observed that CAT2-/- MDSC have
comparable levels of p53 and p21 expression, suggesting that NO does not play a role in
increased p53 levels of tumor site MDSC. In order to further evaluate the role of NO, we
investigated its contribution to differentiation of M-MDSC. We cultured bone marrow
and tumor site M-MDSC with a NO donor, S-Nitrosoglutathione (SNOG) and a NOS
inhibitor, NG-Monomethyl-L-arginine (L-NMMA), and monitored differentiation into GMDSC. Data demonstrated that M-MDSC capacity to differentiate into G-MDSC is
similar upon supplementation of NO, blockade of NOS activity or in the absence of
CAT2 (Figure 5.5), suggesting that NO is not involved in M-MDSC differentiation.
Altogether, our findings indicate that the anatomical location in which MDSC
reside at controls the plasticity of MDSC. The in vitro differentiation of M-MDSC into
either G-MDSC or osteoclasts is limited to precursor MDSC at the peripheral site. Tumor
M-MDSC do not differentiate into G-MDSC or osteoclasts in vitro. In addition, MDSC
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differentiation into different cell types are likely to be regulated by unique factors, since
NO modulates M-MDSC osteoclastogenesis but not the differentiation into G-MDSC.

Discussion
Despite the common view that monocytic and granulocytic immature cells have
distinct development paths, in cancer precursor M-MDSC from the spleen and bone
marrow have the ability to differentiate into G-MDSC in vitro. In this study we show that
this differentiation process is limited to precursor M-MDSC and is not observed in vitro
in functionally active M-MDSC of the tumor site. Moreover, we demonstrate that this
phenomenon is not limited to differentiation into G-MDSC. The capability of forming
osteoclasts in vitro is also limited to precursor M-MDSC from the spleen. Thus, our
results signify the impact of anatomical location in the differentiation process of MMDSC.
Our previous results identified that anatomical location of MDSC controls the
suppressor function (5). Only MDSC at the tumor site possess suppressor activity as
orchestrated by the increased Arginase 1 and NOS2 activity accompanied by NO
production. Several studies indicated that NO has inhibitory effects on osteoclast
formation (17, 20, 21), which led to the hypothesis that increased NO in tumor M-MDSC
might be responsible from blocking osteoclast differentiation. To test this, we evaluated
the differentiation capacity of tumor CAT2-/- M-MDSC. One of the hallmarks of CAT2-/MDSC is the reduced NO formation. Therefore, we expected tumor CAT2-/- M-MDSC to
form osteoclasts. In contrast to the intact tumor M-MDSC, CAT2-/- M-MDSC indeed
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were capable of differentiating into osteoclasts. MDSC have previously been shown to
contribute to bone resorption in cancer by differentiation into osteoclasts (10, 11, 22, 23).
One of these studies reported that NO signaling was necessary for osteoclastogenesis of
MDSC (11, 24). The discrepancies between our and Sawant et al.’s findings necessitate a
more direct evaluation of the role of NO in tumor M-MDSC osteoclastogenesis.
Although the inhibitory effects of NO in osteoclast formation are well established, most
of these data come from studies involving macrophages (17, 20, 21). NO might be
playing a different role in the osteoclast differentiation of MDSC. It is possible that
CAT2 mediates regulation of osteoclast formation through NO-independent mechanisms.
Therefore to directly measure the effect of NO, further experiments are needed to be
performed utilizing Nos2-/- MDSC or specific NOS inhibitors.
We also investigated the role of NO in regulating M-MDSC differentiation into
G-MDSC. Interestingly, NO did not play a role in differentiation into G-MDSC. Both
intact and CAT2-/- M-MDSC displayed a similar ratio of differentiation. In addition,
supplementation of NO to the cell culture or the blockade of NOS activity had no effect
on G-MDSC differentiation. These results indicate that differentiation of M-MDSC into
different cell types might be mediated by unique factors, such that NO is important in
osteoclastogenesis but not in differentiation into G-MDSC. We were then interested in
identifying the factors regulating the latter.
p53 is an important factor for the regulation of differentiation. Our data identified
p53 as a mediator of M-MDSC differentiation into G-MDSC. Induction of p53 activity in
vitro increased the capacity of the bone marrow M-MDSC to form G-MDSC 4-fold.
However, the tumor M-MDSC retained the inability to form G-MDSC. Unlike precursor
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M-MDSC at the bone marrow, expression of p53 and its target gene p21 is up-regulated
in the tumor site M-MDSC. This observation led us to speculate that increased p53 levels
may lead to in vivo differentiation of M-MDSC at tumor site, thereby reducing the
plasticity of tumor site M-MDSC. Hence, representing a more differentiated state tumor
site M-MDSC do not further differentiate in vitro. On the other hand precursor M-MDSC
of bone marrow with lower p53 levels represent a more plastic population and have the
ability to differentiate in vitro. In favor of our hypothesis, Gabrilovich et al. showed that
tumor microenvironment induces differentiation of CD11b+Gr-1+ MDSC in vivo (7).
Moreover, there is a recent paper that shows p53-/- mice have higher numbers of MMDSC at the tumor site compared to p53+/+ mice (25). We reason that this is because in
vivo increased p53 levels induce differentiation of M-MDSC into G-MDSC. In the
absence of p53 this process is inhibited, thereby resulting in accumulation of M-MDSC
population.
MDSC-mediated T cell suppression has detrimental effects in cancer patients.
MDSC are demonstrated to correlate with increased tumor progression and metastasis
accompanied by decreased patient survival (26, 27). Therefore, MDSC present a major
obstacle for cancer therapy. One of the strategies for eliminating MDSC population in
cancer patients is to induce differentiation of MDSC into non-immune suppressor cells.
All-trans retinoic acid (ATRA) has been shown to drive the differentiation of MDSC in
vitro and treatment with ATRA improved immune response in cancer patients (28).
Therefore, identification of MDSC development and differentiation is very important in
that knowledge of underlying mechanisms can enable us to modulate MDSC population.
We believe that our observations in this study may provide a foundation for strategies to
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eliminate MDSC in cancer patients by stimulating their differentiation into other cells
types.
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Figure 5.1. MDSC differentiation into osteoclasts is limited to precursor M-MDSC.
CD11b+Ly6C+Ly6G- (M-MDSC) and CD11b+Ly6C+Ly6G+ (G-MDSC) isolated from
spleens and ascites of RM1 tumor bearing wild type or Cat2-/- mice (n=5/group, pooled).
M-MDSC (50000 cells/well) and G-MDSC (250000 cells/well) are cultured with M-CSF
and RANKL for 7 days. Immunohistochemistry is performed for TRAP in M-MDSC and
G-MDSC cultures (A) and TRAP+ cells are counted (B). P < 0.01, 1-way ANOVA using
Boneferroni’s posttest.
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Figure 5.2. In vitro Differentiation of M-MDSC into G-MDSC is restricted to
precursor cells of bone marrow and spleen.
C57Bl/6J mice are injected with RM1 tumor cells i.p. After 6 days CD11b+Ly6C+Ly6Gcells are isolated by FACS sorting from bone marrow, spleen and ascites of tumor
bearing animals (n=5, pooled) and cultured with GM-CSF containing media. After 5 days
cells are harvested and stained for Ly6C and Ly6G surface markers. Proportion of Ly6G+
cells are determined by flow cytometry (A). Percentages of Ly6C+Ly6G+ cells after 5
days (B) or 3 days (C) of culture. Data are pooled from 1-3 independent experiments.
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Figure 5.3. Tumor site M-MDSC have up-regulated levels of p53 expression.
Bone marrow and ascites of RM1 tumor bearing animals (n=3, pooled) are stained for
CD11b, Ly6C, Ly6G and fixed with ethanol to be processed for intracellular p53
staining. Flow cytometry analysis of p53 expression are performed under
CD11b+Ly6C+Ly6G- gate (A). CD11b+Ly6C+Ly6G- cells are isolated by FACS sorting
from bone marrow and ascites of i.p. RM1 tumor bearing animals (n=3). mRNA is
freshly isolated from sorted cells and analyzed by qPCR for p21 expression. Each data
point indicates one mouse (B).
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Figure 5.4. p53 activity induces M-MDSC differentiation.
C57Bl/6J mice are injected with RM1 tumor cells i.p. After 6 days CD11b+Ly6C+Ly6Gcells are isolated by FACS sorting from bone marrow and ascites of tumor bearing
animals (n=4, pooled) and cultured with GM-CSF containing media with or without
Nutlin-3 (8 μM). After 3 days of culture Ly6C and Ly6G expression is determined by
flow cytometry (A). Percentages of Ly6C+Ly6G+ cells are calculated. Data are pooled
from 2 independent experiments (B). After 3 days cells are harvested p21 expression is
analyzed by qPCR using mRNA freshly isolated from sorted cells before and after culture
(C).
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Figure 5.5. NO does not modulate p53 activity and its role in M-MDSC
differentiation.
C57Bl/6J and Cat2-/- mice are injected with RM1 tumor cells i.p. After 6 days
CD11b+Ly6C+Ly6G- cells are isolated by FACS sorting from bone marrow and ascites of
tumor bearing animals (n=4/group, pooled) and cultured with GM-CSF containing media
with or without Nutlin-3 (8 μM), SNOG (25 μM), L-NMMA (0.5 μM). After 3 days cells
are harvested and stained for Ly6C and Ly6G surface markers and analyzed by flow (A).
Percentages of Ly6C+Ly6G+ cells are calculated (B).
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CHAPTER 6. SUMMARY AND FUTURE DIRECTIONS

The goal of the research presented in this dissertation is to understand the regulation
of immunological environment in benign and tumor-induced inflammation. Based on our
findings that myeloid-derived suppressor cells (MDSC) constitute a major portion of
immune populations recruited to the inflammatory sites in prostatitis and cancer, we
focused on MDSC-mediated regulation of inflammation in both diseases. To this end, we
aimed to identify molecular mechanisms that mediate MDSC functional activity with an
ultimate goal of providing unique control points that can be utilized in the clinic to
modulate MDSC function in disease.
MDSC are a heterogeneous population of immature myeloid cells that expand
during pathological conditions. MDSC are characterized by their immature phenotype
and immunosuppressive function. The hallmark activity of MDSC is the inhibition of T
cell responses. Therefore, MDSC are beneficial in autoimmune diseases, where they
ameliorate the disease by suppressing T cell activity, and deleterious in cancer. By
inhibiting antitumor immunity, they promote cancer progression (1). As a result,
controlling MDSC function is a critical strategy to improve disease therapies.
Identification of molecular pathways that control MDSC suppressive function and
differentiation is necessary for the development of effective strategies to target MDSC.
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Data we present herein identify two novel pathways, p38 and p53, that are
involved in MDSC functional activity and differentiation capacity, respectively. We
showed that p38-MAPK pathway regulates prostatic inflammation by controlling
cytokine production and by modifying MDSC-mediated immunoregulatory processes. In
the absence of p38 signaling, MDSC expansion in the inflamed prostate was diminished,
whereas there was an increase in T cell populations. Moreover, we provided evidence
that p38 directly regulates MDSC suppressive function. Inhibition of p38 reduced Nos2
expression in MDSC and abrogated their suppressor activity. Our findings are significant
in that a direct role for p38 pathway in regulating MDSC suppressive function has not
been previously demonstrated. Although the data we present here show p38-mediated
regulation of MDSC function, additional experiments are necessary to delineate the
components in this regulation. p38 signaling has been indicated to increase MDSC
survival (2). This observation might explain the diminished MDSC expansion in prostate
when p38 signaling was inhibited. The importance of molecules that are involved in
MDSC death pathways has recently been recognized and several key molecules are
identified (3). Therefore, it would be interesting to investigate p38-mediated MDSC
survival/death pathways in prostatitis.
Our findings demonstrate that cells with monocytic MDSC (M-MDSC)
phenotype from the spleen and bone marrow are capable of differentiating into
osteoclasts and granulocytic cells in vitro. Tumor site M-MDSC lacked this plasticity and
could not form other cell types in vitro. We identified p53 as a critical regulator of this
differentiation process. Induction of p53 signaling increased the differentiation capacity
of bone marrow M-MDSC by 4-fold. To the best of our knowledge, our findings are the
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first to identify p53 as a regulator of MDSC differentiation into other cell types.
However, we investigated the role of p53 only in the context of differentiation into GMDSC. Further experiments are required to strengthen our conclusions by showing that
formation of other cell types by MDSC is also dependent on p53 activity. Additionally,
our findings are limited in that they are not tested in vivo. To this end, we analyzed p53
activity in MDSC in vivo. Comparative analysis of p53 levels revealed that p53 activity
in vivo was greater in tumor M-MDSC than in bone marrow counterparts. Given the
differentiation inducing effects of p53, these observation led us to speculate that in vivo
p53 activity triggers tumor site M-MDSC to obtain a more differentiated phenotype,
rendering them less plastic. This reduced plasticity of in vivo tumor M-MDSC might
explain the inability of these cells to differentiate in vitro. Further experiments are needed
to test this hypothesis. To evaluate the p53 induced M-MDSC differentiation in vivo,
adoptive transfer experiments can be performed where we label and transfer the precursor
bone marrow M-MDSC into tumor bearing mouse. Later we can isolate adoptively
transferred cells from the bone marrow and tumor site to evaluate p53 levels and
differentiation into G-MDSC. We expect to see that only cells that are at the tumor site
would have increased p53 levels and would express Ly6G. In addition, loss of p53 is
associated with increased cellular plasticity and it is suggested that p53 loss can reverse
the differentiated state of a cell (4). So, we would use p53-/- mice to see if tumor site MMDSC are more plastic in the absence of p53 that it can differentiate into G-MDSC in
vitro. p53 inhibitors can also be utilized to test if loss of p53 can destabilize proposed
differentiated state of tumor M-MDSC.
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The major work that is presented in this dissertation is the role of L-Arginine
transportation in MDSC. We identified that transporters of y+ and y+L systems are
responsible from L-Arg uptake in MDSC. Among these transporters CAT2 is particularly
important. Our data demonstrate that Cat2 expression in MDSC is coordinately induced
with Arg1 and Nos2. In vitro, Cat2 expression is induced in CD11b+Gr-1+ cells that gain
suppressive activity by the exposure to activating cytokines. In vivo, only MDSC that
reside at the tumor sites, but not at peripheral sites, have elevated Cat2 expression. CAT2
is a critical regulator of MDSC suppressive function. In the absence of CAT2, the ability
of MDSC to inhibit T cell responses is significantly reduced. The reduced suppressive
activity can be attributed to the diminished NO formation in CAT2-ablated MDSC. It is
interesting that CAT2 transports only around 20% of total L-Arginine that is uptaken by
MDSC, yet its absence can reduce NO formation by 70%. This observation can be
explained by L-Arg compartmentalization. It is proposed that there are distinct L-Arg
pools inside the cells and the access of NOS2 to the substrate L-Arg might be restricted to
distinct polls (5, 6). Therefore, we are interested in studying the compartmentalization of
L-Arg in MDSC in order to explain the critical role of CAT2 in MDSC suppressive
function.
Animal studies showed that MDSC-modulated T cell immunity is compromised
in the absence of CAT2. Thus, CAT2 may be useful in defining the functional state of
CD11b+Gr-1+ cells. Utilizing CAT2 as a marker to discriminate between the suppressive
and non-suppressive MDSC subpopulations can help to discover novel mechanisms and
pathways underlying MDSC suppressor function. In fact, our laboratory has already
started developing tools that will enable us to isolate CAT2+ and CAT2- MDSC
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populations. Unfortunately, there are no specific antibodies that can be used to isolate
murine cells based on CAT2 expression. To overcome this problem, using CRISPR/Cas9
technology we are developing a transgenic mouse model that express HA-tagged CAT2.
We will isolate CAT2+ and CAT2- MDSC populations using antibodies against the HA
tag and perform comparative analyses between these two populations. These analyses
will provide a comprehensive understanding of molecular processes related to MDSC
suppressive function.
Identification of factors that induce CAT2 expression is another prospective
research interest. Discovery of these factors can enable us to modulate MDSC function. A
hypoxic microenvironment is a common characteristic of tumors (7). Importantly, hypoxia
has been shown to regulate MDSC function by increasing Arg1 and Nos2 expression (8).
It is possible that hypoxia modulates MDSC function also by inducing CAT2 expression.
Since our work has shown that CAT2 induction parallels ARG1 and NOS2 induction, it is
expected that CAT2 expression is also induced under hypoxia. In order to address the
hypoxic regulation of CAT2 expression, we cultured CD11b+Gr-1+ cells under normoxic
and hypoxic conditions and investigated Cat2 expression. Data showed that hypoxia
induces Cat2 expression in MDSC (Figure 6.1A). Corzo et al. reported that the effects of
hypoxia on MDSC can be recapitulated by HIF-1α (8). Therefore, it is possible that hypoxia
regulate Cat2 expression through HIF-1α. HIF-1α is a transcription factor and can regulate
gene expression (9). HIF-1α induces target gene expression by binding to a core RCGTG
motif (10). The RCGTG motif is highly conserved and can be used for HIF-1α target
predictions (11). Promoter sequence analysis of Cat2 gene revealed that the promoter
region of exon 1A of Cat2 includes the binding pattern for HIF-1α (12). Hence, it can be
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speculated that hypoxia induces Cat2 expression by direct binding of HIF-1α to Cat2
promoter region. Additional experiments are needed to evaluate the mechanisms of
hypoxia-mediated CAT2 expression in MDSC.
Since CAT2 is induced under hypoxia and the findings presented in this
dissertation demonstrate a correlation between CAT2 expression and MDSC suppressive
activity, we hypothesized that hypoxia increases the suppressive capacity of MDSC.
Indeed, our results showed that hypoxia increased MDSC suppressor function (Figure
6.2). Interestingly, hypoxia increased the suppressive activity in both Cat2+/+ and Cat2-/MDSC (Figure 6.2), suggesting that CAT2-independent mechanisms may also play a
role in hypoxia-regulated control of MDSC inhibitory activities. Investigation of these
mechanisms is also a prospective research area. One potential mechanism that we plan to
investigate is the expression of PD-L1 by MDSC. A recent study by Noman et al.
demonstrated that hypoxia increases MDSC suppressive activity by inducing the
expression of PD-L1, the ligand for the immune checkpoint receptor PD-1 (13). PD-L1mediated MDSC suppressive activity might be a CAT2-independent mechanisms that is
responsible from enhanced MDSC suppressive function under hypoxia. An alternative
CAT2-independent mechanism that contributes to enhanced MDSC suppressive function
under hypoxia is ER stress. Hypoxia is an inducer of endoplasmic reticulum (ER) stress
(14) and ER stress is recently proposed to be a critical factor inducing MDSC suppressive
activity (15).
Altogether, this work identified novel aspects of MDSC biology and potential
control points to modulate MDSC suppressive function. Additionally, these findings
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provide strong foundations to initiate further research to investigate regulation of MDSC
function.
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Figure 6.1. Hypoxia is an inducer of Cat2 expression in MDSC.
CD11b+Gr-1+ cells were isolated from the bone marrow of naïve Cat2+/+ or Cat2-/- mice
(n=3-4 mice/group) and cultured for 3 days in the presence of activating cytokines GMCSF, IFN-γ and IL-13 under either normoxic conditions (21% oxygen) or hypoxic
conditions (1% oxygen). At the end of culture, mRNA was isolated and analyzed by
qPCR for Cat2 (A), Arg1 (B) and Nos2 (C) expression. Data are representative of 4
independently performed experiments. Error bars indicate ±SEM.
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Figure 6.2. Hypoxia increases MDSC suppressor activity.
CD11b+Gr-1+ cells were isolated from the bone marrow of naïve Cat2+/+ (A) or Cat2-/(B) mice (n=3 mice/group) and cultured for 3 days in the presence of activating cytokines
GM-CSF, IFN-γ and IL-13 under either normoxic conditions (21% oxygen) or hypoxic
conditions (1% oxygen). After 3 days naïve OTI cells were added to the culture and cocultures were continued to be kept under normoxia or hypoxia. After 48 hours of OTI
addition, OTI proliferation was evaluated by measuring BrdU incorporation. BrdU was
added 6 hours before harvest. Error bars indicate ±SEM.
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Figure 6.3. L-Arginine transportation through CAT2 regulates MDSC suppressive
function.
L-Arginine transport into MDSC is mediated by the members of y+ and y+L systems.
Cationic amino acid transporter 2 (CAT2), a member of y+ system, is induced in MDSC
that gains suppressive function and is functional transporter of L-Arginine in MDSC.
CAT2 regulates MDSC suppressive function by supplying enough L-Arginine to sustain
NOS2 activity. In the absence of CAT2 MDSC-mediated control of T cell immunity is
impaired, leading to greater T cell expansion and slower tumor growth in tumor bearing
mice.
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